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ABSTRACT 
Background: With substantial comorbidity, high levels of medication use and age-related 
physiological changes, older adults are at an increased risk of drug-related errors and adverse 
events. Of particular concern are (i) antipsychotic medications, which are often prescribed off-
label to individuals with dementia; and (ii) high-risk (HR) drugs (anticoagulants, oral 
antiplatelet agents, insulins, and oral hypoglycemic agents), which have been shown to be 
responsible for the majority of drug-related hospital admissions. Given the risk associated with 
these medications, medication management and monitoring are particularly important for older 
individuals at risk of adverse drug events. However, assisted living (AL) facilities, increasingly 
popular residential options for older adults requiring supportive care, are often characterized by 
lower levels of staffing and professional service, raising concerns about the care and oversight 
of vulnerable older adults in these settings. The concept of frailty offers a promising avenue for 
identifying vulnerable older adults who may require increased monitoring when using high-risk 
medications; however, frailty has been relatively unexplored in this context or setting. 
Objectives: The present research addresses knowledge gaps with respect to frailty and 
medication use by: (i) estimating the baseline prevalence of HR (anticoagulants, oral 
antiplatelet agents, insulins, and oral hypoglycemic agents) /antipsychotic medication use and 
frailty among AL residents using the frailty index (FI), cardiovascular health study (CHS) 
criteria, and health instability (CHESS) scale (ii) examining the associations of high-risk / 
antipsychotic medication use and selected frailty measures with risk of inpatient hospitalization 
over 1 year; and, (iii) examine the role of these 3 frailty measures in modifying the association 
between high-risk/antipsychotic medication exposure and hospitalization risk over 1 year. 
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Methods: 1,089 residents of 59 Assisted Living (AL) facilities from the Alberta Continuing 
Care Epidemiological Studies (ACCES) were included as participants (mean age 84.9±7.3; 
77% female). Baseline (2006-08) and 1-year follow-up assessments of resident clinical and 
drug use data were carried out by research nurses using the interRAI-AL. Facility-level data 
was captured through administrator interviews. Hospitalization events were captured through 
linkage with provincial health service utilization data from the Alberta Inpatient Discharge 
Abstract Database. Multivariable Cox proportional hazards models were used to estimate risk 
of hospitalization associated with frailty, medication exposure, and medication -frailty 
interaction terms. 
Results: Among AL residents, the prevalence of pre-frail/frail residents was 38.9%/27.5% for 
the FI; 55.0%/19.2% for the CHS; and, 29.4%/24.4% for the CHESS scale. The cumulative 
annual incidence of hospitalization was 38.9% (35.9-41.9%). All 3 frailty measures were 
significantly associated with hospitalization after adjusting for age, sex and comorbidity, with 
the highest risk observed for frail (vs. non-frail) residents defined by the CHS criteria (adj. 
HR=2.11, 95% CI 1.53-2.92). Overall, use of antipsychotics (26.4% [94.0% atypical agents]), 
and use of any of the specified HR medication classes (63.5% using at least 1 HR medication 
class) showed no association with hospitalization. However, the FI, and occasionally CHS, 
acted as effect modifiers of drug-outcome associations for certain medication classes. Relative 
to non-frail resident using the medication class of interest, pre-frail/frail individuals had an 
increased risk of hospitalization when using antipsychotic agents (adj. HR=2.30, 95%CI 1.43-
3.70 and adj. HR=2.20, 95% CI 1.3-3.74, with frailty defined using FI and CHS, respectively), 
anticoagulants (adj. HR=1.64, 95% CI 1.06-2.53, with frailty defined using FI) and antiplatelet 
agents (adj. HR=1.66, 95% CI 1.15-2.38, with frailty defined using FI). The CHESS measure 
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was a weaker effect modifier. Pre-frail/frail residents using antipsychotic agents were also 
significantly more likely than non-frail antipsychotic users to reside in facilities with no 
licensed practical and/or registered nurse on site (25.5% vs. 13.6%) and with no pharmacist 
involvement in the past month (34.4% vs. 19.7%). 
Conclusions: These findings suggest that frailty (particularly when measured using FI) may be 
a means of identifying older individuals vulnerable to drug-related adverse events. Clinical and 
policy-level interventions in AL settings may enhance quality of care and reduce 
hospitalizations among residents. 
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1. INTRODUCTION 
The high burden of chronic illness in older individuals often results in high levels of 
medication use among this population.
1
 Considerable comorbidity and exposure to high 
numbers of medications among older adults (with consequent drug-drug and drug-disease 
interactions)  increase their risk for drug-related errors and adverse events.
2,3,4,5
  
Physiological changes associated with aging influence pharmacokinetic processes (i.e., the 
ways in which the body absorbs, distributes and excretes drugs).
 6
   The heterogeneity in these 
processes and in the fitness of older adults,
7
 along with considerable variability in comorbidity 
and concurrent medication use, present challenges in making generalizations about the 
appropriateness of medications. Further, older adults with significant comorbidity are rarely 
included as subjects in clinical trials, limiting the evidence that exists on safe prescribing in 
this population.
8,9,10,11
 
Despite limitations in clinical trials, a strong base of epidemiologic evidence suggests that 
certain pharmaceuticals pose an increased risk in older adults.
12,13,14
 Further research suggests 
that this risk is heightened for frail, when compared to robust (not frail), older individuals.
15, 
16,17
 Frail older adults are a subset of the older population who have a decreased capacity to 
recover from stressors.
18,19
 Frailty has been conceptually linked with  reduced physiologic 
reserves across multiple organ systems,
18,20
 and as such, its presence could feasibly modify 
pharmacokinetic processes above and beyond the effects of aging. In fact, there is evidence 
that clearance of certain medications is reduced in frail individuals when compared to more 
robust older adults.
21,22 
Depending on the frailty definition considered, cognitive, psychological 
and social vulnerabilities may also contribute to the identification of frailty in older 
2 
 
adults.
19,20,23
  Cognitive, psychological and social concerns, including associated issues with 
medication administration and adherence, have a considerable impact on the safety of 
medication use.
24,25,26
 For example, depressive symptoms and low social support have both 
been observed to be independently associated with reduced medication adherence in those with 
type 2 diabetes.
26 
Attempts have been made to identify drugs that are particularly dangerous in older adults, and 
thus are deemed inappropriate under any circumstances, or when considering potential drug-
drug or drug-disease interactions. Sets of explicit guidelines have been developed to aid 
physicians when making prescribing decisions for older patients.
27,28,29
 Several observational 
studies have explored the ability of such explicit criteria to identify potentially inappropriate 
medication use and predict adverse outcomes, with considerable variability in findings. Other 
evidence suggests that a greater risk of adverse outcomes comes from supratherapeutic effects 
of otherwise helpful medications.
30
 Medications often implicated in such events are known as 
narrow therapeutic window (NTW) drugs and include warfarin, oral antiplatelet agents,  
insulin, and oral antidiabetic agents.
30
 These drugs are appropriate and often necessary, but 
they pose serious risks if their use is not carefully monitored and adjusted as needed. 
Understanding the relative benefit/risk ratios of these drugs in older adults is important given 
the high rates of adverse events associated with their use.
30
 Frailty status has been relatively 
unexplored in relation to medication-related adverse events, and may be particularly relevant in 
altering the benefit/risk profile of several important medications. 
The overall aim of the present research was to investigate whether selected measures of frailty 
act as effect modifiers of associations between certain high-risk or potentially inappropriate 
medications and hospitalization risk in a vulnerable older population. Using linked clinical, 
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functional and administrative health data for a cohort of Designated (publicly funded) Assisted 
Living (DAL) residents aged 65+ years, associations between specific high-risk medication use 
and hospitalization during the 1-year follow-up period were examined, considering frailty as a 
potential effect modifier. 
The present research is focused on the four high-risk medication classes mentioned above 
(anticoagulants, oral antiplatelet agents, insulins, and oral hypoglycemic agents). In addition to 
this, a fifth class of potentially inappropriate medications (antipsychotics) was examined. 
Antipsychotics warrant consideration because they continue to be commonly used despite 
serious risks for older frail populations.
31,32,33 
Additionally, examination of antipsychotic 
medications allows for comparison with other drug-outcome studies that examined this class. 
The present research addresses gaps in the literature with respect to the role of frailty in 
modifying the effects of high-risk and antipsychotic medication use. Additionally, this research 
explores frailty measures as a means of identifying those older adults who are most vulnerable 
to adverse drug events when using high-risk medications.  
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2. LITERATURE REVIEW 
2.1 Pharmacotherapy Concerns in Older Adults 
Suboptimal medication use puts older adults at heightened risk of morbidity and mortality
2,3,4
 
while adding to the burden on the health care system through increased levels of service use 
and cost.
34
 Indeed, one study found that the estimated cost of emergency department visits and 
hospitalizations of older adults in Canada due to adverse drug reactions in 2007 was $35.7 
million.
34
 Older adults are at increased risk for sub-optimal prescribing due to frequent 
polypharmacy and comorbidities, as well as age-related changes in pharmacokinetics.
35
  
The heightened variability in the health status of older adults, known as aged heterogeneity,
7 
introduces further challenges to health care providers in making the correct prescribing 
decisions.
 
Changes in body composition accompanying advanced age lead to an increased 
proportion of body fat, reduced lean muscle and decreased total body water, influencing 
absorption and storage of medications.
6
 Additionally, clinically complex older adults often 
have impaired liver and kidney function, resulting in altered metabolism and excretion of 
medications, as well as altered permeability of the blood-brain barrier, and enhanced sensitivity 
to certain drugs.
6 
At the same time, older adults with significant comorbidity are rarely 
included as subjects in clinical trials,
8,9,11
 limiting the evidence that exists on the relative risks 
and benefits of selected drugs in this population. 
2.1.1 High-risk/Potentially Inappropriate Medications 
In an effort to identify potentially inappropriate drug use leading to adverse drug events, lists 
of medications which pose unnecessarily high risk in older adults have been developed. The 
Beers criteria, a list of potentially inappropriate medications (PIM) originally formulated by 
5 
 
consensus review in 1991,
36
 are the most commonly used of these explicit lists. The Beers 
criteria have been updated three times
27,37,38
 since their original development and have been 
applied under many circumstances from research to clinical prescribing decisions to federal 
regulations on long-term care (LTC).
39
 
Published evidence is not consistent regarding the ability of the Beer’s criteria to identify 
potentially harmful medication use. A limited number of observational studies have found an 
association between PIMs, as defined by the Beer’s criteria, and adverse outcomes such as 
hospitalization, mortality, and diminished quality of life.
40-46
 Other studies, in contrast, have 
found no significant associations between Beers list medications and adverse outcomes.
47-54
  
In fact, using US nationally representative health surveillance data, one study
55 
determined that 
only 3.6% of drug-related emergency department visits in older adults were associated with 
inappropriate drugs, as defined by the 2003 Beers criteria.
38
 In contrast, three drugs (warfarin, 
insulin, and digoxin) were associated with one third (33.3%) of visits for adverse drug events.
55 
In a later study,
30
  the same group found that two-thirds (67%) of emergency hospitalizations 
resulting from adverse drug events in older adults were associated with four drugs or drug 
classes (warfarin, oral antiplatelet agents, insulin, and oral hypoglycemic agents).  A Canadian 
study found that the drug class most commonly associated with hospitalizations related to 
adverse drug reactions (ADR) was anticoagulants (including warfarin) , accounting for 12.6% 
of ADR-related hospitalizations from 2006 to 2011.
56
  
2.1.2 Narrow Therapeutic Window Drugs 
The four drug classes which were observed by Budnitz and colleagues to be implicated in the 
majority of emergency hospitalizations (warfarin, oral antiplatelet agents, insulin, and oral 
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hypoglycemic agents)
30
 are referred to as narrow therapeutic window (NTW) drugs. NTW 
drugs are medically necessary and beneficial when used correctly, but can cause substantial 
harm if drug administration and dosage is not monitored properly.
57,58,59
 It seems likely that a 
greater risk of harm from NTW drugs would also be associated with a higher degree of clinical 
complexity, as potential drug-disease and drug-drug interactions would modify the benefit-risk 
profile of these drugs. 
The challenge of medication management involved in the use of certain NTW drugs is 
illustrated by the observation of Lispka and colleagues that rates of hospital admission for 
hypoglycemia among diabetic older adults have exceeded rates for hyperglycemia between 
1999 and 2010.
60
 The authors point out that overall rates of hospitalization (after adjusting for 
increasing rates of diabetes) for both hypoglycemia and hyperglycemia have decreased since 
2007, but hypoglycemia hospitalizations have decreased at a much slower rate. These findings 
offer evidence that the emphasis on lowering blood glucose levels in those with diabetes may 
have resulted in hypoglycemia surpassing hyperglycemia as the major adverse effect associated 
with diabetes treatment, suggesting that overtreatment of diabetes is potentially more 
concerning than under treatment. However, the authors maintain that both over- and under-
treatment remain serious concerns.
60 
Similar challenges exist with regard to prescription and management of oral anticoagulant and 
antiplatelet medication. Low rates of prescription of these medications in patients with a 
history of stroke or atrial fibrillation has been identified as underprescription by some.
61,62
 
However, when considering the specific circumstances, many physicians consider long-term 
use of anticoagulant therapy to be inappropriate, placing patients at an increased risk of falls 
and bleeding.
63
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The term high-risk (HR) medication is often used in the literature to refer to NTW drugs and 
will be used primarily to refer to such medications for the remainder of the thesis document. 
NTW drugs can be considered HR medications because, unlike PIMs, they may be appropriate 
for some older adults and are often medically necessary, but also carry an elevated risk of 
adverse drug events. 
2.1.3 Antipsychotic Agents 
Despite the fact that PIMs, as a group, are implicated in few adverse drug events when 
compared to NTW drugs, certain drug classes included in the Beers list have relatively greater  
evidence of risk in vulnerable older adults. In particular, antipsychotic agents have been shown 
to be associated with adverse events including stroke,
32 
 sudden cardiac death
 33 
and falls
 31,64
 in 
older adults.  
Antipsychotic agents are used for the management of psychiatric disorders, including 
schizophrenia and bipolar disorder. Antipsychotics are classified into the groups conventional 
or atypical, based on biological activity. Conventional antipsychotics block dopamine 
receptors, while atypical antipsychotics act on both dopamine and serotonin receptors.
65
 In 
LTC settings, these agents are often used for treatment of psychiatric disorders, but are also 
commonly used to manage the behavioural problems associated with dementia, despite strong 
indications of increased risk of death (mostly due to stroke
 
and sudden cardiac death)
 
 in those 
with dementia.
66,67,68 
In fact, in 2005 both the US Food and Drug Administration (FDA), as 
well as Health Canada issued an alert stating that atypical antipsychotics (with the exception of 
risperidone, in the Health Canada alert) are associated with an increased risk of death in older 
adults with dementia.
69,70
 In 2008, the FDA statement was expanded to include conventional 
antipsychotics, as well.
69
 However, a US Department of Health and Human Services report 
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found that 83% of claims for atypical antipsychotic drugs were prescribed for off-label 
conditions (i.e., conditions other than those for which the drug was approved). In 88% of these 
cases, the drug was used for conditions which were cautioned against by the FDA (e.g., 
dementia).
71
  
In a study of Ontario nursing home residents, Rochon and colleagues observed that 
approximately one-third of LTC residents were prescribed antipsychotic agents in 2003.
72
 
Despite similar resident characteristics across facilities, rates of prescription in different LTC 
facilities ranged from 20% to 40%.
72 
Although this study was conducted prior to the release of 
the Health Canada alerts regarding antipsychotic use, subsequent research examined the impact 
of these alerts on rates of antipsychotic prescription. It was observed that following the release 
of the Health Canada alerts, growth in the use of atypical antipsychotics slowed; however, no 
reductions were observed in the overall rate of prescription of these drugs.
73 
Current data from the Canadian Institute for Health Information (CIHI) indicate that 30.3% of 
Canadian LTC residents were using antipsychotic drugs without a diagnosis of psychosis from 
2013 to 2014.
74 
This rate has been steadily decreasing from 34.1% in 2010. Similar to the 
observations of Rochon and colleagues,
72
 CIHI reported considerable variation in prevalence 
of antipsychotic use across long-term care homes, ranging from approximately 1 in 5 residents 
to 1 in 2 residents. The reported rate of potentially inappropriate antipsychotic use in Alberta 
LTC homes was lower than the Canadian rate, with a 2013-2014 prevalence of 25.3%.
74 
The latest version of the Beer’s criteria, updated by the American Geriatrics Society (AGS), 
recommends that antipsychotics not be prescribed to those with dementia.
27
 Furthermore, 
certain antipsychotic agents can worsen the symptoms of Parkinsonism through their dopamine 
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receptor antagonist function,
75
 and are not recommended for individuals with Parkinson’s 
disease.
27
 Additional evidence suggests a strong association between antipsychotic use and 
falls in older individuals.
31,64
 Falls are a significant concern among older adults, associated 
with hospitalization, institutionalization, death, disability, reduced quality of life, and social 
isolation.
76
 The AGS recommends that in all older individuals, antipsychotic agents should be 
used with caution.
27 
 
The high prevalence of antipsychotic medication use in nursing home and residential care 
settings,
71,72,74
 along with the pervasive use of these drugs for off-label conditions and 
dementia,
71,74
 suggest that antipsychotic use may be a source of concern in residential and LTC 
settings. The US Department of Health and Human Services reported that in 22% of Medicare 
claims for atypical antipsychotics in nursing homes, the drug was not administered in 
accordance with the standards set by the Centres for Medicare and Medicaid Services.
71 
The 
drugs were either administered “in excessive dose, for excessive duration, without adequate 
indication for use, without adequate monitoring, or in the presence of adverse consequences 
that indicate that the drug should be reduced or discontinued.” (Levinson, 2011).71  
The concerns regarding inappropriate prescription, administration and monitoring of 
antipsychotic agents in LTC settings suggest a need for interventions to improve management 
of these medications. In particular, the evidence of risk associated with use of antipsychotics in 
many older, vulnerable populations (with or without dementia) indicates a need for a means of 
identifying those older individuals at highest risk of harm associated with antipsychotic use in 
order to emphasize the importance of caution with antipsychotic prescription and management 
in such groups. Similarly, given the high rate of adverse outcomes associated with use of NTW 
drugs, it is important that the use of these high-risk medications be monitored closely, 
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particularly in individuals who are most vulnerable to experiencing adverse drug events. The 
concept of frailty may offer an approach for the identification of older residential and LTC 
residents who are particularly vulnerable to adverse events from the use of HR medications and 
antipsychotic drugs. 
2.2 Frailty 
Although there is no universally acknowledged standard definition for frailty, the most widely 
accepted definition describes a reduction in physiologic reserves due to deficiencies in several 
inter-related systems, resulting in decreased ability to endure and recover from stressors.
23 
Due 
to the multi-dimensional nature of this syndrome and the absence of definitive biomarkers, this 
definition is difficult to operationalize. Moreover, since the definition is based on an 
individual’s response to a stressful or adverse event, identifying frailty prior to exposure to a 
stressor is an added challenge. 
The concept of frailty as a result of reduced physiologic reserves is considered in a review by 
Bortz.
77
 He explains that all organ systems feature redundancy such that the systems continue 
to operate properly, even when function decreases. Bortz identified several body systems that, 
when acting at 30% of normal function, continue to be operational. However, once the 
functionality of these organ systems drops below 30%, symptoms of damage become evident.
77 
Based on this concept, frailty would be the state in which loss and damage to several body 
systems has exceeded the threshold of redundancy and evidence of these losses become 
apparent collectively as increased vulnerability to stressors. 
The occurrence of damage to multiple body systems leading to the development of frailty in 
older adults may be explained by a theory of aging known as the Theory of Inflammaging.
78
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This theory suggests that an imbalance of pro-inflammatory over anti-inflammatory responses 
(possibly due to genetic and lifestyle factors) may lead to poorly controlled low-grade 
inflammation during aging, resulting in gradual damage to the body systems.
78 
Other models suggest a cycle of decline involving neuroendocrine dysregulation, immune 
dysfunction, chronic under-nutrition, and reduction in muscle mass (sarcopenia).
79
 This cycle 
leads to impaired homeostasis and biological reserves, decreased physical activity and 
continued sarcopenic decline. The dysfunction of these biological systems contributes to 
development of frailty, and can be exacerbated by co-existing acute and chronic illness.
79 
Several measurement tools have been developed to identify and quantify frailty. The most 
commonly used of these measures is the Cardiovascular Health Study (CHS) criteria 
developed by Fried and colleagues.
80
 Meeting 3 or more of 5 criteria (weight loss, low grip 
strength, slow walking speed, low physical activity, and exhaustion) indicates a frail 
phenotype, using this tool.
80
 A more comprehensive measure developed by Rockwood, 
Mitnitski and colleagues is the Frailty Index (FI), which measures accumulation of health 
deficits. This tool assigns a score based on the ratio of the total number of deficits existing in 
an individual out of an inventory of potential deficits considered and/or measured.
81,82 
The FI 
can consider a flexible list of deficits including diseases, functional impairments, signs, 
symptoms, and laboratory test findings, but should include at least 30 variables encompassing 
multiple organ systems.
81,83
 The FI expands on the criteria considered in the CHS, 
incorporating aspects of clinical, social, functional, and psychological frailty, in addition to 
physical components. The FI shows high predictive validity,
82,84
 but can be time-intensive. 
However, the FI measure can often be generated using pre-existing data sources, typically from 
the results of a comprehensive geriatric assessment. As noted in prior publications, if data from 
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such assessments are automated, the FI could be feasibly applied as a measure across many 
clinical settings.
85
 
Through observational studies, frailty, as measured by both the CHS criteria and the FI, has 
been found to be independently associated with various adverse outcomes including falls and 
injuries, hospitalization, ADL disability, institutionalization, and death.
18,80,86,87
 Additionally, 
both approaches consistently detect higher prevalence of frailty among women, and with 
increasing age.
 79,80,84,86
 
The Changes in Health, End-stage disease and Signs and Symptoms of Medical Problems 
(CHESS) scale is a tool derived from items included in the Resident Assessment Instrument 
(interRAI) group of instruments.
88
 The interRAI instruments are standardized clinical 
assessments which are used across various health and social service settings to collect data on 
the characteristics and outcomes of those served.
88
 The CHESS scale is intended for the 
measurement of instability in health status and, as with the frailty measures outlined above, can 
be used to identify vulnerability in older adults.
88
 The CHESS scale was designed to identify 
residents at high-risk for decline in health status.
88
 In studies of LTC residents, greater health 
instability, as determined by the CHESS scale, has been shown to be highly predictive of 
mortality and hospitalization.
88,89
 The CHESS scale has been compared to established 
measures of frailty in existing publications,
 85,90
 and has also been suggested to act as a frailty 
measurement tool in others.
88,90 
In a recent editorial, Hubbard and Lang
91
 discussed the frequent co-occurrence of frailty, 
depression and dementia in older adults and offered evidence suggesting that each of these 
conditions may lead to development or worsening of the others. They argue that improved 
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understanding of these conditions, their risk factors and the inter-relationships between them 
may allow for the development of interventions to reduce the prevalence of all three 
conditions.
91 
The concept of frailty (or other markers of vulnerability) may be useful for identifying older 
adults at risk for decline in health status, offering health care providers the opportunity to make 
informed choices regarding treatment and monitoring of patients, particularly with respect to 
pharmacotherapy. 
2.3 Frailty and Medication Use 
Potentially inappropriate medication use has been found to be highly prevalent among frail 
older adults,
92,93
 as has polypharmacy,
17,94,95,96
 and the occurrence of adverse drug 
reactions.
97,98
 With conflicting evidence regarding the ability of explicit criteria such as the 
Beer’s criteria to predict adverse drug events, frailty status may serve as a tool to identify 
individuals who are more likely to be vulnerable to adverse events when using potentially 
inappropriate  medications. Additionally, with strong evidence suggesting that a high 
proportion of drug-related hospitalizations result from use of NTW drugs,
30,56
 frail individuals 
may represent a portion of the population who are at particular risk and in need of targeted care 
and monitoring associated with the use of these NTW drugs. 
The altered pharmacokinetics associated with the physical state of frailty have been 
investigated in studies which have found decreased gentamicin clearance in frail older adults 
compared to non-frail.
21,22
 Physiologic changes associated with frailty, including changes in 
body composition (reduced muscle, and increased proportion of body fat), albumin levels, 
elevated inflammatory markers, and the accompanying changes in pharmacokinetic responses 
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to medications, may place frail individuals at higher risk of adverse drug events, when 
compared to robust older adults.
99-103
 While there is evidence suggesting that changing 
pharmacokinetics may occur with frailty, increasing the risk of adverse drug events, there has 
been limited investigation regarding pharmacodynamics changes in frail older adults. Changes 
in pharmacodynamics would be expected to result in altered sensitivity to certain medications 
when frail individuals are compared to robust individuals. The paucity of data regarding 
pharmacodynamic changes in frailty further complicates individual and policy-level 
recommendations regarding pharmacotherapy in frail older adults.  
When considering frailty as defined by the FI, cognitive, social and psychological concerns, in 
addition to physical deficits, contribute to frailty status. The cognitive, psychological and social 
aspects of frailty are likely to have a considerable impact on adherence, maintenance of correct 
dosage and overall medication management in frail older adults.
24-26
  For example, medication 
non-adherence in older adults has been linked to depressive symptoms,
 26 
  low social support,
26 
 
and cognitive changes.
24
 Additionally, unmet medication support needs have been linked to 
increased risk of hospitalization in older adults.
25
 It has been suggested that guidelines for 
prescribing in healthy older adults are likely not suitable for frail individuals, and more 
research is needed to inform appropriate medication use in this group.
102,104 
Medication use in frail older adults is an emerging area of research, with very few publications 
considering the potential importance of frailty status as an indicator of vulnerability to drug-
related adverse outcomes. Observational studies have noted that suboptimal pharmacotherapy 
increases the risk of hospital admission
105,106
 and adverse drug reactions
97
among frail older 
adults. In the case of these studies, suboptimal pharmacotherapy includes polypharmacy,
97
 
therapeutic failure,
106
 and inappropriate prescribing according to STOPP/START (an explicit 
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drug list, similar to the Beers criteria).
105
 In all of these studies, frailty was not determined 
using any commonly accepted assessment tool, but was identified based on meeting a certain 
number of a list of frailty criteria (common elements include recent falls, limited functional 
capabilities, recent hospital admission and dementia).
97,105,106
  
The studies mentioned thus far were focused on determining the prevalence of inappropriate 
medication use or adverse drug reactions in frail older adults. However, very few studies have 
examined inappropriate drug use in frail, compared to non-frail older adults, or sought to 
identify outcomes associated with suboptimal pharmacotherapy in frail older adults compared 
to their non-frail counterparts. In the studies that did examine these issues, it was
 
observed that 
frail older adults are prescribed more inappropriate drugs than non-frail members of the same 
population,
16,17
 and that suboptimal pharmacotherapy is associated with greater risk of hospital 
re-admissions,
15 
falls,
16,17
 and  poor functional outcomes
17 
in frail older adults when compared 
to non-frail older adults.
 
 
Of those studies, one
 17
 considered only polypharmacy as the medication exposure of interest; 
one
16
  considered polypharmacy, drugs associated with an increased risk of falls (Fall Risk 
Increasing Drugs, FRIDs) and potential drug-drug interactions;
107
 and the other
15
 utilized an 
explicit list of High-risk Medications in the Elderly (HRME),
29
 similar to the Beer’s criteria. 
Given the evidence suggesting that the majority of adverse drug events result from use of NTW 
drugs,
30
 an important next step in the research into frailty and medication use would be an 
examination of the effect of frailty on adverse events related to NTW drug use. 
Of the studies considering drug-related adverse events in frail older adults compared to robust 
older adults, the measures of frailty used differed considerably. One study
16
 utilized the 
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Edmonton Frail Scale, one
17
 used the FI, and another
15
 designated frailty based on the presence 
of one or more conditions (coagulotherapy, involuntary weight loss, fluid and electrolyte 
imbalance, anemia, and fall or fracture) that have been observed to be associated with CHS 
frailty status in prior studies. Although many valid tools exist for identifying frailty, the CHS 
frailty criteria and the FI represent two distinct views of frailty: frailty as a physical phenotype 
(CHS), or frailty as an accumulation of deficits, including physical, psychosocial and clinical 
concerns (FI).  Another important gap in current research is a comparison of these key 
conceptualizations of frailty with respect to identifying which measurement tool may be best 
able to predict the occurrence of particular outcomes associated with medication use. 
Bennett and colleagues
16 
observed that frail participants were more likely to use a higher 
number of FRIDs, to use a higher number of drugs, and to have potential drug-drug 
interactions. They also found that falls are likely to occur in frail individuals taking fewer 
concurrent FRIDs (falls predicted at 1.5 FRIDs) when compared to robust individuals (falls 
predicted at 2.5 FRIDs).
16
 In the study by Pugh and colleagues,
15
 an interaction effect was 
observed between frailty-related diagnoses and chronic use of HRME. Individuals without 
frailty-related diagnoses using chronic HRME were protected from hospital re-admission, 
while those with frailty-related diagnoses using chronic HRME were not protected. However, 
in this study, no interaction was observed between incident HRME use and frailty-related 
diagnosis. Rangunga and colleagues
17 
found that frailty (as defined by the FI) mediated the 
relationship between polypharmacy and adverse outcomes (including poor functional outcomes 
and falls).  A summary table of these studies is given in Appendix A. 
A study involving the use of oral anticoagulants in older adults with atrial fibrillation offers 
evidence that use of NTW drugs may present particular challenges with regard to medication 
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management and monitoring in frail older adults. Perera and colleagues
108
 found that frail 
patients were significantly less likely to be prescribed warfarin upon hospital admission or 
discharge. After six months, frail patients were significantly more likely to experience an 
embolic stroke compared to non-frail patients (RR 3.5, 95% CI 1.0-12.0), but also had a small 
non-significant increase in the risk of major hemorrhage (RR 1.5, 95% CI 0.7-3.0).
108
 The 
unique characteristics of frail older adults lead to a complex set of risk factors with regard to 
anticoagulant medication use and the balance between stroke prevention and bleeding 
risk.
109,110 
Additionally, with respect to antidiabetic medications, vulnerable older adults have been found 
to experience different outcomes compared to less vulnerable older adults. The odds of 
hypoglycemia have been reported to be particularly elevated in those with dementia when 
using sulfonylurea or combined metformin and sulfonylurea (oral antidiabetic agents), with 
more favorable odds reported for dementia patients using insulin.
111
 Given the high rate of 
dementia in continuing care facilities, the inconsistencies in risk associated with diabetes 
medications in those with dementia compared to those without may be particularly relevant in 
such populations. Additionally, given the fact that dementia has been found to overlap 
considerably with frailty,
91
 it may be relevant to explore the impact of frailty on risk associated 
with use of these medications. 
The issues surrounding frailty and medication management are likely to be an emerging quality 
of care concern for older residents of residential care facilities (including assisted living [AL]), 
given the growing reliance on such facilities to accommodate increasingly vulnerable older 
adults.
112,113,114,115 
As argued in the following sections, despite the increasing reliance on AL 
facilities for care of clinically complex older adults (including residents with dementia and 
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related disorders), these facilities have been the subject of limited research, particularly in 
Canada. 
2.4 Assisted Living 
Assisted living describes a broad range of group residential settings offering care and support 
to older adults.
 116,117
 Assisted living facilities differ from retirement homes, because they offer 
a higher level of care, including assistance with activities of daily living and some degree of 
assistance with health needs.
116,117,118
 These facilities do not fall under federal regulations for 
LTC, and thus, are distinct from nursing facilities.
116,117
 In general, assisted living facilities are 
often regarded as an alternative to nursing home care for those older adults without complex 
medical needs who require support, but desire a comfortable, home-like atmosphere, in 
contrast to the institutional setting of LTC.
116,118 
The broad array of assisted living facilities available results in considerable diversity in 
resident case-mix as well as level of care offered between different facilities.
119,120
 Despite the 
fact that AL facilities are generally considered to offer supportive residential care for older 
adults without complex medical needs, research studies have revealed that many AL residents 
have significant physical, cognitive and functional concerns.
112,113,114,115
 Additionally, clinical 
complexity among assisted living residents may increase over time. Indeed, certain assisted 
living facilities ascribe to the concept of ‘aging in place’, which emphasizes the idea that 
residents should be able to remain at the assisted living facility as they age, rather than being 
transferred to LTC. As a result, the complexity of care required in these settings will increase 
over time as residents age.
121
 This is of particular concern as AL facilities tend to employ fewer 
licensed nurses and have fewer hours of skilled staffing on average, when compared to LTC 
facilities.
112,120,121,122 
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Most knowledge regarding assisted living has been based on US research. As AL has become 
increasingly popular in Canada over the past 5-10 years, Canadian researchers have identified 
similar concerns to those expressed in previous US studies.
112,120,123
 In both Canada
117 
and the 
US,
118
 there is limited government standardization and considerable variability between AL 
facilities. As such, there is concern that limited skilled staffing could result in decreased 
detection and poorer management of health concerns, and a resulting increased risk of 
hospitalization.
112,120,121,122,124
 This concern is well represented by a study comparing various 
AL facilities across Maryland in which it was found that residents with higher levels of 
comorbidity were no more likely to be in a facility with higher levels of skilled staffing per 
resident, higher facility level-of-care certification, a licensed nurse on staff, or a physician who 
made regular visits to the facility.
113
 The annual incidence of hospitalization from assisted 
living facilities across Alberta was reported to be 38.9%,
112
 with similar rates reported in two 
American studies.
122,125
 In contrast, the annual incidence of hospitalization from LTC facilities 
in the same Alberta study was considerably lower at 13.7%.
112
 Although this may reflect better 
care and disease management in LTC facilities, it may also be related to the general higher 
severity of disease among LTC residents (leading to a greater reluctance to hospitalize) and/or 
the existence of advance directives discouraging hospitalization of these patients.
112 
Despite the existence of the ‘aging in place’ philosophy in many assisted living facilities, 
research has indicated a relatively high rate of admission to LTC from Alberta AL facilities (an 
annual incidence estimated at 18.3%).
120
 This is a source of concern due to the high risk of 
adverse outcomes associated with care transitions in older individuals.
126,127 
The high proportion of AL residents with dementia and mental health concerns reported in 
both US
113,114,115
 and Canadian
123 
literature adds to concerns regarding the capability of AL 
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facilities and staff to manage resident needs. In Alberta this is of particular concern due to the 
2008 continuing care reform strategy which proposed AL as a substitute for LTC for those 
individuals with lower care needs.
128
 Conversely, in Ontario and British Columbia, AL is 
primarily considered an option only for those without significant physical or cognitive 
impairment.
129,130
 However, as the demand for LTC surpasses availability, assisted living 
facilities across Canada may begin to take on residents with increasingly complex care needs. 
The limitation in skilled staffing in AL facilities in the face of increasing complexity of 
residents is a cause for particular concern when considering the issue of medication oversight 
and management.  
2.5 Assisted Living and Medication Management 
Several studies have identified medication prescription and management as an area for 
improvement in AL facilities.
113,131,132,133 
A Maryland study showed that the average number of 
medications prescribed to AL residents was 4.5
113 
while a later study from Alberta found an 
average of 8.3 prescriptions per AL resident.
112 
Interview-based studies have found that 
medical professionals have reported a lack of confidence that AL staff are adequately trained to 
properly manage the complex care and medication management needs of residents.
134,135
 This 
is an area of concern considering that AL staff are often responsible for the administration of 
prescription medications to residents. The Maryland study found that AL staff carried out 
medication administration for 87.4% of residents.
113
 
Issues surrounding medication  management are especially concerning considering the lower 
levels of licensed nursing care available in AL compared to LTC.
112,120,121,122
 The majority of 
health care staff in AL facilities are non-nurse health care aides (including nurse’s aides and 
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personal support workers),
112,120,121,122
 who may have very little training in terms of clinical and 
medication management of  residents. Some AL facilities also employ more highly trained, 
licensed nurses including Licensed Practical Nurses (LPNs) and Registered Nurses (RNs, who 
have the higher level of training and skill set, compared to LPNs). In a study of 11 AL facilities 
in South Carolina and Tennessee, it was found that the odds of medication errors for non-
nurses were twice as high as the odds among LPNs or non-nurses trained as medication 
aides.
132
 Despite the general shortage of licensed care in AL facilities, one AL study found that 
half of residents were receiving a medication that generally required additional monitoring.
113 
Observational studies have revealed error rates of 28-42% in medication administration in AL 
facilities.
131,132
 However, these rates reduced to 8-20% when excluding timing errors.
131,132
 One 
of these studies
132 
found that 7% of medication administrations had moderate or high potential 
for harm, while the other
131 
found that only 0.2% of medication administrations observed had 
potential clinical significance. Both studies reported that the errors with the greatest potential 
for harm commonly involved administration of insulin or warfarin (two NTW drugs).
131,132
 
Warfarin and insulin were also identified as drugs commonly involved in errors in nursing 
home settings.
136 
 
Another study of AL facilities in Florida, Maryland, North Carolina and New Jersey used a 
modified version of the Beer’s criteria to identify that 16% of residents were receiving 
inappropriate medications.
137 
The high levels of inappropriate prescribing may be explained by 
low physician involvement in many AL facilities. A study of antibiotic prescription to AL 
residents demonstrated that prescribing physicians often had limited knowledge of the resident 
and were often unaware of the level of support available through family members or AL staff. 
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Additionally, in 21% of cases of antibiotic prescribing, it was found that the physician did not 
examine the resident prior to prescribing.
138
 
Other studies have noted underprescription of drugs in assisted living including such drugs as 
angiotensin-converting enzyme (ACE) inhibitors, anticoagulants and antiplatelet agents, 
aspirin, and beta-blockers,
61
 as well as medications for dementia and psychiatric disorders.
115
 
Underprescription may include prescription of an inadequate amount of medication, or no 
prescription for a necessary or beneficial medication, and is an important consideration of 
suboptimal pharmacotherapy. 
An earlier study based on the ACCES cohort
112
 determined that a higher overall drug number 
(particularly 11+) in AL residents was found to be a significant risk factor for hospitalization 
after adjusting for potential confounders. Further work with this cohort is needed to examine 
which drugs may be linked to hospitalization risk and whether any observed risks are modified 
further by frailty.  
As the complexity of AL residents increases and with the shortage of skilled staffing and 
limited services, it may become important to have a means of identifying particularly 
vulnerable residents who will require additional skilled support and monitoring in the areas of 
medication prescribing, oversight and management within this setting. Providing additional 
support to these vulnerable residents may improve health outcomes and decrease adverse drug 
events, leading to reduced need for health service use, particularly hospitalization, among AL 
residents.  
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2.6 Predictors of Hospitalization from Assisted Living and Long-term Care 
Although sometimes appropriate, hospitalizations can be detrimental to the health of older 
adults, and represent significant cost to the healthcare system.
139
 At the patient level, adverse 
outcomes associated with hospitalization of older adults include delirium, dehydration, falls, 
medication problems,
 
and psychological distress associated with a change of setting.
140,141,142
 In 
a US study, Mor and colleagues
143
 comment on issues in care coordination between nursing 
facilities and hospitals by pointing out the high rates of re-hospitalization among nursing home 
residents. In this study, it was found that, following a hospitalization event, nursing home 
residents had a 30 day re-hospitalization rate of 26.8% in 2006.
143
 The Medicaid 
reimbursement costs of these re-hospitalizations amounted to approximately $2.23 billion.
143 
There is a strong base of evidence suggesting that many hospitalizations from LTC and AL 
could be prevented with increased monitoring of residents and timely care 
provision.
144,145,146,147
 
 
2.6.1 Assisted Living 
Previous publications from the Alberta Continuing Care Epidemiological Studies (ACCES) 
study have concluded that there is a higher risk of hospital admission from DAL in residents 
with health instability (as indicated by CHESS score).
85,112 
 Additional factors found to be 
associated with higher risk of hospitalization in the ACCES study included moderate to severe 
fatigue, hyperpolypharmacy (11 or more medications), and at least 2 hospital admissions 
during the previous year.
112
 There was also a slightly higher risk of hospital admissions in 
residents aged 90 or older and those with poor social relationships.
112 
Another study revealed 
an increased risk of hospitalization in AL residents with higher Charlson comorbidity scores, 
those without an available informal caregiver, and those who were incontinent.
148
 Lower 
24 
 
skilled staff hours were also found to be associated with higher risk of hospitalization in 
assisted living.
121,122 
2.6.2 Long-term Care 
In LTC settings, factors that have been found to be associated with risk of hospitalization 
include male gender,
149,150
 non-white race,
144,145
 increased comorbidity,
144,151 
higher number of 
prescriptions,
149,150,152
 previous hospital admission,
146,150,152
 and for-profit status of the 
facility.
145,152,153
 The evidence regarding dementia as a risk factor for hospitalizations from 
LTC has been contradictory. Two studies found that risk of hospitalization would tend to 
increase with physical comorbidity, but would actually decrease among those with Alzheimer’s 
or dementia.
150,154
 In contrast, other studies showed dementia to be associated with higher risk 
of hospitalization.
121,145 
In relation to facility-level factors, lower skilled staff hours were found to be associated with 
higher risk of hospitalization in LTC.
149,155,156 
Specifically, one LTC study found an inverse 
association between skilled staff hours and risk of avoidable hospitalizations only, with no 
difference in risk of unavoidable hospitalizations.
152
 Some studies of LTC facilities, in the US, 
have also identified reimbursement policies as a key factor in determining the risk of 
hospitalization among residents.
143,152,157
 That is, in some cases, facilities, residents or families 
may have a financial incentive for choosing hospitalization over care in the LTC facility.
 
143,152,157 
Evidently, there is a diverse range of factors contributing to the risk of hospitalization among 
older adults in continuing care, including sociodemographic factors, health status, previous 
health service use, medication use, facility factors, financial incentives, and others. An 
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independent means of identifying those at highest risk for hospitalization when using certain 
high-risk medications could allow for the introduction of interventions to not only improve the 
health of the resident, but also reduce unnecessary hospitalizations. 
  
26 
 
3. STUDY RATIONALE AND OBJECTIVES 
With substantial comorbidity, high levels of medication use and age-related physiological 
changes, older adults are at an increased risk of drug-related errors and adverse events.
2,3,4,5,35
  
Existing research into explicit measures of potentially inappropriate medications (PIM) has 
shown conflicting evidence regarding the ability of these measures to predict adverse outcomes 
among older adults.
40-54
 The present research will address this gap by exploring the use of 
frailty as a marker of vulnerability which can be used to identify those older adults who are at 
increased risk of harm associated with the use of high-risk or potentially inappropriate 
medications.  
The following research focuses on high-risk (HR) drugs, those medications that are medically 
necessary under many circumstances, but have been associated with adverse events in older 
adults. Specifically, these drugs include the following narrow therapeutic window (NTW) drug 
classes: anticoagulants, oral antiplatelet agents, insulins and oral hypoglycemic agents. Use of 
antipsychotic agents, a class of potentially inappropriate medication (PIM), was also 
considered as a medication exposure of interest due to the high prevalence of antipsychotic use 
in long term care (LTC) and residential care settings
71,72 
and high potential for risk associated 
with stroke, cardiac death and falls in vulnerable populations of older adults.
31,64,65
 The NTW 
drugs of interest, antithrombotic and antidiabetic agents, are necessary for the management of 
cardiovascular disease and diabetes; however, errors in dosage and timing of administration as 
well as a failure to adjust prescriptions based on need, can lead to adverse events.
57,58,59 
NTW 
drugs have been shown to be responsible for the majority of drug-related hospital admissions.
30
 
Given the high risk associated with these necessary medications, it is important to improve the 
medication management and monitoring for individuals at risk of adverse drug events. 
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However, no published research has suggested a means of identifying older adults who have an 
increased risk of adverse outcomes when using these high-risk medications. This research 
considers frailty as a means of identifying those older adults who are particularly vulnerable to 
adverse events related to high-risk medication use, and who thus may require additional 
monitoring. Two  measures for identifying frailty were considered (the CHS Frailty criteria and 
the FI), as well as another marker of health instability (the CHESS scale) in order to consider 
which method of identifying vulnerability was best able to predict the outcome of interest. 
The primary outcome of interest is hospitalization. Hospital admission of vulnerable older 
adults is associated with high risk of negative outcomes, including delirium, falls, and 
medication problems,
 140,141,142
 as well as substantial cost to the health care system.
139
 Recent 
research points to the relevance of this outcome for this research, with the observations that 
NTW drugs
30,55
 and frailty
85 
may increase risk for hospitalization. Additional research shows 
high rate of hospitalization events from AL settings.
112,122
 
The study population consists of residents of designated (publicly funded) assisted living 
(DAL) facilities in the province of Alberta. As the Canadian population ages and more 
individuals are in need of supportive housing, assisted living facilities are becoming an 
increasingly important residential care option.
117
 Despite the growing need for assisted living, 
there is an absence of comprehensive regulation at the national and provincial levels.
117
 
Additionally, there has been very little Canadian research into the characteristics of these 
facilities and the health outcomes of residents. Of the available Canadian and U.S. research, 
there is strong evidence suggesting that assisted living (AL) facilities employ fewer licensed 
nurses per resident when compared to LTC facilities.
112,120-122
 However, residents of AL tend to 
have high levels of physical and cognitive comorbidity as well as considerable functional 
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needs.
112-115 
The current research will make an important contribution to the small base of 
Canadian literature considering the AL setting. Specifically, this research involves 
investigation of the important issue of outcomes associated with high-risk and antipsychotic 
medication use in assisted living settings. Given the evidence suggesting low levels of skilled 
staffing in AL facilities,
112,120-122
  it is particularly relevant to consider safety of medication 
management in this setting. This research will investigate whether a frailty measure could be 
used to identify AL residents who are most vulnerable to adverse drug events, and thus require 
additional monitoring by skilled staff. 
As stated previously, the aim of the current research is to investigate whether selected 
measures of frailty act as effect modifiers of associations between certain high-risk and 
antipsychotic medications and health outcomes (with a particular focus on hospitalization risk) 
in a vulnerable older population. In order to examine this question, linked clinical, functional, 
facility-level and administrative health data for a cohort of DAL residents aged 65+ years was 
used to address the following objectives: 
1a.  Examine [at baseline] the frailty status of DAL residents, as identified by three 
measures of vulnerability (the CHS frailty criteria, the Frailty Index, and the 
CHESS scale), and the resident-level correlates of frailty status; 
1b.  Examine [at baseline] the distribution in the use of specific high-risk 
medications (anticoagulants, oral antiplatelet agents, insulins, and oral 
hypoglycemic agents) and a class of potentially inappropriate medications 
(antipsychotic agents) by resident-level characteristics and frailty status (as 
identified by three measures of vulnerability); 
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2a.  Examine associations between frailty status (as defined by three measures of 
vulnerability) and first-event hospitalization during a 1-year follow-up; 
2b.  Examine the associations between exposure to antipsychotic and high-risk 
medication classes and first-event hospitalization during a 1-year follow-up; 
3.  Determine whether frailty measures act to modify the associations of 
antipsychotic and high-risk medication use with hospitalization during the 1-
year follow-up.  
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4. METHODS 
4.1 Data Source: The Alberta Continuing Care Epidemiologic Studies (ACCES) 
4.1.1 Study Population 
The Alberta Continuing Care Epidemiologic Studies (ACCES) program was a longitudinal 
study consisting of baseline assessments and 1-year follow-up assessments of residents of 
designated (publicly funded) assisted living (DAL) and long-term care (LTC) facilities across 
Alberta from 2006-2009. In addition to resident data, the assessments also included data 
collection from family caregivers and facility representatives. Of 60 eligible DAL facilities, 59 
facilities agreed to participate in the study.
158,159 
All eligible DAL residents from the 59 facilities were approached for participation. Exclusion 
criteria included age less than 65 years, recent admission (<21 days) or receiving palliative 
care.  Of 1510 eligible DAL residents from the 59 facilities, 1089 consented to participate in 
the study (response rate = 72%). Of those not enrolled, 339 (22.5% of all eligible residents) 
refused to participate, and for the remaining 82 (5.4%), the legally designated surrogate could 
not be contacted. A similar age and sex distribution to that of participants was observed for the 
364 (86.5%) nonparticipants for whom age and sex data were available (mean age 84.4 ± 7.1 
years, 74% women). 
In addition to baseline and 1-year follow-up assessments, participants or surrogate decision 
makers provided consent allowing investigators to access residents’ health utilization data for 
1069 residents (98% of participants).  
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4.1.2 Data Collection 
Baseline and 1-year follow-up assessments of residents were carried out by trained research 
nurses, who administered the Resident Assessment Instrument for Assisted Living (interRAI-
AL see www.interrai.org/instruments.html). The interRAI-AL captures information on residents’ 
sociodemographic characteristics, health conditions, physical and cognitive status, behavioural 
problems, and use of medications and services. These assessments were carried out using 
information obtained directly from the resident, as well as information from family caregivers, 
staff members and chart review.  
For each participating DAL facility, a facility representative (facility administrator, manager, 
or director of care) assisted in the completion of the facility survey which included questions 
related to the following subjects: location, ownership, type and size of the facility, admission 
and retention criteria, staffing, health and wellness services, hospitality services, physical and 
social environment, fees, and challenges facing DAL or LTC.  
In the case of discharge or death of a participant prior to the 1-year follow-up assessment, a 
discharge tracking form given to the facilities was to be filled out and returned to the study 
coordinators. At this point, the study coordinators would contact a family caregiver to 
coordinate a discharge or decedent interview. Additionally, a Moves Addendum was added to 
the family caregiver interview of the 1-year follow-up assessment for any participant who had 
died or moved within the follow-up period. Generally, the most trusted information regarding 
participant discharge or death was obtained from facility files. 
If consent was provided by participants, study coordinators accessed health service utilization 
data from Alberta Health and Wellness and Regional Health Authorities. This included 
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information related to hospitalizations, emergency room visits, and day procedures. This health 
utilization data was linked with the resident-level data from the interRAI-AL assessment and 
facility records.
 
4.2 Analytic Sample 
For the present research, the analytic sample consisted of the subset of ACCES participants 
residing in DAL facilities.  
For descriptive analyses and Objective 1, the full cohort of 1,089 residents was included in the 
analytic sample because complete data was available to address this objective for all enrolled 
residents. One exception was in the examination of baseline characteristics, in which case both 
the full cohort of 1,089 residents and a sub-cohort of 1,066 residents were shown in order to 
compare the distribution of key resident and facility characteristics in the sub-cohort. The sub-
cohort of 1,066 residents consists of those enrolled participants with a known outcome over the 
1-year follow-up who provided consent for linkage with their health utilization data. This 
sample of 1,066 residents serves as the analytic sample for Objectives 2 and 3. Access to health 
utilization data is necessary for completion of these objectives because hospitalization is the 
outcome of interest. 
Due to issues with the feasibility of applying the CHS measure to a vulnerable population, (an 
important limitation of the CHS approach, as noted in a previous publication)
123
 missing data 
prevented determination of CHS frailty status for some residents. For those analyses involving 
the CHS frailty measure, the CHS cohort of 946 residents was the analytic sample for 
descriptive analyses and Objective 1, while the linkage consent cohort of 930 served as the 
analytic sample for Objectives 2 and 3. 
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The reasons for inclusion and exclusion of residents are shown in Figure 4.2.1, along with the 
numbers of residents meeting criteria for inclusion in the sample. 
 
Figure 4.2.1. Flow Diagram of Analytic Sample from ACCES DAL Cohort 
  
60 Eligible facilities 
59 Enrolled facilities 
1 facility refused 
1510 Eligible residents 
1089 Enrolled residents 
1069 Residents with hospital 
data linkage 
1066 Residents in analytic 
sample 
291 residents/spaces excluded 
96 discharged or died prior to consent 
56 Age < 65 
42 Empty spaces 
31 Not DAL residents 
26 In hospital at time of data collection 
14 Receiving palliative care 
26 Ineligible for other reasons 
332 consent refused 
82 surrogate nonresponse 
7 incomplete/withdrawal 
20 linkage consent refused 
 
2 lost to follow-up 
1 left province 
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4.3 Measures 
4.3.1 Exposures of Interest (High-risk Medications and Antipsychotics) 
The primary exposure of interest for the current research includes measures capturing the use 
of narrow therapeutic window (NTW) drugs (including oral anticoagulants, oral antiplatelet 
agents, insulins, and oral hypoglycemic agents) and antipsychotic drugs at baseline. The 
specific medications that are included in these drug classes were identified using the 
literature,
30
 provincial drug formularies, and a review of all medications used by DAL residents 
at baseline.  
A comprehensive list of all active prescribed and non-prescribed medications taken by the 
resident in the last 3 days was captured in the interRAI-AL assessments administered by 
research nurses. Data items included drug name, dose, route of administration, frequency of 
administration, and how the drug was administered (i.e., by self, by assistive device, by family 
member, by RN, by LPN, by aide, or other).  
The original drug records were translated into the Anatomical Therapeutic Chemical (ATC) 
classification system for ease of identifying specific therapeutic classes and subclasses of 
medications. In the ATC classification system, drugs are coded into five levels based on their 
active substance.
160
 The drugs are categorized, first, based on the organ system on which they 
act, and are assigned a corresponding letter as the first digit of the code (e.g., N for nervous 
system). The next level of classification is based on the pharmacological/therapeutic subgroup 
and corresponds to a two-digit number, occupying the next two digits of the code (e.g., N05 for 
psycholeptics). The third and fourth levels are used to classify the chemical/pharmacological/ 
therapeutic subgroups and each corresponds to a different letter, providing the next two digits 
of the code (e.g., N05A for antipsychotics; and N05AE for indole derivatives). The fifth and 
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final level defines the specific chemical substance and is represented by a two-digit number 
which provides the last two digits of the ATC code (e.g., N05AE04 for ziprasidone).
160 
The ATC codes corresponding to the medication classes of interest (i.e., the first four digits of 
the ATC code) were used to search out and identify all of the medications within each class 
from the drug records in the ACCES database. The medication classes of interest and the 
corresponding ATC codes are shown in Appendix B. 
The use of any of the high-risk medication classes of interest was captured using a variable 
coded as: 0 (no use of any high-risk medication classes), 1 (use of medication(s) from 1 high-
risk medication class), and 2 (use of medications from 2 or more high-risk medication classes). 
Use of the high-risk medication classes was also captured with binary variables for each drug 
class (anticoagulants, oral antiplatelet agents, insulins, and oral antidiabetic agents) coded as: 0 
(no use of any drugs within the selected class) vs 1 (use of 1 or more drugs within the selected 
class). Due to low numbers of residents using antidiabetic medications, use of any diabetes 
medication (insulin and/or oral antidiabetics) was explored as a binary summary variable. An 
additional binary variable defined by use of insulin and/or sulfonylurea was explored due to the 
particularly high hypoglycemia risk associated with use of insulin and with use of 
sulfonylurea.
59,111
 In addition to the binary variable, use of oral antiplatelet agents was also 
explored as a three level categorical variable, in order to elucidate the effects of acetylsalicylic 
acid (ASA) and non-ASA antiplatelet agents, with the following coding scheme: 0 (no use of 
any oral antiplatelet agents), 1 (use of ASA antiplatelet agents with or without non-ASA 
antiplatelet agents), and 2 (use of non-ASA antiplatelet agents only). A binary variable was 
employed to capture residents’ use of antipsychotics (PIM class under study) and was similarly 
coded as 0 (no use of any antipsychotic agents) vs.1 (use of 1 or more antipsychotic agents). 
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4.3.2 Frailty Measures 
Frailty was considered as an independent variable of interest and as a possible effect modifier 
of the association between high-risk medication use and hospitalization in DAL residents. 
Frailty was hypothesized to act as an effect modifier because a resident’s level of frailty may 
be associated with pharmacokinetic and pharmacodynamics changes,
21,22,99-103
 or decreased 
ability to manage medications,
24-26 
leading to a greater risk of adverse events and 
hospitalization when considering use of certain high-risk medications. Two separate measures 
of frailty were examined in the present research, specifically the Cardiovascular Health Study 
(CHS) criteria for frailty and the Frailty Index (FI). Both measures may be derived from data 
captured by the interRAI-AL assessment and are of interest in the present research as they 
represent two distinct approaches to (and conceptualizations of) frailty. Consequently, they 
may be expected to have varying effects as possible effect modifiers of any observed 
associations between the selected high-risk medications and hospitalization.  
An 86-item frailty index
82
 was derived from the interRAI-AL (see Appendix C) based on the 
methodology utilized by Searle et al,
83
 and largely consistent with the 83-item index used in a 
previous ACCES publication, designated the Full Frailty Index (Full FI).
85
 Additionally, a 44-
item frailty index was derived also from the interRAI-AL (see Appendix D) based on the report 
by Armstrong et al,
90
 and mostly consistent with the 43-item frailty index designated the 
Armstrong Frailty Index (Armstrong FI) in a previous ACCES publication.
85
 Consistent with 
other studies,
83,85,161
 for each frailty index, a score of less than 0.2 was selected to capture 
robust participants, while scores in the range of 0.2-0.3 indicate pre-frail status, and scores 
greater than 0.3 indicate a frail participant. 
37 
 
The CHS method identifies frailty using the following five criteria: slow gait speed, muscle 
weakness, unintentional weight loss, low physical activity, and exhaustion (see Appendix E).
 80
 
Absence of these criteria indicates that the participant is robust, while presence of one or two 
of the criteria denotes pre-frail status and three or more indicates frailty.
80 
Two versions of the 
CHS criteria were employed to assess whether residents were considered impaired for select 
criteria (gait speed, grip strength, physical activity). One, referred to here as the CHS absolute 
cut-points (CHSabs), used the cut-points specified in the original CHS frailty assessment.
80
 
The other, referred to as the CHS relative cut-points or CHSrel, was based on the score for 
each resident relative to the cohort, and identified the poorest performers for each of these 
criterion, within the study population, as determined in a previous ACCES study
123 
(see 
Appendix E).  
Resident status for three of the CHS criteria (unintentional weight loss, low physical activity 
and exhaustion) can be determined using pre-existing interRAI-AL questions. The CHS 
performance measures (gait speed test and grip strength test) were added as a supplement to the 
resident assessments in ACCES. However, data on all five CHS frailty criteria were 
unavailable for almost 40% of participants due to issues with the feasibility of assessing the 
CHS criteria in a vulnerable population.
123
 Comments from research nurses indicated that 
missing values usually occurred when residents refused or failed to comprehend what was 
requested. This is likely explained by the high proportion (58%) of participants with dementia 
in the DAL cohort. In order to supplement missing data for those residents missing 
information, observed functional and health items from the interRAI-AL assessment were 
substituted, in the following manner.  
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For residents missing data on gait speed, if the research nurses documented that at least 
“limited assistance” was required with “walking between locations on the same floor indoors” 
and that “in the last 3 days the longest distance walked without sitting down was less than 5 
meters”, the resident was coded as impaired. If research nurses indicated that the reason for 
missing grip test data was that the resident was physically unable to perform the grip test, the 
resident was coded as impaired. Missing data on weight loss and exhaustion were 
supplemented based on yes/no responses to interRAI-AL items as assessed by research nurses. 
A positive response to the item, “Subject has had weight loss of 5% or more in last 30 days, or 
10% or more in last 180 days” was used for weight loss while a positive response to the item 
“Due to diminished energy, is unable to finish normal day-to-day activities, or start some or 
any normal day-to-day activities” was used for exhaustion. Using these modifications, the 
proportion of participants with missing data for the CHS frailty assessment was reduced to 
15%. 
In addition to the two measures of frailty, the inter-RAI Changes in Health, End-stage disease 
and Signs and Symptoms of medical problems (CHESS) scale was also used to stratify 
participants by health stability status using items from the interRAI-AL assessment (see 
Appendix F). The interRAI-AL did not include two out of six symptoms that were originally 
included in the CHESS scale. Therefore, these two symptoms (dehydration, and decline in 
food/fluid intake) were not included in the symptom component of the CHESS score. Although 
CHESS is not specifically a frailty measurement tool, it has been shown to be predictive of 
mortality and hospitalization.
85,88-90
 In order to present CHESS scores in a comparable fashion 
to frailty scores, the 5-point scale were condensed into a 3-point scale, as described by Hogan 
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et al.
85
 A score of 0 will indicate low risk for serious decline, a score of 1 will indicate 
intermediate risk, and a score of 2 or more will indicate high-risk. 
For initial analyses (Objective 1a), the two versions of each frailty measure were considered 
(CHSabs, CHSrel, Full FI and Armstrong FI), as well as the CHESS scale, and a one-item 
measure of fatigue,  in order to identify the vulnerability measures best suited to the sample 
population and best able to predict hospitalization. For further analyses, the three frailty (or 
vulnerability) measures that were judged to be best suited to the sample population and to the 
research objectives were selected. These measures were the CHSrel frailty mearsure, Full FI 
and CHESS. For some descriptive analyses, findings for only these three key frailty measures 
are shown. Where it is relevant for understanding the selection of the final key measures, other 
descriptive tables include findings for all frailty (or vulnerability) measures. 
4.3.3 Outcome 
Time to first admission to an acute care hospital within 1 year of the baseline assessment was 
the primary outcome of interest. Hospitalization events were determined using the Alberta 
Inpatient Discharge Abstract Database, which has been linked to resident assessment data. The 
first discharge event associated with an admission to acute care will be assessed, rather than 
total hospital admissions. This stipulation was meant to address the possibility that residents 
may move from the original setting, and thus any subsequent admissions could reflect 
characteristics of the new location.  
4.3.4 Covariates 
Appropriate covariates were chosen from the sociodemographic, functional, and clinical items 
available from the interRAI-AL assessment and from the linked administrative health data. 
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Certain facility-level variables relevant to medication oversight were also considered for 
descriptive purposes. Based on previous publications from the ACCES study as well as insight 
from the literature, items considered for inclusion in the multivariable models included age, 
sex, comorbidity, number of distinct medications used, and history of health system use 
(hospitalizations, Emergency Department visits) in the year prior to the date of baseline 
assessment. The findings of the descriptive analyses were used to inform which covariates 
were considered for inclusion in the model. 
There has been some evidence from previous publications that age greater than 90 years
112
 and 
male sex
149,150
 may be associated with risk of hospital admissions. Based on these findings, and 
on the importance of these variables for most outcomes in older individuals, age and sex were 
included as covariates in the models. As in a previous ACCES publication,
112
 age was coded 
into the following categories: 65-79, 80-85, 86-89, and ≥90 years. 
Comorbidity has been shown to be associated with hospitalization risk in previous ACCES 
publications,
112
 as well as other studies of AL
148
and LTC
 144,151
 residents. In addition, 
comorbidity is highly associated with frailty status, and it is likely that comorbidity may be 
independently associated with the medication exposures of interest. Given the fact that 
comorbidity is a risk factor for hospitalization and is also associated with frailty status, 
multivariate models considering frailty as the exposure of interest (objective 2a) included 
adjustment for comorbidity level.  Comorbidity was measured as the sum of the diagnoses 
documented on the interRAI-AL instrument. Consistent with previous ACCES 
publications,
112,120
 the comorbidity score considered 49 possible diagnoses, and was coded into 
the following three groups: 0-3, 4-5, and ≥6 chronic conditions. 
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 For multivariable models in which medication use was the exposure of interest (objectives 2b 
and 3), specific diagnoses relevant to the use of the medication class were adjusted for, rather 
than a measure of comorbidity. Inclusion of specific diagnoses, rather than comorbidity, allows 
for more direct adjustment for conditions relevant to both the medication use and the risk of 
hospitalization. In particular, this is relevant for insulin and oral antidiabetic agents, since only 
those with diabetes are eligible to use these medications. Additionally, these steps avoid the 
risk of masking the impact of frailty as an effect modifier, as the Full FI includes many of the 
same diagnoses included in the comorbidity measure. However, there was adjustment for 
medication number, which can be considered a proxy measure for comorbidity number, and is 
described in more detail below. 
Previous publications from the ACCES study
112 
and elsewhere
149,150,152
  have identified an 
association between higher numbers of medications used and risk of hospitalization. There is 
also likely an association between use of specific medications and overall medication use. For 
models in which the exposure of interest was the use of certain medication classes (objectives 
2b and 3), there was adjustment for ‘number of medications’, subtracting the medications 
which fall into the medication class of interest. The medication number variable was coded into 
the following four categories: 0-6, 7-8, 9-10, and ≥11 medications, consistent with a previous 
ACCES publication.
112
 
Previous hospitalizations have also been identified as associated with risk of hospitalizations in 
AL
112 
and LTC
 146,150,152
 residents. History of hospitalizations may also be associated with the 
exposure of interest, use of high-risk medications (e.g., if previous hospitalizations were due to 
adverse drug events, or if new medications were prescribed during the hospital stay). Thus, the 
multivariate models included adjustment for previous hospitalizations. History of health system 
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use was determined using the linked health service utilization data for the year prior to baseline 
assessment. As in a previous ACCES publication,
112
 hospitalizations in the past year were 
coded into the following three groups: 0, 1 or ≥2 inpatient hospital admissions in the past year. 
Additional variables which have been explored as predictors of hospitalization from DAL in 
previous ACCES publications were also considered as potential covariates, including marital 
status; strength of social relationships; fatigue; time involved in activities; and cognition and 
function, as determined by the interRAI Cognitive Performance Scale (CPS) and Activities of 
Daily Living (ADL) score. However, these variables were not included as covariates in the 
final multivariable models due to their importance as components of frailty measures (e.g., 
strength of social relationships, activity involvement, and cognition in the Full FI; function in 
CHESS and the Full FI; fatigue in CHSrel). 
For descriptive purposes, associations between facility factors and frailty/medication use status 
of residents were investigated. In particular, factors related to skilled care and oversight of 
medication use were considered in order to explore the distribution of frailty and high-risk 
(HR)/antipsychotic medication use based on these measures of resident oversight. In previous 
ACCES studies
112,120
 level of skilled staffing was represented by the presence of Licensed 
Practical Nurse (LPN) or Registered Nurse (RN) staff on site, and coded in the following three 
categories: neither on site, LPN/RN on site <24/7, and LPN/RN on site 24/7. Similarly, 
affiliation of a physician with the facility (especially, presence of a physician office on site) 
was considered, coded into the following three groups, as in a previous ACCES study:
112
 no 
physician affiliated with site, affiliated physician with no office on site, and affiliated physician 
with office on site. Lastly, involvement of a pharmacist in the facility over the past month was 
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considered as the following three categories: no pharmacist involvement, pharmacist 
consultant, and pharmacist on staff. 
4.4 Ethics 
Ethics approval for ACCES was originally obtained from the University of Calgary Conjoint 
Health Research Ethics Board, the University of Alberta Research Ethics Board, and the 
University of Lethbridge Human Subject Research Committee. This ACCES sub-study was 
granted ethics approval by the University of Waterloo, Office of Research Ethics on March 16, 
2015 (ORE # 20569). 
4.5 Analytic Plan 
All analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, North Carolina). 
4.5.1 Descriptive and Bivariate Analyses 
Univariate analyses were used to determine the frequency and percentage distribution of all 
resident (including HR and antipsychotic medication use and frailty status) and facility 
variables of interest among the DAL cohort. Additionally, bivariate analyses were carried out 
to examine: (i) the distribution of resident variables by frailty status (as determined by CHSabs, 
CHSrel, Full FI, Armstrong FI, and CHESS); (ii) the distribution in the use of selected HR 
medication classes and use of antipsychotics by DAL residents’ frailty status and other 
characteristics; and (iii) the distribution of resident variables (including frailty and 
HR/antipsychotic medication use status) by outcome status over the 1-year follow-up 
(hospitalization, LTC admission/death, remained alive and in DAL facility). These unadjusted 
comparative analyses were used for identification of associations between selected independent 
and dependent variables of interest. Contingency tables were run to assess the association 
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between categorical variables, and chi-square tests were used to determine statistical 
significance. T-tests and analysis of variance were carried out to determine the association 
between continuous variables and the categorical exposure or outcome variables.  No 
corrections were made for multiple comparisons with the bivariate analyses. The purpose of 
the analyses was not to draw conclusions regarding the observed associations between 
variables, but was rather to inform covariates to be included in multivariable models. 
4.5.2 Multivariable Analysis 
For the multivariable analysis, Cox proportional hazards models were utilized to estimate the 
importance of frailty and HR/antipsychotic medication use (individually and in combination) 
as predictors of first event hospitalization in the DAL cohort, controlling for possible 
confounders. Following a strategy used in an earlier ACCES study,
112
 residents were classified 
into groups based on the date of their first event over the 1-year follow-up: (i) inpatient 
hospital admission; (ii) admission to LTC or death without prior hospital admission; (iii) other 
transitions without prior hospital admission; and (iv) no event and remained in DAL 
throughout the year. Residents were censored on the date of occurrence of LTC admission, 
death, or discharge to a new setting. Those who experienced none of these events and remained 
in a DAL facility throughout the year were censored on the date of their 1-year follow-up 
assessment. Possible concerns related to clustering of residents within facilities were accounted 
for by adjusting for facility ID in all multivariable models. 
To consider the role of frailty status as an effect modifier, Cox proportional hazards models 
were run using four-level variables that combined measures of frailty and specified 
HR/antipsychotic medication use (i.e,. not frail with no use of drugs from specified medication 
class; frail with no use of drugs from specified class; not frail with use of 1+ drugs from 
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specified class; and frail with use of 1+ drugs from specified class). For the purpose of these 
analyses, pre-frail residents were collapsed with frail residents. Pre-frail residents would be 
expected to have heightened vulnerability compared to robust residents, and since frailty is 
used as an indicator of vulnerability in the present analyses, it was decided that it would be 
most reasonable to include both frail and pre-frail residents in the vulnerable category, while 
keeping only robust residents in the less vulnerable category. Hazard models run with 
medication-frailty interaction terms yielded estimates of the relative risk that a participant 
using certain HR/antipsychotic medications would be hospitalized (as a first event), given their 
frailty status. Sensitivity analyses were carried out in which pre-frail residents were collapsed 
with non-frail residents for the binary frailty measure. However, this approach yielded 
inconsistent results and findings were less clear compared to the analysis collapsing pre-frail 
and frail residents.  
As explained above, using information from previous literature (including previous ACCES 
publications) and the results of the descriptive analyses, selected covariates were included in 
models in order to adjust for potential confounding.  For frailty-hospitalization models, there 
was adjustment for age, sex and comorbidity, allowing for consistency in the models used for 
each of the key frailty measures. Inclusion of additional variables in these models may have 
adjusted away important components of these frailty measures, as described previously.  
For models of first-event hospitalization by HR/antipsychotic medication use (with or without 
frailty status), there was adjustment for age, sex, specified diagnoses relevant to the medication 
class in question, number of distinct medications used (excluding any medications from the 
class of interest), and hospital admissions in the past year. 
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5. RESULTS 
5.1 Univariate Descriptive Results 
5.1.1 Baseline Resident Characteristics, Full and Linked Cohorts (Table 5.1.1) 
Of the 1089 designated assisted living (DAL) residents enrolled in the Alberta Continuing Care 
Epidemiological Studies (ACCES) at baseline, the average age was 84.9 ± 7.3, and the 
majority of participants were female (76.6%) and widowed (71.4%).  Residents had on average 
4.6 ± 2.0 comorbid diagnoses, and were using 8.3 ± 3.7 different medications. The top 5 most 
common chronic conditions in descending order were dementia (57.6%), hypertension 
(56.5%), arthritis (53.8%), depression (34.3%) and osteoporosis (31.6%). The prevalence of 
mild to severe cognitive impairment (CPS score ≥2) was 59.9%, while the prevalence of 
limited or higher activities of daily living (ADL) impairment (ADL score ≥2) was 40.6%, 
suggesting a higher degree of impairment in cognitive function than physical function in DAL 
residents. An estimated 59.1% of residents had some degree of bladder incontinence, and 
28.1% had some degree of bowel incontinence. Almost half (46.6%) of residents had little to 
no involvement in activities and 18.5% had weak or no meaningful social relationships. About 
one-fifth (19%) of residents had clinically meaningful depressive symptoms (DRS ≥ 3) and 
29.2% showed moderate to very severe aggressive behaviour (ABS ≥ 1). In the previous 90 
days, 28.4% of residents experienced at least one fall, and in the last year, 37.8% had at least 
one hospital admission. An estimated 10.4% of residents had an advance directive specifying 
that they did not wish to be hospitalized.  
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Table 5.1.1. Baseline Characteristics of DAL Residents: Full DAL Cohort (n=1,089) and 
Linked Cohort (n=1,066). 
Resident Characteristic,  
n (%), unless otherwise noted 
Full DAL Cohort 
(n=1,089) 
Linked Consent Cohort 
(n=1,066)
 §
 
Sociodemographic and Social Well-being 
  
Age, yr   
 Mean ± SD 84.9 ± 7.3 84.9 ± 7.3 
 65-79 272 (25.0) 268 (25.1) 
 80-85 285 (26.2) 280 (26.3) 
 86-89 247 (22.7) 243 (22.8) 
 ≥90 285 (26.1) 275 (25.8) 
Sex   
 Male 254 (23.3) 248 (23.3) 
 Female 835 (76.7) 818 (76.7) 
Marital Status   
 Widowed 778 (71.4) 761 (71.4) 
 Married or with a partner 159 (14.6) 156 (14.6) 
 Never married, separated, or 
divorced 
152 (14.0) 149 (14.0) 
Strength of Social Relationships 
ǁ
   
 Moderate to high (3-5) 888 (81.5) 873 (81.9) 
 Low to none (0-2) 201 (18.5) 193 (18.1) 
Time Involved in Activities 
ǂ
   
 Most (> 2/3 time) 158 (14.5) 157 (14.7) 
 Some (1/3 to 2/3 time) 424 (38.9) 417 (39.1) 
 Little to none (< 1/3 time) 507 (46.6) 492 (46.2) 
Health and Functional Status 
  
Cognition (CPS score)   
 Intact (0) 224 (20.6) 223 (20.9) 
 Borderline intact (1) 213 (19.6) 211 (19.8) 
 Mild impairment (2) 342 (31.4) 336 (31.5) 
 Moderate to severe impairment 
(≥ 3) 
310 (28.4) 296 (27.8) 
Activities of Daily Living (ADL score)   
 Independent (0) 458 (42.1) 454 (42.6) 
 Supervision required (1) 189 (17.4) 186 (17.5) 
 Limited impairment (2) 134 (12.3) 126 (11.8) 
 Extensive assistance required or 
dependent (≥ 3) 
308 (28.2) 300 (28.1) 
Bladder Incontinence   
 Continent 445 (40.9) 436 (40.9) 
 Some control, infrequent 
episodes 
159 (14.6) 156 (14.6) 
 Occasional incontinence 118 (10.8) 114 (10.7) 
 Frequent episodes, no control 367 (33.7) 360 (33.8) 
Bowel Incontinence   
 Continent 783 (71.9) 766 (71.9) 
 Some control, infrequent 
episodes 
166 (15.2) 165 (15.5) 
 Occasional incontinence 86 (7.9) 83 (7.8) 
 Frequent episodes, no control 54 (5.0) 52 (4.8) 
 
 
48 
 
 Full DAL Cohort 
(n=1,089) 
Linked Consent Cohort 
(n=1,066)
 §
 
Fatigue (inability to complete ADL in past 3 
days) 
  
 None 442 (40.6) 433 (40.6) 
 Minimal 470 (43.2) 461 (43.3) 
 Moderate to Severe 177 (16.2) 172 (16.1) 
Falls CAP   
 None 780 (71.6) 761 (71.4) 
 ≥1 falls/ 90 days 309 (28.4) 305 (28.6) 
Depressive Symptoms (DRS score)   
 No (<3) 880 (80.8) 863 (81.0) 
 Yes (≥3) 209 (19.2) 203 (19.0) 
Aggressive Behaviour (ABS Score) 
ɸ   
 None (0) 771 (70.8) 760 (71.3) 
 Moderate (1-2) 183 (16.8) 174 (16.3) 
 Severe to very severe (≥3) 135 (12.4) 132 (12.4) 
No. of Chronic Conditions 
Ɏ
   
 Mean ± SD 4.6 ± 2.0 4.7 ± 2.0 
 0-3 333 (30.6) 323 (30.3) 
 4-5 406 (37.3) 398 (37.3) 
 ≥6 350 (32.1) 345 (32.4) 
Selected Diagnoses 
¶
   
 Dementia 627 (57.6) 609 (57.1) 
 Hypertension 615 (56.5) 604 (56.7) 
 Arthritis 586 (53.8) 572 (53.7) 
 Depression 374 (34.3) 369 (34.6) 
 Osteoporosis 344 (31.6) 338 (31.7) 
 Coronary Heart Disease 310 (29.2) 315 (29.6) 
 Stroke 266 (24.4) 264 (24.8) 
 Diabetes 246 (22.6) 243 (22.8) 
 Congestive Heart Failure 244 (22.4) 238 (22.3) 
 COPD 200 (18.4) 196 (18.4) 
 Anxiety 179 (16.4) 177 (16.6) 
 Cardiac Dysrhythmias 71 (6.5) 70 (6.6) 
 Lipid Abnormality 51 (4.7) 51 (4.8) 
 Schizophrenia 17 (1.6) 16 (1.5) 
 Venous Disorders 10 (0.9) 10 (0.9) 
No. of Medications   
 Mean ± SD 8.3 ± 3.7 8.3 ± 3.8 
 0-6 360 (33.1) 349 (32.7) 
 7-8 235 (21.6) 232 (21.8) 
 9-10 220 (20.2) 214 (20.1) 
 ≥11 274 (25.1) 271 (25.4) 
Advance Directive: Do Not Hospitalize   
 Yes 113 (10.4) 109 (10.2) 
 No 976 (89.6) 957 (89.8) 
No. of Inpatient Hospital Admissions in Past 
Year 
  
 0 - 663 (62.2) 
 1 - 254 (23.8) 
 ≥2 - 149 (14.0) 
Abbreviations: DAL=Designated Assisted Living; CPS=Cognitive Performance Scale; CAP=Clinical Assessment 
Protocol; DRS=Depression Rating Scale; ABS=Aggressive Behaviour Scale; SD=Standard Deviation 
§ Sample excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for 
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administrative data linkage. 
ǁ Social relationships based on a summary score of items assessing whether the resident was close to someone in the 
facility, had a strong or supportive relationship with the family, participated in social activities of long-standing interest, 
and visited or had other interactions with at least one long-standing social relation or family member in the past week. 
ǂ Activity involvement reflects time when the person was awake and not receiving treatments or ADL care. 
ɸ ABS: a summary scale of 4 behaviours (verbal abuse, physical abuse, socially inappropriate or disruptive, resists 
care), with higher scores indicating a greater number and frequency of behavioural issues 
Ɏ Based on the sum of diagnoses existing out of 49 chronic conditions listed on the interRAI-AL 
¶ The five most common diagnoses are listed in addition to diagnoses explored as covariates in multivariable models 
 
5.1.2 Baseline Facility Characteristics, Full and Linked Cohorts (Table 5.1.2)  
DAL residents resided in facilities with an average of 44.3 (±26.0) DAL spaces and 140.8 
(±111.2) total beds. A small majority (60.5%) of residents were living in a not-for-profit or 
regional health authority facility and 53.9% were in a facility that was affiliated with a larger 
chain of AL and long-term care (LTC) facilities. Over a quarter (27.3%) of  residents resided in 
a facility without a  licensed practical nurse or registered nurse (LPN/RN) on site at any time, 
while 61.9% lived in a facility with an LPN and/or RN on site at all times. A minority (35.7%) 
of residents resided in a facility with an affiliated physician; for fewer than half of these 
residents (16.1% of total cohort), the affiliated physician had an office on-site. One third 
(33.6%) of residents were in a facility reporting no pharmacist involvement on site during the 
past month. Among those residing in a facility with some pharmacist input in the past month, 
only 4.0% (29/723) resided in a facility where the pharmacist was on staff.  Approximately one 
half of residents (51.9%) resided in a facility within a large urban community (i.e., population 
one million or greater).  
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Table 5.1.2. Baseline Facility Characteristics: Full DAL Cohort (n=1,089) and Linked Cohort 
(n=1,066). 
Facility Characteristic, 
n (%), unless otherwise noted 
Full DAL Cohort 
(n=1,089) 
Linked Consent Cohort 
(n=1,066) 
Ownership 
  
 For-profit 430 (39.5) 420 (39.4) 
 Not-for-profit or RHA 659 (60.5) 646 (60.6) 
Part of a Chain   
 Not part of a chain or RHA-
operated 
159 (14.6) 157 (14.7) 
 Part of AL chain only 343 (31.5) 334 (31.3) 
 Part of AL & LTC chain 587 (53.9) 575 (53.9) 
No. of DAL Spaces   
 Mean ± SD 44.3 ± 26.0 44.1 ± 25.9 
 < 20 112 (10.3) 109 (10.2) 
 20-29 173 (15.9) 172 (16.1) 
 30-39 296 (27.2) 293 (27.5) 
 ≥ 40 508 (46.7) 492 (46.2) 
Total  No. of Spaces   
 Mean ± SD 140.8 ± 111.2 140.0 ± 109.7 
 <55 151 (13.9) 148 (13.9) 
 55-89 269 (24.7) 263 (24.7) 
 90-147 263 (24.2) 259 (24.3) 
 ≥148 406 (37.3) 396 (37.2) 
LPN/RN coverage on site   
 Neither on site 297 (27.3) 295 (27.7) 
 LPN &/or RN on site <24/7 118 (10.8) 108 (10.1) 
 LPN &/or RN on site 24/7 674 (61.9) 663 (62.2) 
Physician (GP) Affiliated with Site   
 No 700 (64.3) 687 (64.5) 
 Yes, no office on site 214 (19.7) 210 (19.7) 
 Yes, office on site 175 (16.1) 169 (15.9) 
Pharmacist Involved with Site/past month   
 No 366 (33.6) 354 (33.2) 
 Yes, consultant 694 (63.7) 684 (64.2) 
 Yes, staff 29 (2.7) 28 (2.6) 
Community Size   
 <1,000 27 (2.5) 26 (2.4) 
 1,000-9,999 200 (18.4) 196 (18.4) 
 10,000-24,999 100 (9.2) 99 (9.3) 
 25,000-999,999 197 (18.1) 193 (18.1) 
 1,000,000 or more 565 (51.9) 552 (51.8) 
Region   
 1 (urban) 311 (28.6) 311 (29.2) 
 2 (mixed urban/rural) 234 (21.5) 228 (21.4) 
 3 (rural) 155 (14.2) 153 (14.4) 
 4 (urban) 281 (25.8) 268 (25.1) 
 5 (rural) 108 (9.9) 106 (9.9) 
Abbreviations: DAL=Designated Assisted Living; RHA=Regional Health Authority; LTC=Long Term Care; 
SD=Standard Deviation; LPN=Licenced Practical Nurse; RN=Registered Nurse; GP=General Practitioner 
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Table 5.1.3. Distribution of Medication Use among DAL Residents Overall (total 
cohort=1,089) and Within Drug Classes. 
Drug % Distribution of Use 
Among All DAL Residents 
(n) 
% Distribution of Use Among 
Residents Using At Least One 
Drug in Drug Class 
Antipsychotic Agents (1+) 26.4 (287)*  
 Atypical Antipsychotic 24.9 (271) ǁ 94.4 
 Risperidone  11.8 (129) 45.0 
 Quetiapine  7.4 (81) 28.2 
 Olanzapine  6.2 (67) 23.3 
 Conventional Antipsychotic 2.3 (25) 8.7 
 Loxapine 0.7 (8) 2.8 
 Methotrimeprazine 0.6 (6) 2.1 
 Haloperidol 0.4 (4) 1.4 
 Chlorpromazine 0.2 (2) 0.7 
 Flupentixol 0.2 (2) 0.7 
 Fluphenazine 0.1 (1) 0.3 
 Perphenazine 0.1 (1) 0.3 
 Zuclopenthixol 0.1 (1) 0.3 
Oral Anticoagulants (1+) 15.2 (166)  
 Warfarin 15.1 (165) 99.4 
 Acenocoumarol 0.1 (1) 0.6 
Oral Antiplatelet Agents (1+) 46.3 (504)
†
  
 Non-ASA Oral Antiplatelet 7.2 (78) 15.5 
 Clopidogrel 6.5 (71) 14.1 
 Aminosalicylic acid, Mesalazine 0.4 (4) 0.8 
 Ticlopidine 0.3 (3) 0.6 
 ASA Oral Antiplatelet 41.3 (450) 89.3 
 ASA 39.1 (426) 84.5 
 ASA+dipyridamole 2.5 (27) 5.4 
Oral Antidiabetic (1+) 14.4 (157) 
ǂ
  
 Metformin 10.3 (112) 71.3 
 Repaglinide  2.2 (24) 15.3 
 Sulfonylurea 6.2 (68) 43.3 
 Gliclazide 4.1 (45) 28.7 
 Glyburide 2.1 (23) 14.7 
 Thiazolidinedione 1.8 (20) 12.7 
 Rosiglitazone 1.7 (18) 11.5 
 Pioglitazone 0.2 (2) 1.27 
Insulin (1+) 5.8 (63) 
ɸ
  
 Insulin (human): Humulin N, 
Novolin NPH, etc. 
3.1 (34) 54.0 
 Insulin (human): Toronto, Novolin, 
Humulin R, etc. 
2.3 (25) 39.7 
 Insulin (human): Novolin 30/70, 
Humulin 30/70, etc. 
1.9 (21) 33.3 
 Insulin Unspecified 0.9 (10) 15.9 
 Insulin  Glargine 0.2 (2) 3.2 
High-Risk Drug Classes
Ɏ
 63.3 (689)  
 Use of 1 HR drug class 47.4 (516) 74.9 
 Use of 2+ HR drug classes 15.9 (173) 25.1 
Abbreviations: DAL=Designated Assisted Living 
* 9 residents were using both conventional and atypical antipsychotic agents 
ǁ 6 residents were using two different atypical antipsychotic agents 
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5.1.3 Baseline Medication Use (Table 5.1.3 and Figure 5.1.3) 
The distribution of the key medication classes and individual drugs examined among DAL 
residents is presented in table 5.1.3. A schematic representation of the frequency distribution of 
medication class exposure is shown in figure 5.1.3. More than one-quarter of residents (26.4%) 
were using one or more antipsychotic agents, of whom 94.4% were using atypical agents. Of 
the 166 residents (15.2% of sample) using oral anticoagulants, all but one resident were using 
warfarin, specifically. Slightly less than half (46.3%) of the sample were using one or more 
oral antiplatelet agents. Of this group, 89.3% were using acetylsalicylic acid (ASA)–containing 
oral antiplatelet agents and 15.5% were using a non-ASA oral antiplatelet agent (primarily 
clopidogrel). A total of 24 residents (2.2% of sample) were using both an ASA and a non-ASA 
antiplatelet agent. An estimated 14.4% of residents were using one or more oral antidiabetic 
agents and 5.8% were using one or more types of insulin. About 40% of insulin users (25/63) 
were also using oral antidiabetic agents. Almost two-thirds of residents (63.3%) were using at 
least one high-risk medication (and among this group, 25.1% were using agents from 2 or more 
HR drug classes). 
† 24 residents were using both ASA and non-ASA antiplatelet agents 
ǂ 43 residents were using two different oral antidiabetic agents; 12 residents were using three different oral antidiabetic agents 
ɸ 23 residents were using two different types of insulin; 3 residents were using three different types of insulin 
Ɏ   Number of HR medication classes is a measure of the number of distinct medication classes used (i.e., 1 HR medication 
class is  any number of medications from only 1 of the 4 HR classes) 
Note: 25 residents were using insulin in addition to an oral antidiabetic drug; of these, 9 residents were using insulin and 
sulfonylurea 
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Figure 5.1.3 Distribution of High-Risk and Antipsychotic Medication Use Among DAL Residents (n=1,089) 
Abbreviations: HR=High-rIsk; ASA=Acetylsalacylic acid; OAp=Oral Antiplatelet; OAd=Oral Antidiabetic; In=Insulin 
Drug subclasses are indicated in bars along with the %  distribution of use among residents using at least 1 drug in the drug class 
Number of HR medication classes is a measure of the number of distinct medication classes used (i.e., 1 HR medication class is  any number of medications from 
only 1 of the 4 HR classes) 
(19%) 
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5.1.4 Baseline Frailty Measures (Figures 5.1.4a & 5.1.4b and Table 5.1.4a & 5.14b) 
The proportion of residents classified as robust, pre-frail and frail by each of the frailty measures 
is shown in figure 5.1.4a and detailed in table 5.1.4a. Of the 946 residents with data for the CHS 
frailty criteria (after value assignment using items from the interRAI-AL tool), about one-fifth 
(19.2%) were considered frail and slightly over half (55.0%) were considered to be pre-frail 
based on the CHSrel (relative cut-points) measure. Using the CHSabs (absolute cut-points) 
measure, almost all residents were considered either frail (48.0%) or pre-frail (48.5%). Based on 
the Full FI, roughly one-quarter (27.5%) of participants were found to be frail, and 38.9% were 
considered pre-frail. The Armstrong FI classified just over half (57.9%) of residents as frail and 
about one-third (32.8%) as pre-frail. Using the CHESS scale, about a quarter (24.4%) of 
participants were considered to be at high risk of decline (i.e., frail), and 29.4% were found to be 
at intermediate risk (i.e., pre-frail).  
Agreement between the frailty measures in the classification of residents as frail, pre-frail, and 
robust is shown in table 5.1.4b. Agreement between the different frailty measures was highest 
between the Full FI and Armstrong FI (weighted kappa score = 0.38, 95% CI 0.35-0.41), with 
slightly under half (48.3%) of participants having equivalent categorizations. The lowest 
agreement was between CHSabs and CHESS (weighted kappa score = 0.12, CI 0.09-0.15), with 
31.2% of participants assigned equivalent categorizations from the two criteria. 
Overlap between classification of frail/vulnerable residents by the CHSrel, Full FI and CHESS 
criteria is shown in Figure 5.1.4b. Only three key measures of frailty are shown in figure 5.1.4b 
(CHSrel, Full FI and CHESS) as these are the three final frailty measures explored in subsequent 
analyses. The reasons for selection of these frailty measures include the observed distribution of 
frail, pre-frail and robust residents (as shown in figure 5.1.4a and table 5.1.4a), as well as the 
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observed associations between frailty measures and hospitalization, explained in further detail 
below.  
Table 5.1.4a Baseline Frailty Status of DAL Residents: Full DAL Cohort and Linked Cohort. 
Frailty Measure; % (n) Full DAL Cohort (n=946) Linked Consent Cohort (n=930)
 §
 
CHSabs   
 Robust 3.5 (33) 3.4 (32) 
 Pre-frail 48.5 (459) 48.7 (453) 
 Frail 48.0 (454) 47.9 (445) 
CHSrel   
 Robust 25.8 (244) 25.8 (240) 
 Pre-frail 55.0 (520) 54.9 (511) 
 Frail 19.2 (182) 19.3 (179) 
Frailty Measure; % (n) Full DAL Cohort (n=1,089) Linked Consent Cohort (n=1,066)
 §
 
Full FI   
 Robust 33.6 (366) 34.2 (365) 
 Pre-frail 38.9 (424) 38.7 (412) 
 Frail 27.5 (299) 27.1 (289) 
Armstrong FI   
 Robust 9.4 (102) 9.5 (101) 
 Pre-frail 32.8 (357) 32.9 (351) 
 Frail 57.8 (630) 57.6 (614) 
CHESS   
 Robust 46.2 (503) 46.5 (496) 
 Pre-frail 29.4 (320) 29.3 (312) 
 Frail 24.4 (266) 24.2 (258) 
Abbreviations: DAL=Designated Assisted Living; CHSabs= Cardiovascular Health Study Frailty Criteria (with absolute 
cut-points); CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); Full FI=Full Frailty Index; 
CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale. 
§ Sample excludes residents with unknown outcome who discontinued study and residents who refused consent for 
administrative data linkage. 
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Figure 5.1.4a Proportion of DAL Residents Classified into Each Frailty Level by Frailty Measure† 
Abbreviations: CHSabs=Cardiovascular Health Study Frailty Criteria (with absolute cut-points); CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-
points); Full FI=Full Frailty Index; Armstrong FI=Armstrong Frailty Index; CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale 
† Based on n=1,089 for Full FI, Armstrong FI and CHESS; n=946 for CHSabs and CHSrel (missing data for CHS for 143/1,089 residents) 
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Table 5.1.4b. Comparison of Agreement among Frailty Measures, Full DAL Cohort (n=1089).
 
Comparison
† 
% Agreement Weighted Kappa 95% CI 
Armstrong FI – Full FI 48.3 0.38 0.35-0.41 
Armstrong FI – CHSabs 56.8 0.28 0.23-0.33 
Armstrong FI - CHSrel 42.9 0.22 0.18-0.26 
Armstrong FI – CHESS 35.9 0.17 0.13-0.20 
Full FI – CHSabs 37.0 0.17 0.13-0.20 
Full FI - CHSrel 49.2 0.30 0.25-0.34 
Full FI – CHESS  52.2 0.36 0.31-0.40 
CHSabs – CHESS 31.2 0.12 0.09-0.15 
CHSrel – CHESS 40.3 0.19 0.15-0.24 
Abbreviations: CHSabs=Cardiovascular Health Study Frailty Criteria (with absolute cut-points); CHSrel=Cardiovascular Health 
Study Frailty Criteria (with relative cut-points); Full FI=Full Frailty Index; Armstrong FI=Armstrong Frailty Index; 
CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale 
†All comparisons based on n=1089 residents except for comparisons involving the CHS Frailty Criteria where n=946 residents 
 
 
 
 
Figure 5.1.4b. Overlap Between Three Key Frailty Measures: CHSrel, Full FI and CHESS 
(n=946)† 
*Note: Only those subjects classified as frail were included in these diagrams; pre-frail subjects were classified with non-
frail (robust) subjects 
†based on n=946 for all measures (common denominator based on missing data for CHS for 143/1089 subjects) 
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5.1.5 Outcomes 
Over the 1-year follow-up period among the linked DAL cohort (n=1,066), 3.3% (n=35) of 
residents died without any prior hospitalization or transfer, 7.5% (n=80) were transferred to LTC 
as their first event, 38.7% (n=413) were admitted to an acute care hospital as their first event, 
0.4% (n=4) were censored for other reasons, and 50.1% (n=534) remained in the DAL facility, 
without experiencing any other outcomes of interest. 
5.2 Objective 1a: Examine Frailty Status (as identified by 3 measures of 
vulnerability) by Resident-Level Characteristics 
5.2.1 Frailty and Resident-Level Characteristics (see Tables 5.2.1a – 5.2.1c) 
Associations between frailty status and resident level characteristics for the three key frailty 
measures are shown in Tables 5.2.1a (CHSrel), 5.2.1b (Full FI) and 5.2.1c (CHESS). Mean age 
was found to be significantly higher in frail residents compared to pre-frail or robust residents 
when considering the Full FI (F = 6.54, p-value = 0.001) or CHSrel (F = 5.50, p-value = 0.004) 
criteria for measuring frailty. Prevalence of CHSrel frailty increased with each subsequent age 
group, but this finding did not reach statistical significance (p-value=0.07), whereas the 
prevalence of Full FI frailty was significantly higher among those aged 80 and over when 
compared to those aged 65-79 (p-value = 0.01). CHESS instability was not significantly 
associated with mean age (F = 1.07, p-value = 0.34) or increasing age group (p-value = 0.80). No 
significant associations were observed between sex and any of the frailty measures considered.  
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Table 5.2.1a. Baseline Characteristics of DAL Residents by Frailty Status [CHSrel] 
  CHS Frailty; % of Row Total (n)  
 Total % (n) Not frail Pre-frail Frail p value 
 946 25.8 (244) 55.0 (520) 19.2 (182)  
Sociodemographic and Social Well-
being 
     
Age, yr      
 Mean ± SD 84.9 ± 7.2 84.0 ± 7.6 84.8 ± 7.2 86.3 ± 7.0 0.0042 
 65-79 24.7 (234) 30.3 (71) 56.4 (132) 13.3 (31) 0.0687 
 80-85 26.4 (250) 27.2 (68) 53.2 (133) 19.6 (49)  
 86-89 22.9 (217) 20.7 (45) 58.1 (126) 21.2 (46)  
 ≥90 25.9 (245) 24.5 (60) 52.7 (129) 22.9 (56)  
Sex      
 Male 24.5 (232) 26.3 (61) 56.0 (130) 17.7 (41) 0.7845 
 Female 75.5 (714) 25.6 (183) 54.6 (390) 19.8 (141)  
Marital Status      
 Widowed 71.4 (675) 26.7 (180) 54.8 (370) 18.5 (125) 0.6951 
 Married or with a partner 14.5 (137) 21.2 (29) 56.9 (78) 21.9 (30)  
 Never married, separated, or 
divorced 
14.2 (134) 26.1 (35) 53.7 (72) 20.2 (27)  
Strength of Social Relationships
 ǁ
      
 Moderate to high (3-5) 83.8 (793) 27.1 (215) 55.1 (437) 17.8 (141) 0.0126 
 Low to none (0-2) 16.2 (153) 19.0 (29) 54.2 (83) 26.8 (41)  
Time Involved in Activities 
ǂ
      
 Most (> 2/3 time) 15.8 (149) 48.3 (72) 47.0 (70) 4.7 (7) <0.0001 
 Some (1/3 to 2/3 time) 40.8 (386) 29.3 (113) 56.5 (218) 14.2 (55)  
 Little to none (< 1/3 time) 23.4 (411) 14.4 (59) 56.4 (232) 29.2 (120)  
Health and Functional Status      
Cognition (CPS score)      
 Intact to borderline intact (0-1) 42.6 (403) 24.1 (97) 56.1 (226) 19.8 (80) 0.7357 
 Mild Impairment (2) 32.9 (311) 27.7 (86) 54.3 (169) 18.0 (56)  
 Moderate to severe impairment (≥ 
3) 
24.5 (232) 26.3 (61) 53.9 (125) 19.8 (46)  
Activities of Daily Living (ADL score)      
 Independent or supervision 
required (0-1) 
62.9 (595) 34.6 (206) 53.6 (319) 11.8 (70) <0.0001 
 Limited impairment (2) 11.6 (110) 21.8 (24) 60.0 (66) 18.2 (20)  
 Extensive supervision required or 
dependent (≥ 3) 
25.5 (241) 5.8 (14) 56.0 (135) 38.2 (92)  
Fatigue (inability to complete ADL in 
past 3 days due to diminished energy) 
     
 None 41.7 (395) 39.5 (156) 52.9 (209) 7.6 (30) <0.0001 
 Minimal 43.9 (415) 20.2 (84) 62.2 (258) 17.6 (73)  
 Moderate to Severe 14.4 (136) 2.9 (4) 39.0 (53) 58.1 (79)  
Falls CAP      
 None 72.0 (681) 28.5 (194) 55.6 (379) 15.9 (108) <0.0001 
 ≥1 falls/ 90 days 28.0 (265) 18.9 (50) 53.2 (141) 27.9 (74)  
Depressive Symptoms (DRS score)      
 No (<3) 82.7 (782) 27.9 (218) 55.1 (431) 17.0 (133) <0.0001 
 Yes (≥3) 17.3 (164) 15.8 (26) 54.3 (89) 29.9 (49)  
Aggressive Behaviour (ABS Score)
 ɸ
      
 None (0) 73.3 (693) 25.4 (176) 56.4 (391) 18.2 (126) 0.6003 
 Moderate (1-2) 16.8 (159) 27.7 (44) 52.2 (83) 20.1 (32)  
 Severe to very severe (≥3) 9.9 (94) 25.5 (24) 48.9 (46) 25.5 (24)  
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  CHS Frailty; % of Row Total (n)  
 Total % (n) Not frail Pre-frail Frail p value 
 946 25.8 (244) 55.0 (520) 19.2 (182)  
No. of chronic conditionsɎ      
 Mean ± SD 4.6 ± 1.9 4.2 ± 1.9 4.6 ± 2.0 5.3 ± 1.9 <0.0001 
 0-3 30.7 (290) 34.8 (101) 56.6 (164) 8.6 (25) <0.0001 
 4-5 36.7 (347) 24.2 (84) 51.9 (180) 23.9 (83)  
 ≥6 32.7 (309) 19.1 (59) 57.0 (176) 23.9 (74)  
No. of medications      
 Mean ± SD 8.3 ± 3.6 7.9 ± 3.5 8.3 ± 3.6 9.2 ± 3.8 0.0017 
 0-6 32.6 (308) 29.2 (90) 54.9 (169) 15.9 (49) 0.0696 
 7-8 21.9 (207) 28.0 (58) 56.0 (116) 15.9 (33)  
 9-10 20.4 (193) 24.4 (47) 54.4 (105) 21.2 (41)  
 ≥11 25.2 (238) 20.6 (49) 54.6 (130) 24.8 (59)  
No. of inpatient hospital admissions in 
past year (n=930) 
     
 0 61.4 (571) 28.9 (165) 56.0 (320) 15.1 (86) 0.0003 
 1 24.6 (229) 23.1 (53) 52.4 (120) 24.5 (56)  
 ≥2 14.0 (130) 16.9 (22) 54.6 (71) 28.5 (37)  
Abbreviations: DAL=Designated Assisted Living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-
points); CPS=Cognitive Performance Scale; CAP=Clinical Assessment Protocol; DRS=Depression Rating Scale; 
ABS=Aggressive Behaviour Scale; SD=Standard Deviation 
ǁ Social relationships based on a summary score of items assessing whether the resident was close to someone in the facility, 
had a strong or supportive relationship with the family, participated in social activities of long-standing interest, and visited or 
had other interactions with at least one long-standing social relation or family member in the past week. 
ǂ Activity involvement reflects time when the person was awake and not receiving treatments or ADL care. 
ɸ ABS: a summary scale of 4 behaviours (verbal abuse, physical abuse, socially inappropriate or disruptive, resists care), with 
higher scores indicating a greater number and frequency of behavioural issues 
Ɏ Based on the sum of diagnoses existing out of 49 chronic conditions listed on the interRAI-AL 
 
Increasing frailty, as measured by the Full FI, was found to be significantly associated (p-value < 
0.05) with limited social relationships, less time spent participating in activities, lower physical 
and cognitive function (ADL and CPS, respectively), higher levels of fatigue, depression, 
aggressive behaviour (ABS), recent falls, higher level of co-occurring chronic conditions, and 
higher  medication number. CHESS health instability was also found to be significantly 
associated with all of these variables, with the exception of strength of social relationships. 
CHSrel frailty was found to be associated with the same variables as Full FI frailty; however, no 
significant associations were observed with cognitive function and aggressive behaviour, while 
the association with higher number of medications was less significant (p-value = 0.07). A 
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significant association was observed between number of hospitalizations in the past year and 
frailty as measured by CHSrel (p-value = 0.0003), but not by the Full FI or CHESS. 
 
Table 5.2.1b. Baseline Characteristics of DAL Residents by Frailty Status [Full FI] 
  Full FI Frailty; % of Row Total (n)  
 Total % (n) Not frail Pre-frail Frail p value 
 1089 33.6 (366) 38.9 (424) 27.5 (299)  
Sociodemographic and Social Well-
being 
     
Age, yr      
 Mean ± SD 84.9 ± 7.3 84.0 ± 7.7 85.0 ± 7.4 86.0 ± 6.6 0.0015 
 65-79 25.0 (272) 41.2 (112) 38.6 (105) 20.2 (55) 0.0141 
 80-85 26.2 (285) 33.0 (94) 35.8 (102) 31.2 (89)  
 86-89 22.7 (247) 28.7 (71) 42.9 (106) 28.3 (70)  
 ≥90 26.2 (285) 31.2 (89) 39.0 (111) 29.8 (85)  
Sex      
 Male 23.3 (254) 33.5 (85) 42.1 (107) 24.4 (62) 0.3700 
 Female 76.7 (835) 33.7 (281) 38.0 (317) 28.4 (237)  
Marital Status      
 Widowed 71.4 (778) 34.3 (267) 37.7 (293) 28.0 (218) 0.0743 
 Married or with a partner 14.6 (159) 27.0 (43) 40.9 (65) 32.1 (51)  
 Never married, separated, or 
divorced 
14.0 (152) 36.8 (56) 43.4 (66) 19.7 (30)  
Strength of Social Relationships 
ǁ
      
 Moderate to high (3-5) 81.5 (888) 38.1 (338) 40.0 (355) 22.0 (195) <0.0001 
 Low to none (0-2) 18.5 (201) 13.9 (28) 34.3 (69) 51.7 (104)  
Time Involved in Activities
 ǂ
      
 Most (> 2/3 time) 14.5 (158) 63.9 (101) 30.4 (48) 5.7 (9) <0.0001 
 Some (1/3 to 2/3 time) 38.9 (424) 39.9 (169) 42.2 (179) 17.9 (76)  
 Little to none (< 1/3 time) 46.6 (507) 18.9 (96) 38.9 (197) 42.2 (214)  
Health and Functional Status      
Cognition (CPS score)      
 Intact to borderline intact (0-1) 40.1 (437) 52.2 (228) 39.8 (174) 8.0 (35) <0.0001 
 Mild Impairment (2) 31.4 (342) 31.3 (107) 42.7 (146) 26.0 (89)  
 Moderate to severe impairment 
(≥ 3) 
28.5 (310) 10.0 (31) 33.6 (104) 56.4 (175)  
Activities of Daily Living (ADL score)      
 Independent or supervision 
required (0-1) 
59.4 (647) 50.4 (326) 39.1 (253) 10.5 (68) <0.0001 
 Limited impairment (2) 12.3 (134) 15.7 (21) 46.3 (62) 38.1 (51)  
 Extensive supervision required 
or dependent (≥ 3) 
28.3 (308) 6.2 (19) 35.4 (109) 58.4 (180)  
Fatigue (inability to complete ADL in 
past 3 days due to diminished energy) 
     
 None 40.6 (442) 48.4 (214) 36.4 (161) 15.2 (67) <0.0001 
 Minimal 43.2 (470) 30.2 (142) 42.6 (200) 27.2 (128)  
 Moderate to Severe 16.2 (177) 5.6 (10) 35.6 (63) 58.8 (104)  
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  Full FI Frailty; % of Row Total (n)  
 Total % (n) Not frail Pre-frail Frail p value 
 1089 33.6 (366) 38.9 (424) 27.5 (299)  
Falls CAP      
 None 71.6 (780) 40.0 (312) 39.1 (305) 20.9 (163) <0.0001 
 ≥1 falls/ 90 days 28.4 (309) 17.5 (54) 38.5 (119) 44.0 (136)  
Depressive Symptoms (DRS score)     <0.0001 
 No (<3) 80.8 (880) 39.9 (351) 39.9 (351) 20.2 (178)  
 Yes (≥3) 19.2 (209) 7.2 (15) 34.9 (73) 57.9 (121)  
Aggressive Behaviour (ABS Score) 
ɸ
      
 None (0) 70.8 (771) 38.8 (299) 41.0 (316) 20.2 (156) <0.0001 
 Moderate (1-2) 16.8 (183) 27.9 (51) 37.2 (68) 35.0 (64)  
 Severe to very severe (≥3) 12.4 (135) 11.9 (16) 29.6 (40) 58.5 (79)  
No. of chronic conditions Ɏ      
 Mean ± SD 4.6 ± 2.0 3.8 ± 1.6 4.8 ± 1.9 5.5 ± 2.1 <0.0001 
 0-3 30.6 (333) 52.9 (176) 32.7 (109) 14.4 (48) <0.0001 
 4-5 37.3 (406) 32.5 (132) 40.9 (166) 26.6 (108)  
 ≥6 32.1 (350) 16.6 (58) 42.6 (149) 40.9 (143)  
No. of medications      
 Mean ± SD 8.3 ± 3.7 7.7 ± 3.4 8.6 ± 3.9 8.7 ± 3.6 0.0002 
 0-6 33.1 (360) 39.7 (143) 35.6 (128) 24.7 (89) 0.0039 
 7-8 21.6 (235) 38.3 (90) 34.9 (82) 26.8 (63)  
 9-10 20.2 (220) 28.6 (63) 41.8 (92) 29.6 (65)  
 ≥11 25.2 (274) 25.6 (70) 44.5 (122) 29.9 (82)  
No. of inpatient hospital admissions in 
past year (n=1,066) 
     
 0 62.2 (663) 36.4 (241) 38.0 (252) 25.6 (170) 0.3622 
 1 23.8 (254) 31.9 (81) 38.6 (98) 29.5 (75)  
 ≥2 14.0 (149) 28.9 (43) 41.6 (62) 29.5 (44)  
Abbreviations: DAL=Designated Assisted Living; Full FI=Full (85-item) Frailty Index; CPS=Cognitive Performance Scale; 
CAP=Clinical Assessment Protocol; DRS=Depression Rating Scale; ABS=Aggressive Behaviour Scale; SD=Standard 
Deviation 
ǁ Social relationships based on a summary score of items assessing whether the resident was close to someone in the facility, 
had a strong or supportive relationship with the family, participated in social activities of long-standing interest, and visited or 
had other interactions with at least one long-standing social relation or family member in the past week. 
ǂ Activity involvement reflects time when the person was awake and not receiving treatments or ADL care. 
ɸ ABS: a summary scale of 4 behaviours (verbal abuse, physical abuse, socially inappropriate or disruptive, resists care), with 
higher scores indicating a greater number and frequency of behavioural issues 
Ɏ Based on the sum of diagnoses existing out of 49 chronic conditions listed on the interRAI-AL 
 
When considering continuous measures, mean number of comorbid diagnoses and mean 
medication number were each significantly higher with increasing vulnerability level in CHSrel 
(F = 16.3, p-value < 0.0001; F = 6.4, p-value = 0.002, respectively), Full FI (F = 76.4,  p-value < 
0.0001; F = 8.6,  p-value = 0.0002,  respectively), and CHESS (F = 12.2,  p-value < 0.0001; F = 
8.5, p-value = 0.0002,  respectively). 
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Table 5.2.1c. Baseline Characteristics of DAL Residents by Frailty Status [CHESS] 
  CHESS Frailty; % of Row Total (n)  
 Total % (n) Not frail Pre-frail Frail p value 
 1089 46.2 (503) 29.4 (320) 24.4 (266)  
Sociodemographic and Social Well-
being 
     
Age, yr      
 Mean ± SD 84.9 ± 7.3 84.6 ± 7.5 84.9 ± 7.2 85.5 ± 7.1 0.3439 
 65-79 25.0 (272) 49.3 (134) 29.8 (81) 21.0 (57) 0.8024 
 80-85 26.2 (285) 43.9 (125) 30.2 (86) 26.0 (74)  
 86-89 22.7 (247) 44.9 (111) 29.6 (73) 25.5 (63)  
 ≥90 26.2 (285)     
Sex      
 Male 23.3 (254) 44.1 (112) 32.3 (82) 23.6 (60) 0.5093 
 Female 76.7 (835) 46.8 (391) 28.5 (238) 24.7 (206)  
Marital Status      
 Widowed 71.4 (778) 47.6 (370) 28.4 (221) 24.0 (187) 0.3570 
 Married or with a partner 14.6 (159) 40.3 (64) 30.8 (49) 28.9 (46)  
 Never married, separated, or 
divorced 
14.0 (152) 45.4 (69) 32.9 (50) 21.7 (33)  
Strength of Social Relationships
 ǁ
      
 Moderate to high (3-5) 81.5 (888) 46.4 (412) 30.1 (267) 23.5 (209) 0.3060 
 Low to none (0-2) 18.5 (201) 45.3 (91) 26.4 (53) 28.4 (57)  
Time Involved in Activities 
ǂ
      
 Most (> 2/3 time) 14.5 (158) 53.2 (84) 31.0 (49) 15.8 (25) <0.0001 
 Some (1/3 to 2/3 time) 38.9 (424) 51.9 (220) 30.4 (129) 17.7 (75)  
 Little to none (< 1/3 time) 46.6 (507) 39.3 (199) 28.0 (142) 32.7 (166)  
Health and Functional Status      
Cognition (CPS score)      
 Intact to borderline intact (0-1) 40.1 (437) 49.2 (215) 31.1 (136) 19.7 (86) <0.0001 
 Mild Impairment (2) 31.4 (342) 50.9 (174) 28.6 (98) 20.5 (70)  
 Moderate to severe impairment 
(≥ 3) 
28.5 (310) 36.8 (114) 27.7 (86) 35.5 (110)  
Activities of Daily Living (ADL score)      
 Independent or supervision 
required (0-1) 
59.4 (647) 53.9 (349) 30.6 (198) 15.5 (100) <0.0001 
 Limited impairment (2) 12.3 (134) 47.0 (63) 22.4 (30) 30.6 (41)  
 Extensive supervision required 
or dependent (≥ 3) 
28.3 (308) 29.5 (91) 29.9 (92) 40.6 (125)  
Fatigue (inability to complete ADL in 
past 3 days due to diminished energy) 
     
 None 40.6 (442) 61.3 (271) 27.2 (120) 11.5 (51) <0.0001 
 Minimal 43.2 (470) 41.3 (194) 33.2 (156) 25.5 (120)  
 Moderate to Severe 16.2 (177) 21.5 (38) 24.9 (44) 53.7 (95)  
Falls CAP      
 None 71.6 (780) 51.1 (399) 29.0 (226) 19.9 (155) <0.0001 
 ≥1 falls/ 90 days 28.4 (309) 33.7 (104) 30.4 (94) 35.9 (111)  
Depressive Symptoms (DRS score)      
 No (<3) 80.8 (880) 49.7 (437) 29.2 (257) 21.2 (186) <0.0001 
 Yes (≥3) 19.2 (209) 31.6 (66) 30.1 (63) 38.3 (80)  
Aggressive Behaviour (ABS Score) 
ɸ
      
 None (0) 70.8 (771) 47.5 (366) 30.5 (235) 22.0 (170) 0.0058 
 Moderate (1-2) 16.8 (183) 48.1 (88) 26.2 (48) 25.7 (47)  
 Severe to very severe (≥3) 12.4 (135) 36.3 (49) 27.4 (37) 36.3 (49)  
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  CHESS Frailty; % of Row Total (n)  
 Total % (n) Not frail Pre-frail Frail p value 
 1089 46.2 (503) 29.4 (320) 24.4 (266)  
No. of chronic conditions Ɏ      
 Mean ± SD 4.6 ± 2.0 4.4 ± 1.9 4.6 ± 2.0 5.1 ± 1.9 <0.0001 
 0-3 30.6 (333) 55.3 (184) 29.4 (98) 15.3 (51) <0.0001 
 4-5 37.3 (406) 43.3 (176) 30.1 (122) 26.6 (108)  
 ≥6 32.1 (350)     
No. of medications      
 Mean ± SD 8.3 ± 3.7 7.9 ± 3.5 8.4 ± 3.6 9.0 ± 3.9 0.0002 
 0-6 33.1 (360) 49.4 (178) 29.7 (107) 20.8 (75) 0.0050 
 7-8 21.6 (235) 54.5 (128) 24.7 (58) 20.8 (49)  
 9-10 20.2 (220) 41.8 (92) 30.0 (66) 28.2 (62)  
 ≥11 25.2 (274) 38.3 (105) 32.5 (89) 29.2 (80)  
No. of inpatient hospital admissions in 
past year (n=1,066) 
     
 0 62.2 (663) 48.3 (320) 28.4 (188) 23.4 (155) 0.2382 
 1 23.8 (254) 46.8 (119) 28.0 (71) 25.2 (64)  
 ≥2 14.0 (149) 38.3 (57) 35.6 (53) 26.2 (39)  
Abbreviations: DAL=Designated Assisted Living; CHESS= Changes in Health, End-Stage Disease, Signs, and Symptoms 
Scale; CPS=Cognitive Performance Scale; CAP=Clinical Assessment Protocol; DRS=Depression Rating Scale; 
ABS=Aggressive Behaviour Scale; SD=Standard Deviation 
ǁ Social relationships based on a summary score of items assessing whether the resident was close to someone in the facility, 
had a strong or supportive relationship with the family, participated in social activities of long-standing interest, and visited or 
had other interactions with at least one long-standing social relation or family member in the past week. 
ǂ Activity involvement reflects time when the person was awake and not receiving treatments or ADL care. 
ɸ ABS: a summary scale of 4 behaviours (verbal abuse, physical abuse, socially inappropriate or disruptive, resists care), with 
higher scores indicating a greater number and frequency of behavioural issues 
Ɏ Based on the sum of diagnoses existing out of 49 chronic conditions listed on the interRAI-AL 
5.2.2 Frailty, Depression and Dementia 
Each of the frailty measures was explored with depression (DRS score of 3+) and dementia 
(diagnosis) in order to determine the extent to which these two conditions were found to coexist 
with being frail within DAL residents. Venn diagrams (presented in Figure 5.2.2a) illustrate the 
overlap between depression, dementia and frail status defined by each of the frailty criteria. The 
findings from the Venn diagrams are summarized in Table 5.2.2. 
The Armstrong FI, which identified the highest number of residents as frail (n = 510), also 
identified the highest proportion of residents as having all three conditions (10.3%), when 
compared to the other frailty criteria. The frailty measure that identified the smallest number of 
residents as frail (n = 182) was the CHSrel measure, which identified 3.4% of participants as 
having frailty, depression and dementia concurrently.  
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Figure 5.2.2a. Frailty,* Dementia, Depression Overlap by selected Frailty Measure Among DAL Residents 
(n=946)† 
A. CHSabs Frailty Measure; B. CHSrel Frailty Measure; C. Full Frailty Index; D. Armstrong Frailty Index; E. CHESS Frailty 
*Note: Only those subjects classified as frail were included in these diagrams; pre-frail subjects were classified with non-frail 
(robust) subjects 
†based on n=946 for all measures (common denominator based on missing data for CHS for 143/1089 subjects) 
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Table 5.2.2 Frailty, Dementia, Depression Overlap by Selected Frailty Measures Among DAL 
Residents (n=946)
†
 
 Frailty Measure* 
Combinations of Frail, 
Dementia, Depression 
Characteristics 
CHS absolute 
cut-points
†
 
 % (n) %§ 
CHS relative 
cut-points
† 
 % (n) %§ 
Full Frailty 
Index
† 
 % (n) %§ 
Armstrong 
Frailty Index
† 
% (n) %§ 
CHESS
† 
 
 % (n) %§ 
Frail + Dementia + Depression  7.1 (67) 8.8  3.4 (32) 4.9  7.5 (71) 11.6 10.3 (97) 13.0  4.4 (42) 6.5 
Frail + Dementia  18.2 (172) 22.5  6.0 (57) 8.7  10.3 (97) 15.8 22.3 (211) 28.3  9.0 (85) 13.1 
Frail + Depression  3.2 (30) 3.9  1.8 (17) 2.6  1.8 (17) 2.8  3.8 (36) 4.8  1.7 (16) 2.5 
Dementia + Depression  5.1 (48) 6.3  8.8 (83) 12.7  4.7 (44) 7.2  1.9 (18) 2.4  7.7 (73) 11.2 
Frail only  19.6 (185) 24.2  8.0 (76) 11.6  3.7 (35) 5.7 17.6 (166) 22.3  7.6 (72) 11.1 
Dementia only  25.7 (243) 31.8  37.8 (358) 54.7  33.6 (318) 51.8 21.6 (204) 27.4 34.9 (330) 50.7 
Depression only  2.0 (19) 2.5  3.4 (32) 4.9  3.4 (32) 5.2  1.4 (13) 1.7  3.5 (33) 5.1 
None of 3  19.2 (182)  30.8 (291)  35.1 (332) 21.3 (201) 31.2 (295) 
*Note: In above table, pre-frail subjects classified with non-frail (robust) subjects 
†based on n=946 for all measures (common denominator based on missing data for CHS for 143/1089 subjects) 
§ % distribution among those with 1 or more of the 3 characteristics 
 
When frailty was defined by the Full FI, compared to the other frailty criteria, the smallest 
proportion of participants were classified as only having frailty (3.7%), and not the other two 
conditions. The CHSabs had the highest proportion of residents classified as only frail (19.6%), 
followed by the Armstrong FI (17.6%). Of the residents identified as frail by each frailty index, 
those identified as frail by the Full FI most frequently included residents with at least one of the 
other two conditions (84.1% (185/220)). When identifying frailty by the Armstrong FI or 
CHESS, roughly 67% of frail individuals also had dementia and/or depression (344/510; 
143/215, respectively), compared to roughly 60% of frail individuals identified by either CHS 
measure (269/454 for CHSabs; 106/182 for CHSrel).  
Figure 5.2.2b displays the proportion of those with and without dementia and depression who 
were identified as frail by each of the five frailty measures (the sample is restricted to the 946 
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residents for whom all frailty criteria could be measured). Each frailty measure identified a 
higher proportion of depressed residents than non-depressed residents as being frail, whereas 
only three of the five measures (Full FI, Armstrong FI, and CHESS) identified more residents 
with dementia as frail, compared to residents without dementia. 
Of all of the frailty measures considered, the Armstrong FI identified the greatest proportion 
(81.1%) of depressed individuals as frail (133/164) and the greatest proportion of residents with 
dementia (58.1%) as frail (308/530). The CHSrel, in contrast, identified the lowest proportion of 
depressed individuals (29.9%) as frail (49/164) and the lowest proportion of residents with 
dementia (16.8%) as frail (89/530).  
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Figure 5.2.2b. Proportion of DAL Residents identified as Frail* by selected Frailty Measure†, for 
Total Cohort and among those with and without Dementia or Depression 
*Note: In above table, pre-frail subjects classified with non-frail (robust) subjects 
†based on n=946 for all measures (common denominator based on missing data for CHS for 143/1089 subjects) 
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5.3 Objective 1b: Examine HR/Antipsychotic Medication Use by Resident Level 
Characteristics and by Frailty Status, as identified by 3 measures of vulnerability 
5.3.1 HR/Antipsychotic Medication Use and Resident Characteristics 
Observed associations between resident-level characteristics and use of HR medication classes 
are displayed in table 5.3.1a. Table 5.3.1b shows results for the association between resident-
level characteristics and overall antipsychotic medication use, as well as atypical antipsychotic 
use, specifically. The distribution in use of each of the HR/antipsychotic medication classes by 
total number of medications used is shown in figure 5.3.1. 
5.3.1.1 Oral Anticoagulant and Oral Antiplatelet Use (Table 5.3.1a) 
Use of oral anticoagulant agents and use of oral antiplatelet agents were not significantly 
associated with age, but were both found to be more common in males than in females (p-value = 
0.008; p-value = 0.038,  respectively). Prevalence of oral anticoagulant use was higher in those 
who were married or were living with a partner (p-value = 0.002) (compared to widowed, never 
married, separated or divorced residents), whereas no significant associations were observed 
between oral antiplatelet use and marital status.  
Neither oral anticoagulant use nor oral antiplatelet use were found to be significantly associated 
with strength of social relationships, time involved in activities, CPS score, ADL impairment, 
fatigue, DRS score, or falls in the last 90 days. Use of oral anticoagulants was significantly more 
prevalent in those without aggressive behaviour (p-value = 0.022) when compared to those with 
moderate to very severe aggressive behaviour (ABS score ≥1). No association was observed 
between ABS score and oral antiplatelet use.  
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Table 5.3.1a. Baseline Sociodemographic, Health and Functional Characteristics Associated with 
High-risk Medication Use among DAL Residents (n=1,089). 
  Use of ≥1 Medications from Given Medication Class;  
% of Row Total (n) † 
 Total  
% (n) 
Oral 
Anticoagulants 
Oral 
Antiplatelet 
Oral 
Antidiabetic 
Insulins 
 1089 15.2 (166) 46.3 (504) 14.4 (157) 5.8 (63) 
Sociodemographic and Social 
Well-being 
     
Age, yr      
 Mean ± SD 84.9 ± 7.3 84.7 ± 6.8 84.6 ± 7.4 83.2 ± 7.6 81.5 ± 7.1 
 65-79 25.0 (272) 14.3 (39) 49.3 (134) 20.6 (56)* 10.3 (28)* 
 80-85 26.2 (285) 17.2 (49) 42.8 (122) 13.0 (37)* 5.3 (15)* 
 86-89 22.7 (247) 16.2 (40) 49.4 (122) 12.6 (31)* 4.5 (11)* 
 ≥90 26.2 (285) 13.3 (38) 44.2 (126) 11.6 (33)* 3.2 (9)* 
Sex      
 Male 23.3 (254) 20.5 (52)* 52.0 (132)* 20.1 (51)* 7.5 (19) 
 Female 76.7 (835) 13.7 (114)* 44.6 (372)* 12.7 (106)* 5.3 (44) 
Marital Status      
 Widowed 71.4 (778) 13.9 (108)* 45.6 (355) 13.2 (103) 5.3 (41)** 
 Married or with a partner 14.6 (159) 24.5 (39)* 44.7 (71) 15.7 (25) 4.4 (7)** 
 Never married, separated, 
or divorced 
14.0 (152) 12.5 (19)* 51.3 (78) 19.1 (29) 9.9 (15)** 
Strength Social Relationships
 ǁ
      
 Moderate to high (3-5) 81.5 (888) 16.0 (142) 46.7 (415) 13.5 (120)** 5.7 (51) 
 Low to none (0-2) 18.5 (201) 11.9 (24) 44.3 (89) 18.4 (37)** 6.0 (12) 
Time Involved in Activities 
ǂ
      
 Most (> 2/3 time) 14.5 (158) 17.1 (27) 43.7 (69) 13.9 (22) 5.7 (9) 
 Some (1/3 to 2/3 time) 38.9 (424) 16.5 (70) 48.4 (205) 15.6 (66) 5.2 (22) 
 Little to none (< 1/3 time) 46.6 (507) 13.6 (69) 45.4 (230) 13.6 (69) 6.3 (32) 
Health and Functional Status      
Cognition (CPS score)      
 Intact to borderline intact 
(0-1) 
40.1 (437)  16.7 (73) 48.3 (211) 18.1 (79)* 7.3 (32) 
 Mild impairment (2) 31.4 (342) 17.0 (58) 47.4 (162) 13.7 (47)* 4.1 (14) 
 Moderate to severe 
impairment (≥ 3) 
28.5 (310) 11.3 (35) 42.3 (131) 10.0 (31)* 5.5 (17) 
Activities of Daily Living 
(ADL score) 
     
 Independent or supervision 
required (0-1) 
59.4 (647) 13.9 (90) 46.7 (302) 15.0 (97) 5.4 (35) 
 Limited impairment (2) 12.3 (134) 14.9 (20) 49.3 (66) 12.3 (134) 9.0 (12) 
 Extensive supervision 
required or dependent (≥ 
3) 
28.3 (308) 18.2 (56) 44.2 (136) 28.3 (308) 5.2 (16) 
Fatigue (inability to complete 
ADL in past 3 days) 
     
 None 40.6 (442) 14.3 (63) 47.5 (210) 14.5 (64) 5.2 (23) 
 Minimal  43.2 (470) 15.3 (72) 44.9 (211) 13.4 (63) 5.1 (24) 
 Moderate to Severe 16.3 (177) 17.5 (31) 46.9 (83) 17.0 (30) 9.0 (16) 
Falls CAP      
 None 71.6 (780) 14.2 (111) 45.5 (355) 13.6 (106) 5.5 (43) 
 ≥1 falls/ 90 days 28.4 (309) 17.8 (55) 48.2 (149) 16.5 (51) 6.5 (20) 
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  Use of ≥1 Medications from Given Medication Class;  
% of Row Total (n) † 
 Total  
% (n) 
Oral 
Anticoagulants 
Oral 
Antiplatelet 
Oral 
Antidiabetic 
Insulins 
 1089 15.2 (166) 46.3 (504) 14.4 (157) 5.8 (63) 
Depressive Symptoms (DRS 
score) 
     
 No (<3) 80.8 (880) 15.8 (139) 46.5 (409) 15.2 (134) 6.4 (56)** 
 Yes (≥3) 19.2 (209) 12.9 (27) 45.5 (95) 11.0 (23) 3.4 (7)** 
Aggressive Behaviour (ABS 
Score) 
ɸ 
     
 None (0) 70.8 (771) 17.4 (134)* 46.2 (356) 14.3 (110) 6.0 (46) 
 Moderate (1-2) 16.8 (183) 9.3 (17)* 51.4 (94) 17.5 (32) 7.1 (13) 
 Severe to very severe (≥3) 12.4 (135) 11.1 (15)* 40.0 (54) 11.1 (15) 3.0 (4) 
No. of chronic conditions Ɏ      
 Mean ± SD 4.6 ± 2.0 5.3 ± 1.8 4.8 ± 1.9 5.4 ± 2.1 5.3 ± 4.9 
 0-3 30.6 (333) 7.8 (26)* 40.2 (134)* 9.9 (33)* 2.1 (7)* 
 4-5 37.3 (406) 15.3 (62)* 50.7 (206)* 12.3 (50)* 7.1 (29)* 
 ≥6 32.1 (350) 22.3 (78)* 46.9 (164)* 21.2 (350)* 7.7 (27)* 
No. of medications      
 Mean ± SD 8.3 ± 3.7 9.5 ± 3.5 9.4 ± 3.6 10.4 ± 3.8 10.7 ± 4.0 
 0-6 33.1 (360) 9.2 (33)* 32.5 (117)* 7.8 (28)* 2.5 (9)* 
 7-8 21.6 (235) 14.0 (33)* 44.7 (105)* 11.1 (26)* 4.3 (10)* 
 9-10 20.2 (220) 19.1 (42)* 47.7 (105)* 14.1 (31)* 6.8 (15)* 
 ≥11 25.2 (274) 21.2 (58)* 64.6 (177)* 26.3 (72)* 10.6 (29)* 
No. of inpatient hospital 
admissions in past year 
(n=1,066) 
     
 0 62.2 (663) 12.7 (84)* 46.3 (307) 13.9 (92) 5.0 (33) 
 1 23.8 (254) 17.7 (45)* 42.9 (109) 13.0 (33) 6.7 (17) 
 ≥2 14.0 (149) 23.5 (35)* 52.3 (78) 20.1 (30) 8.1 (12) 
Abbreviations: DAL=Designated Assisted Living; CPS=Cognitive Performance Scale; CAP=Clinical Assessment Protocol; 
DRS=Depression Rating Scale; ABS=Aggressive Behaviour Scale; SD=Standard Deviation 
†Row percentage values represent the percentage of residents within each category using one or more medication from the 
specified class 
*p-value≤0.05 for the use of one or more medications from the specified class when compared to use of no medications from the 
specified class 
**p-value≤0.10 for the use of one or more medications from the specified class when compared to use of no medications from the 
specified class 
ǁ Social relationships based on a summary score of items assessing whether the resident was close to someone in the facility, had 
a strong or supportive relationship with the family, participated in social activities of long-standing interest, and visited or had 
other interactions with at least one long-standing social relation or family member in the past week. 
ǂ Activity involvement reflects time when the person was awake and not receiving treatments or ADL care. 
ɸ ABS: a summary scale of 4 behaviours (verbal abuse, physical abuse, socially inappropriate or disruptive, resists care), with 
higher scores indicating a greater number and frequency of behavioural issues 
Ɏ Based on the sum of diagnoses existing out of 49 chronic conditions listed on the interRAI-AL 
 
Prevalence of oral anticoagulant use increased with each increasing level of co-occurring 
morbidities (p-value < 0.0001), and prevalence of oral antiplatelet use was significantly lower 
among those with fewer than 4 chronic conditions, compared to those with 4 or more comorbid 
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diagnoses (p-value = 0.02). Oral antiplatelet use and oral anticoagulant use were both more 
prevalent with each increasing level of medication number (p-value < 0.0001). 
Prevalence of oral anticoagulant use was significantly associated with increasing number of 
hospital admissions in the past year (p-value = 0.0021), whereas no significant association was 
observed between use of oral antiplatelet agents and previous hospitalizations. 
5.3.1.2 Oral Antidiabetic and Insulin Use (Table 5.3.1a) 
Use of oral antidiabetic agents was found to be significantly more prevalent in men compared to 
women (p-value = 0.003), while no significant association with sex was observed for the use of 
insulin. Use of oral antidiabetic agents and use of insulin were both more prevalent among those 
aged 65-79, compared with older residents (p-value = 0.01; p-value = 0.002, respectively). Oral 
antidiabetic use was not associated with marital status, while use of insulin was more prevalent 
among those never married, separated or divorced compared to married or widowed residents (p-
value = 0.061).  
A higher prevalence of oral antidiabetic use was observed in those without strong social 
relationships compared to those with moderate to high strength of social relationships (p-
value=0.074). Use of oral antidiabetic agents was significantly more common in those with intact 
to borderline intact cognition (CPS score 0-1) compared to those with a higher level of 
impairment (CPS Score ≥2) (p-value = 0.007), whereas no association was observed between 
insulin use and CPS score. Insulin use was found to be less prevalent in those with depressive 
symptoms (DRS score ≥3) compared to those without (DRS score<3) (p-value=0.093), but no 
such association was observed for use of oral antidiabetic agents. Neither oral antidiabetic use 
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nor insulin use were found to be significantly associated with time involved in activities, ADL 
dependency, fatigue, falls in the last 90 days, ABS score, or previous hospital admissions.  
Increasing prevalence of both oral antidiabetic use and insulin use were observed with each 
increasing level of comorbid diagnoses (p-value < 0.0001; p-value = 0.002, respectively) and 
medication number (p-value < 0.0001; p-value = 0.0002, respectively). 
5.3.1.3 Antipsychotic Use (Table 5.3.1b) 
No significant associations were observed between overall use of antipsychotics and age or sex, 
whereas use of atypical antipsychotic agents specifically was found to decrease with increasing 
age (p-value = 0.0888). For all other covariates considered, significant trends observed for 
atypical antipsychotic use were similar to the trends for overall antipsychotic use. Use of 
antipsychotic agents was found to be significantly more prevalent in those who were never 
married, separated or divorced compared to married or widowed residents (p-value = 0.009).  
Antipsychotic use was also found to be more prevalent in those lacking strong social 
relationships compared to those with moderate to high strength of social relationships (p-value < 
0.0001) and in those with decreasing levels of active time (p-value = 0.0002).  
Use of antipsychotics was significantly associated with increasing levels of cognitive impairment 
(CPS score) (p-value < 0.0001) and was significantly more prevalent in those requiring any level 
of assistance with ADLs (ADL score ≥1), compared to those who were independent in ADLs 
(ADL score 0) (p-value < 0.0001). Prevalence of antipsychotic use was also found to be more 
common in those with symptoms of depression (DRS score ≥3) compared to those without (DRS 
score <3) (p-value < 0.0001), and was observed to increase with each increasing level of 
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aggressive behaviour (ABS score) (p-value < 0.0001). Antipsychotic use was not found to be 
associated with fatigue or falls in the last 90 days.  
Table 5.3.1b.  Baseline Sociodemographic, Health and Functional Characteristics Associated 
with Antipsychotic Medication Use among DAL Residents (n=1,089). 
  Use of ≥1 Medications from Given Medication 
Class/Subclass; % of Row Total (n) † 
 Total % (n) Overall Antipsychotic Use Atypical Antipsychotic 
 1089 26.4 (287) 24.9 (271) 
Sociodemographic and Social Well-
being 
   
Age, yr    
 Mean ± SD 84.9 ± 7.3 84.2 ± 7.3 84.2 ± 7.4 
 65-79 25.0 (272) 30.9 (84) 29.4 (80)** 
 80-85 26.2 (285) 27.4 (78) 26.7 (76)** 
 86-89 22.7 (247) 24.7 (61) 21.9 (54)** 
 ≥90 26.2 (285) 22.5 (64) 21.4 (61)** 
Sex    
 Male 23.3 (254) 26.0 (66) 24.0 (61) 
 Female 76.7 (835) 26.5 (221) 25.2 (210) 
Marital Status    
 Widowed 71.4 (778) 25.3 (197)* 23.9 (186)* 
 Married or with a partner 14.6 (159) 22.0 (35)* 20.8 (33)* 
 Never married, separated, or 
divorced 
14.0 (152) 36.2 (55)* 34.2 (52)* 
Strength of Social Relationships 
ǁ
    
 Moderate to high (3-5) 81.5 (888) 23.7 (210)* 22.4 (199)* 
 Low to none (0-2) 18.5 (201) 38.3 (77)* 35.8 (72)* 
Time Involved in Activities 
ǂ
    
 Most (> 2/3 time) 14.5 (158) 17.1 (27)* 15.8 (25)* 
 Some (1/3 to 2/3 time) 38.9 (424) 23.1 (98)* 22.2 (94)* 
 Little to none (< 1/3 time) 46.6 (507) 32.0 (162)* 30.0 (152)* 
Health and Functional Status    
Cognition (CPS score)    
 Intact to borderline intact (0-1) 40.1 (437) 14.4 (63)* 13.7 (60)* 
 Mild Impairment (2) 31.4 (342) 25.4 (87)* 24.0 (82)* 
 Moderate to severe impairment(≥ 3) 28.5 (310) 44.2 (137)* 41.6 (129)* 
Activities of Daily Living (ADL score)    
 Independent or supervision required 
(0-1) 
59.4 (647) 23.3 (151)* 21.9 (142)* 
 Limited impairment (2) 12.3 (134) 32.1 (43)* 29.9 (40)* 
 Extensive supervision required or 
dependent (≥ 3) 
28.3 (308) 30.2 (93)* 28.9 (89)* 
Fatigue (inability to complete ADL in 
past 3 days) 
   
 None 40.6 (442) 28.5 (126) 26.9 (119) 
 Minimal  43.2 (470) 23.6 (111) 21.9 (103) 
 Moderate to Severe 16.2 (177) 28.3 (50) 27.7 (49) 
Falls CAP    
 None 71.6 (780) 26.0 (203) 24.7 (193) 
 ≥1 falls/ 90 days 28.4 (309) 27.2 (84) 25.2 (78) 
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  Use of ≥1 Medications from Given Medication 
Class/Subclass; % of Row Total (n) † 
 Total %(n) Overall Antipsychotic Use Atypical Antipsychotic 
 1089 26.4 (287) 24.9 (271) 
Depressive Symptoms (DRS score)    
 No (<3) 80.8 (880) 22.6 (199)* 21.1 (186)* 
 Yes (≥3) 19.2 (209) 42.1 (88)* 40.7 (85)* 
Aggressive Behaviour (ABS Score) 
ɸ 
   
 None (0) 70.8 (771) 20.2 (156)* 18.7 (144)* 
 Moderate (1-2) 16.8 (183) 34.4 (63)* 33.9 (62)* 
 Severe to very severe (≥3) 12.4 (135) 50.4 (68)* 48.1 (65)* 
No. of chronic conditions Ɏ
 
   
 Mean ± SD 4.6 ± 2.0 4.7 ± 2.2 4.7 ± 2.1 
 0-3 30.6 (333) 30.9 (103)* 27.9 (93)** 
 4-5 37.3 (406) 21.7 (88)* 20.9 (85)** 
 ≥6 32.1 (350) 27.4 (96)* 26.6 (93)** 
No. of medications    
 Mean ± SD 8.3 ± 3.7 8.8 ± 3.5 8.9 ± 3.5 
 0-6 33.1 (360) 21.4 (77)** 19.7 (71)* 
 7-8 21.6 (235) 27.2 (64)** 26.4 (62)* 
 9-10 20.2 (220) 28.6 (63)** 27.3 (60)* 
 ≥11 25.2 (274) 30.3 (83)** 28.5 (78)* 
No. of inpatient hospital admissions in 
past year (n=1,066) 
   
 0 62.2 (663) 26.9 (178)* 24.9 (165)** 
 1 23.8 (254) 28.7 (73)* 27.6 (70)** 
 ≥2 14.0 (149) 18.1 (27)* 18.1 (27)** 
Abbreviations: CPS=Cognitive Performance Scale; CAP=Clinical Assessment Protocol; DRS=Depression Rating 
Scale; ABS=Aggressive Behaviour Scale 
†Row percentage values represent the percentage of residents within each category using one or more medication 
from the specified class/subclass 
*p-value≤0.05 for the use of one or more medications from the specified class when compared to use of no 
medications from the specified class 
**p-value≤0.10 for the use of one or more medications from the specified class when compared to use of no 
medications from the specified class 
ǁ Social relationships based on a summary score of items assessing whether the resident was close to someone in the 
facility, had a strong or supportive relationship with the family, participated in social activities of long-standing 
interest, and visited or had other interactions with at least one long-standing social relation or family member in the 
past week. 
ǂ Activity involvement reflects time when the resident was awake and not receiving treatments or ADL care. 
ɸ ABS: a summary scale of 4 behaviours (verbal abuse, physical abuse, socially inappropriate or disruptive, resists 
care), with higher scores indicating a greater number and frequency of behavioural issues 
Ɏ Based on the sum of diagnoses existing out of 49 chronic conditions listed on the interRAI-AL 
Use of antipsychotics was observed to be most prevalent in those with less than 3 or with more 
than 5 diagnoses (p-value = 0.015) when compared to those with 4 or 5 comorbid diagnoses, 
whereas prevalence was found to increase with each increasing level of medication number (p-
value = 0.059). Prevalence of antipsychotic use was highest among those with one or zero 
hospital admissions in the past year, when compared to those with two or more (p-value=0.049). 
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Of the residents taking antipsychotic agents, 78.4% (225/287) had a dementia diagnosis, and 
roughly 4.9% (14/287) had a schizophrenia diagnosis. In comparison, of the residents not taking 
antipsychotic agents, 50.1% (402/802) had a dementia diagnosis and 0.4% (3/802) were 
diagnosed with schizophrenia. 
 
5.3.2 HR/Antipsychotic Medication Use and Frailty Status (Tables 5.3.2a-c) 
Associations between HR/antipsychotic medication classes and frailty status, as defined by each 
of the three key frailty measures, are shown in table 5.3.2a (CHSrel), table 5.3.2b (Full FI) and 
table 5.3.2c (CHESS). No statistically significant associations were observed between the three 
key frailty criteria and any of the major HR medication classes of interest. Only CHSrel frailty 
was found to have a borderline significant (p-value = 0.069) association with oral antiplatelet 
use, when use of non-ASA antiplatelet agents was examined as a category distinct from use of 
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ASA antiplatelet agents (with or without non-ASA), compared to no use of oral antiplatelet 
agents. In this case CHSrel pre-frail and frail residents were found to have a lower prevalence of 
both non-ASA antiplatelet use and ASA antiplatelet use when compared to robust residents. 
A statistically significant association of a higher prevalence of antipsychotic use was observed 
among those resident who were found to be frail by the Full FI, or at high risk of decline by 
CHESS, when compared to less vulnerable residents (p-value < 0.0001; p-value = 0.029, 
respectively). No significant association was observed between antipsychotic use and frailty as 
classified by the CHSrel criteria. 
Frailty (or health instability), as determined by both the Full FI and CHESS, was also found to be 
significantly associated with the number of distinct medications used by residents (p-value = 
0.004; p-value = 0.005, respectively), while CHSrel frailty showed a borderline significant 
association with medication number (p-value = 0.070). 
Appendix G shows the baseline distribution of selected diagnoses (associated with use of these 
medication classes) and the association with frailty status, as measured by CHSrel (table a), Full 
FI (table b) and CHESS (table c). In all cases, the prevalence of diagnoses possibly indicating 
use of the drug classes of interest (Appendix G, tables a-c) was much higher than the prevalence 
of use of the corresponding medication classes (Tables 5.3.2a-c).  Further, the selected diagnoses 
were found to be significantly associated with frailty status, according to the Full FI (Appendix 
G, table b). Examining the other measures of frailty status (CHSrel and CHESS), diagnoses 
associated with the use of oral anticoagulants, oral antidiabetics, combined use of insulin/oral 
antidiabetics, and antipsychotics (CHESS only) were found to be associated with frailty status 
Appendix G, tables a and c). 
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Table 5.3.2a. Baseline Distribution of High-risk / Antipsychotic Medication Use by Frailty 
Status [CHSrel Frailty Measure] among DAL Residents 
 Total 
% (n) 
CHSrel Frailty; % of column total (n)  
Robust Pre-Frail Frail p-value 
 946 25.8 (244) 55.0 (520) 19.2 (182)  
Oral Anticoagulant Use      
 No anticoagulant use 84.3 (797) 88.1 (215) 83.3 (433) 81.9 (149) 0.1422 
 Use of 1+ anticoagulant(s) 15.8 (149) 11.9 (29) 16.7 (87) 18.1 (33)  
Oral Antiplatelet Use      
 No antiplatelet use 53.3 (504) 50.4 (123) 55.2 (287) 51.7 (94) 0.4135 
 Use of 1+ antiplatelet(s) 46.7 (442) 49.6 (121) 44.8 (233) 48.4 (88)  
 Use of non-ASA 
antiplatelet only 
4.7 (44) 18.2 (8) 4.0 (21) 8.2 (15) 0.0691 
 Use of 1+ ASA 
(with/without non-ASA) 
antiplatelet(s) 
42.1 (398) 46.3 (113) 40.8 (212) 40.1 (73)  
Oral Antidiabetic Use      
 No oral antidiabetic use 84.3 (797) 86.5 (211) 84.6 (440) 80.2 (146) 0.2028 
 Use of 1+ oral antidiabetic(s) 15.8 (149) 13.5 (33) 15.4 (80) 19.8 (36)  
Insulin Use      
 No insulin use 94.1 (890) 94.3 (230) 93.5 (486) 95.6 (174) 0.5680 
 Use of 1+ insulin(s) 5.9 (56) 5.7 (14) 6.5 (34) 4.4 (8)  
Insulin/Sulfonylurea Use      
 No insulin or sulfonylurea use 88.2 (834) 88.1 (215) 87.7 (456) 89.6 (163) 0.7979 
 Use of insulin and/or 
sulfonylurea 
11.8 (112) 11.9 (29) 12.3 (64) 10.4 (19)  
Any Diabetic Drug Use      
 No insulin or oral antidiabetic 
use 
80.8 (764) 82.0 (200) 81.1 (422) 78.0 (142) 0.5602 
 Use of insulin and/or oral 
antidiabetic(s) 
19.2 (182) 18.0 (44) 18.9 (98) 22.0 (40)  
No. of Separate High-risk 
Medication Classes Used Ɏ 
     
 No use of any of the 4 HR 
drug classes 
35.5 (336) 34.4 (84) 36.9 (192) 33.0 (60) 0.4832 
 Use of 1 HR drug class 47.5 (449) 51.2 (125) 45.2 (235) 48.9 (89)  
 Use of 2+ HR drug classes 17.0 (161) 14.3 (35) 17.9 (93) 18.1 (33)  
Antipsychotic Agents      
 No antipsychotic use 75.7 (716) 75.8 (185) 76.5 (398) 73.1 (133) 0.6437 
 Use of 1+ antipsychotic(s) 24.3 (230) 24.2 (59) 23.5 (122) 26.9 (49)  
No. of Medications      
 0-6 32.6 (308) 36.9 (90) 32.5 (169) 26.9 (49) 0.0696 
 7 or 8 21.9 (207) 23.8 (58) 22.3 (116) 18.1 (33)  
 9 or 10 20.4 (193) 19.3 (47) 20.2 (105) 22.5 (41)  
 ≥11 25.2 (238) 20.1 (49) 25.0 (130) 32.4 (59)  
Abbreviations: DAL=Designated Assisted Living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points) 
Ɏ  The High-Risk Medication Classes variable is a measure of the number of distinct medication classes used (i.e. 1 HR 
medication class is  any number of medications from only 1 of the 4 HR classes) 
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Table 5.3.2b. Baseline Distribution of High-risk / Antipsychotic Medication Use by Frailty 
Status [Full FI Frailty Measure] among DAL Residents  
 Total 
% (n) 
Full FI Frailty; % of column total (n)  
Robust Pre-Frail Frail p-value 
Overall 1089 33.6 (366) 38.9 (424) 27.5 (299)  
Oral Anticoagulant Use      
 No anticoagulant use 84.8 (923) 86.9 (318) 84.7 (359) 82.3 (246) 0.2577 
 Use of 1+ anticoagulant(s) 15.2 (166) 13.1 (48) 15.3 (65) 17.7 (53)  
Oral Antiplatelet Use      
 No antiplatelet use 53.7 (585) 56.3 (206) 51.4 (218) 53.9 (161) 0.3914 
 Use of 1+ antiplatelet(s) 46.3 (504) 43.7 (160) 48.6 (206) 46.1 (138)  
 Use of non-ASA antiplatelet 
only 
5.0 (54) 3.5 (13) 5.4 (23) 6.0 (18) 0.4393 
 Use of 1+ ASA 
(with/without non-ASA) 
antiplatelet(s) 
41.3 (450) 40.2 (147) 43.2 (183) 40.1 (120)  
Oral Antidiabetic Use      
 No oral antidiabetic use 85.6 (932) 83.9 (307) 86.3 (366) 86.6 (259) 0.5196 
 Use of 1+ oral antidiabetic(s) 14.4 (157) 16.1 (59) 13.7 (58) 13.4 (40)  
Insulin Use      
 No insulin use 94.2 (1026) 95.9 (351) 92.4 (392) 94.6 (283) 0.1092 
 Use of 1+ insulin(s) 5.8 (63) 4.1 (15) 7.5 (32) 5.4 (16)  
Insulin/Sulfonylurea Use      
 No insulin or sulfonylurea use 88.8 (967) 89.9 (329) 87.7 (372) 89.0 (266) 0.6287 
 Use of insulin and/or 
sulfonylurea 
11.2 (122) 10.1 (37) 12.3 (52) 11.0 (33)  
Any Diabetic Drug Use      
 No insulin or oral antidiabetic 
use 
82.1 (894) 81.7 (299) 81.6 (346) 83.3 (249) 0.8211 
 Use of insulin and/or oral 
antidiabetic(s) 
17.9 (195) 18.3 (67) 18.4 (78) 16.7 (50)  
No. of Separate High-risk 
Medication Classes Used Ɏ 
     
 No use of any of the 4 HR 
drug classes 
36.7 (400) 39.3 (144) 35.6 (151) 35.1 (105) 0.5807 
 Use of 1 HR drug class 47.4 (516) 45.6 (167) 46.9 (199) 50.2 (150)  
 Use of 2+ HR drug classes 15.9 (173) 15.0 (55) 17.5 (74) 14.7 (44)  
Antipsychotic Agents      
 No antipsychotic use 73.6 (802) 82.0 (300) 76.6 (325) 59.2 (177) <0.0001 
 Use of 1+ antipsychotic(s) 26.4 (287) 18.0 (66) 23.4 (99) 40.8 (122)  
No. of Medications      
 0-6 33.1 (360) 39.1 (143) 30.2 (128) 29.8 (89) 0.0039 
 7 or 8 21.6 (235) 24.6 (90) 19.3 (82) 21.2 (63)  
 9 or 10 20.2 (220) 17.2 (63) 21.7 (92) 21.7 (65)  
 ≥11 25.2 (274) 19.1 (70) 28.8 (122) 27.4 (82)  
Abbreviations: DAL=Designated Assisted Living; Full FI= Full (86-item) Frailty Index 
Ɏ  The High-Risk Medication Classes variable is a measure of the number of distinct medication classes used (i.e. 1 HR 
medication class is  any number of medications from only 1 of the 4 HR classes) 
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Table 5.3.2c. Baseline Distribution of High-risk / Antipsychotic Medication Use by Frailty 
Status [CHESS Health Instability Measure] among DAL Residents 
 Total 
% (n) 
CHESS Frailty; % of column total (n)  
Robust Pre-Frail Frail p-value 
 1089 46.2 (503) 29.4 (320) 24.4 (266)  
Oral Anticoagulant Use      
 No anticoagulant use 84.8 (923) 85.5 (430) 85.3 (273) 82.7 (23.8) 0.5629 
 Use of 1+ anticoagulant(s) 15.2 (166) 14.5 (73) 14.7 (47) 17.3 (46)  
Oral Antiplatelet Use      
 No antiplatelet use 53.7 (585) 54.3 (273) 53.7 (172) 52.6 (140) 0.9098 
 Use of 1+ antiplatelet(s) 46.3 (504) 45.7 (230) 46.3 (148) 47.4 (126)  
 Use of non-ASA antiplatelet 
only 
5.0 (54) 4.2 (21) 5.0 (16) 6.4 (17) 0.7676 
 Use of 1+ ASA 
(with/without non-ASA) 
antiplatelet(s) 
41.3 (450) 41.5 (209) 41.3 (132) 41.0 (109)  
Oral Antidiabetic Use      
 No oral antidiabetic use 85.6 (932) 85.1 (428) 86.9 (278) 85.0 (226) 0.7352 
 Use of 1+ oral antidiabetic(s) 14.4 (157) 47.8 (75) 13.1 (42) 15.0 (40)  
Insulin Use      
 No insulin use 94.2 (1026) 94.0 (473) 94.1 (301) 94.7 (252) 0.9157 
 Use of 1+ insulin(s) 5.8 (63) 6.0 (30) 5.9 (19) 5.3 (14)  
Insulin/Sulfonylurea Use      
 No insulin or sulfonylurea use 88.8 (967) 88.9 (447) 89.7 (287) 87.6 (233) 0.7245 
 Use of insulin and/or 
sulfonylurea 
11.2 (122) 11.1 (56) 10.3 (33) 12.4 (33)  
Any Diabetic Drug Use      
 No insulin or oral antidiabetic 
use 
82.1 (894) 82.1 (413) 82.5 (264) 81.6 (217) 0.9589 
 Use of insulin and/or oral 
antidiabetic(s) 
17.9 (195) 17.9 (90) 17.5 (56) 18.4 (49)  
No. of Separate High-risk 
Medication Classes Used Ɏ
 
     
 No use of any of the 4 HR 
drug classes 
36.7 (400) 38.2 (192) 36.6 (117) 34.2 (91) 0.7311 
 Use of 1 HR drug class 47.4 (516) 45.3 (228) 48.8 (156) 49.6 (132)  
 Use of 2+ HR drug classes 15.9 (173) 16.5 (83) 14.7 (47) 16.2 (43)  
Antipsychotic Agents      
 No antipsychotic use 73.6 (802) 73.6 (370) 78.1 (250) 68.4 (182) 0.0294 
 Use of 1+ antipsychotic(s) 26.4 (287) 26.4 (133) 21.9 (70) 31.6 (84)  
No. of Medications      
 0-6 33.1 (360) 35.4 (178) 33.4 (107) 28.2 (75) 0.0050 
 7 or 8 21.6 (235) 25.4 (128) 18.1 (58) 18.4 (49)  
 9 or 10 20.2 (220) 18.3 (92) 20.6 (66) 23.3 (62)  
 ≥11 25.2 (274) 20.9 (105) 27.8 (89) 30.1 (80)  
Abbreviations: DAL=Designated Assisted Living; CHESS= Changes in Health, End-stage disease and Signs and Symptoms of 
medical problems scale 
Ɏ  The High-Risk Medication Classes variable is a measure of the number of distinct medication classes used (i.e. 1 HR 
medication class is  any number of medications from only 1 of the 4 HR classes) 
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5.4 Objective 2a: Examine Association between Frailty Status and First Event 
Hospitalization during a 1-year follow-up 
5.4.1 Bivariate Analysis: Resident-level Covariates and Outcome (Table 5.4.1) 
In order to gain insight into covariates relevant to the outcome of interest, chi-square analyses 
were conducted using resident-level correlates found to be associated with hospitalization in the 
literature and previous ACCES publications (see Table 5.4.1). Increased rates of first-event 
hospitalization were found to be significantly associated (p-value < 0.05) with decreased strength 
of social relationships, less time spent engaged in activities, lower levels of cognitive 
impairment, ADL scores greater than 2 (compared to ADL of 2 or lower), greater fatigue, fewer 
depressive symptoms, more chronic conditions, a higher number of medications, and a higher 
number of hospital admissions in the past year. There were also marginally significant 
associations (p-value < 0.1) observed between increased hospitalization and two resident-level 
variables of interest: one or more falls in the past 90 days, and lower levels of aggressive 
behaviour. 
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Table 5.4.1. Distribution of First Event Outcome by Baseline Sociodemographic, Health and 
Functional Characteristics among DAL Residents 
  Outcome; % of row total (n) †  
 Total* % (n) Hospital LTC or death Still in DAL p value 
 1066 38.9 (413) 10.8 (115) 50.3 (534)  
Age, yr      
 Mean ± SD 84.9 ± 7.3 85.2 ± 7.1 86.1 ± 6.5 84.4 ± 7.5  
 65-79 25.1 (268) 36.6 (97) 8.3 (22) 55.1 (146) 0.3925 
 80-85 26.3 (280) 39.4 (110) 10.0 (28) 50.5 (141)  
 86-89 22.8 (243) 37.9 (92) 13.2 (32) 49.0 (119)  
 ≥90 25.8 (275) 41.5 (114) 12.0 (33) 46.5 (275)  
Sex      
 Male 23.3 (248) 41.1 (101) 11.8 (29) 47.2 (116) 0.5266 
 Female 76.7 (818) 38.2 (312) 10.5 (86) 51.2 (418)  
Marital Status      
 Widowed 71.4 (761) 38.7 (293) 10.8 (82) 50.5 (383) 0.7711 
 Married or with a partner 14. 6 (156) 40.4 (63) 12.8 (20) 46.8 (73)  
 Never married, separated, 
or divorced 
14.0 (149) 38.5 (57) 8.8 (13) 52.7 (78)  
 
Strength of Social Relationships
 ǁ
      
 Moderate to high (3-5) 81.9 (873) 38.2 (332) 9.5 (83) 52.3 (455) 0.0026 
 Low to none (0-2) 18.1 (193) 42.2 (81) 16.7 (32) 41.1 (79)  
Time Involved in Activities
 ǂ
      
 Most (> 2/3 time) 14.7 (157) 34.8 (54) 5.8 (9) 59.4 (92) 0.0002 
 Some (1/3 to 2/3 time) 39.1 (417) 39.6 (165) 7.7 (32) 52.8 (220)  
 Little to none (< 1/3 time) 46.2 (492) 39.6 (194) 15.1 (74) 45.3 (222)  
Cognition (CPS score)      
 Intact to borderline intact 
(0-1) 
40.7 (434) 41.8 (180) 5.3 (23) 52.9 (228) <0.0001 
 Mild Impairment (2) 31.5 (336) 39.1 (131) 9.3 (31) 51.6 (173)  
 Moderate to severe 
impairment (≥ 3) 
27.8 (296) 34.5 (102) 20.6 (61) 44.9 (133)  
Activities of Daily Living (ADL 
score) 
     
 Independent or supervision 
required (0-1) 
60.1 (640) 37.8 (241) 6.1 (39) 56.0 (357) <0.0001 
 Limited impairment (2) 11.8 (126) 33.3 (42) 16.7 (21) 50.0 (63)  
 Extensive supervision 
required or dependent (≥ 
3) 
28.1 (300) 43.5 (130) 18.4 (55) 38.1 (114)  
 
Fatigue (inability to complete 
ADL in past 3 days) 
     
 None 40.6 (433) 34.2 (147) 8.6 (37) 57.2 (246) <0.0001 
 Minimal  43.3 (461) 39.4 (181) 10.0 (46) 50.6 (233)  
 Moderate to Severe 16.1 (172) 49.4 (85) 18.6 (32) 32.0 (55)  
Falls CAP      
 None 71.4 (761) 37.5 (284) 10.0 (76) 52.5 (398) 0.0622 
 ≥1 falls/ 90 days 28.6 (305) 42.4 (129) 12.8 (39) 44.7 (136)  
Depressive Symptoms (DRS 
score) 
     
 No (<3) 81.0 (863) 39.3 (338) 9.3 (80) 51.4 (442) 0.0040 
 Yes (≥3) 19.0 (203) 37.1 (75) 17.3 (35) 45.5 (92)  
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  Outcome; % of row total (n) †  
 Total* % (n) Hospital LTC or death Still in DAL p value 
 1066 38.9 (413) 10.8 (115) 50.3 (534)  
Aggressive Behaviour (ABS  
score) 
ɸ
 
     
 None (0) 71.3 (760) 40.2 (305) 9.1 (69) 50.7 (384) 0.0649 
 Moderate (1-2) 16.3 (174) 37.8 (65) 13.4 (23) 48.8 (84)  
 Severe to very severe (≥3) 12.4 (132) 32.6 (43) 17.4 (23) 50.0 (66)  
No. of chronic conditions Ɏ      
 Mean ± SD 4.7 ± 2.0 4.8 ± 2.0 4.9 ± 2.1 4.4 ± 1.9  
 0-3 30.3 (323) 33.2 (107) 9.3 (30) 57.5 (185) 0.0195 
 4-5 37.3 (398) 39.0 (155) 11.3 (45) 49.6 (197)  
 ≥6 32.4 (345) 44.0 (151) 11.7 (40) 44.3 (152)  
No. of medications      
 Mean ± SD 8.3 ± 3.8 9.1 ± 3.8 8.5 ± 3.6 7.7 ± 3.4  
 0-6 32.7 (349) 30.5 (106) 10.3 (36) 59.2 (206) 0.0002 
 7-8 21.8 (232) 37.9 (88) 13.4 (31) 48.7 (113)  
 9-10 20.1 (214) 41.0 (87) 9.4 (20) 49.5 (105)  
 ≥11 25.4 (271) 48.9 (132) 10.4 (28) 40.7 (110)  
No. of inpatient hospital 
admissions in past year 
     
 0 62.2 (663) 34.5 (228) 11.3 (75) 54.2 (358) <0.0001 
 1 23.8 (254) 39.7 (100) 9.1 (23) 51.2 (129)  
 ≥2 14.0 (149) 57.1 (85) 11.4 (17) 31.5 (47)  
Abbreviations: LTC=Long Term Care; DAL=designated assisted living; CPS=Cognitive Performance Scale; CAP=Clinical Assessment 
Protocol; DRS=Depression Rating Scale; ABS=Aggressive Behaviour Scale 
* Sample excludes 3 residents with unknown outcome who discontinued the study and 20 who refused linkage consent for administrative data. 
† Four residents (0.4% of the cohort) had other outcomes (censored at date of first discharge from DAL) and were omitted from the 
comparisons. 
ǁ Social relationships based on a summary score of items assessing whether the resident was close to someone in the facility, had a strong or 
supportive relationship with the family, participated in social activities of long-standing interest, and visited or had other interactions with at 
least one long-standing social relation or family member in the past week. 
ǂ Activity involvement reflects time when the person was awake and not receiving treatments or ADL care. 
ɸ The ABS is a summary scale of 4 behaviours (verbal abuse, physical abuse, socially inappropriate or disruptive, resists care), with higher 
scores indicating a greater number and frequency of behavioural issues 
Ɏ Based on the sum of diagnoses existing out of 49 chronic conditions listed on the interRAI-AL 
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5.4.2 Bivariate Analyses: Frailty and Outcome (Table 5.4.2) 
Preliminary chi-square analyses revealed that all of the vulnerability measures considered (four 
frailty measures [CHSabs, CHSrel, Full FI, and Armstrong FI] and one health instability measure 
[CHESS]) along with a single clinical item (fatigue, i.e., ability to complete ADLs over past 3 
days) were each significantly associated (p-value < 0.0001) with the categorical first-event 
outcome variable (hospitalization; transfer to LTC or death; and remaining in DAL) over a 1-
year follow-up. The results of the analyses are shown in table 5.4.2. In general, as vulnerability 
level increased for any of the measures considered, rates of first-event hospitalization and 
transfer to LTC or death were observed to increase, while the proportion of residents remaining 
in DAL decreased. Exceptions were (1) the association between hospitalization and both CHSabs 
and Armstrong FI, where pre-frail residents had the lowest rate of first-event hospitalization, and 
(2) the association between hospitalization and Full FI, where pre-frail residents had the highest 
rate of first-event hospitalization. 
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Table 5.4.2. Distribution of First Event Outcome by Baseline Frailty Status among DAL 
Residents 
  Outcome; % of row total (n)†  
 Total* % (n) Hospital LTC or death Still in DAL p value 
 1066 38.7 (413) 10.8 (115) 50.1 (534)  
Frailty Measure      
CHSabs (n=930)      
 Robust 3.4 (32) 37.5 (12) 3.1 (1) 59.4 (19) <0.0001 
 Pre-frail 48.7 (453) 31.9 (144) 7.1 (32) 61.0 (275)  
 Frail 47.9 (445) 47.3 (210) 13.5 (60) 39.2 (174)  
CHSrel  (n=930)      
 Robust 25.8 (240) 31.0 (74) 6.7 (16) 62.3 (149) <0.0001 
 Pre-frail 55.0 (511) 39.6 (202) 8.4 (43) 52.0 (265)  
 Frail 19.2 (179) 50.6 (90) 19.1 (34) 30.3 (54)  
Full FI      
 Robust 34.2 (365) 32.5 (118) 3.3 (12) 64.2 (233) <0.0001 
 Pre-frail 38.7 (412) 45.5 (187) 10.0 (41) 44.5 (183)  
 Frail 27.1 (289) 37.5 (108) 21.5 (62) 41.0 (118)  
Armstrong FI      
 Robust 9.5 (101) 37.0 (37) 3.0 (3) 60.0 (60) <0.0001 
 Pre-frail 32.9 (351) 33.7 (118) 5.1 (18) 61.1 (214)  
 Frail 57.6 (614) 42.2 (258) 15.4 (94) 42.5 (260)  
CHESS      
 Low risk 46.5 (496) 33.5 (165) 8.1 (40) 58.4 (288) <0.0001 
 Intermediate risk 29.3 (312) 43.9 (137) 9.9 (31) 46.2 (144)  
 High-risk 24.2 (258) 43.2 (111) 17.1 (44) 39.7 (102)  
Fatigue (past 3 days) ɸ
 
     
 None 40.6 (433) 34.2 (147) 8.6 (37) 57.2 (246) <0.0001 
 Minimal 43.3 (461) 39.4 (181) 10.0 (46) 50.7 (233)  
 Moderate to severe 16.1 (172) 49.4 (85) 18.6 (32) 32.0 (55)  
Abbreviations: LTC=Long Term Care; DAL=designated assisted living; CHSabs= Cardiovascular Health Study Frailty Criteria 
(with absolute cut-points); CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); Full FI=Full Frailty 
Index; CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; ADL=Activities of Daily Living 
* Sample excludes 3 residents with unknown outcome who discontinued the study and 20 who refused consent for linkage of 
administrative data. 
† Four residents (0.4% of the cohort) had other outcomes (censored at date of first discharge from DAL) and were omitted from 
the comparisons. 
ɸ Fatigue is defined by the interRAI-AL as inability to complete normal day-to-day activities (e.g. ADLs, IADLs) in last 3 days, 
due to diminished energy 
 
5.4.3 Cox Proportional Hazards Models: Frailty and Hospitalization (Table 5.4.3.) 
The six frailty and vulnerability measures were examined in unadjusted and adjusted Cox 
proportional hazards regression models to determine associations between measures of 
vulnerability and time to first event hospitalization over a 1-year follow-up (Table 5.4.3). 
Adjusted models included age, sex and comorbidity level, and all models were adjusted for 
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clustering by facility. Significant associations were observed in unadjusted and adjusted models 
when considering the CHSrel, Full FI and CHESS measures, as well as fatigue. However, no 
statistically significant associations were observed between CHSabs or Armstrong FI frailty 
measures and first event hospitalization in either unadjusted or adjusted analyses. 
Table 5.4.3. Unadjusted and adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1 year 
follow-up associated with selected frailty measures, DAL Residents (n=1,066). 
 HR (95% CI) 
 Unadjusted Adjusted† 
Frailty Measure   
CHS Absolute (n=930) 
  
 Robust (reference) 1.00 1.00 
 Pre-frail 0.80 (0.46-1.40) 0.77 (0.44-1.33) 
 Frail 1.47 (0.87-2.48) 1.32 (0.78-2.24) 
CHS Relative (n=930) 
  
 Robust (reference) 1.00 1.00 
 Pre-frail 1.43 (1.07-1.91) 1.37 (1.02-1.83) 
 Frail 2.30 (1.69-3.13) 2.11 (1.53-2.92) 
Full Frailty Index (n=1066) 
  
 Robust (reference) 1.00 1.00 
 Pre-frail 1.63 (1.23-2.08) 1.51 (1.19-1.92) 
 Frail 1.50 (1.14-1.99) 1.33 (1.02-1.75) 
Armstrong Frailty Index (n=1066) 
  
 Robust (reference) 1.00 1.00 
 Pre-frail 0.90 (0.62-1.29) 0.85 (0.59-1.24) 
 Frail 1.34 (0.93-1.94) 1.17 (0.80-1.71) 
CHESS Health Instability (n=1066) 
  
 Low Risk (0) (reference) 1.00 1.00 
 Intermediate Risk (1-2) 1.44 (1.16-1.80) 1.40 (1.13-1.73) 
 High Risk (≥3) 1.63 (1.27-2.10) 1.53 (1.18-1.99) 
Fatigue, past 3 days (n=1066) 
ɸ
 
  
 None (0) (reference) 1.00 1.00 
 Minimal (1) 1.25 (1.01-1.55) 1.17 (0.94-1.45) 
 Moderate to Severe (≥2) 1.99 (1.50-2.62) 1.81 (1.37-2.40) 
Abbreviations: DAL=designated assisted living; CHS=Cardiovascular Health Study Frailty Criteria; CHESS=Changes in Health, 
End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval.  
§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage.  
Estimates in Bold indicate p<0.05. 
†Adjusted for age, sex and comorbidity level (sum of 49 possible diagnoses recorded on the interRAI-AL) 
ɸ Fatigue is defined by the interRAI-AL as inability to complete normal day-to-day activities (e.g. ADLs, IADLs) in last 3 days, 
due to diminished energy 
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CHSrel frailty was most highly associated with time to first event hospitalization when compared 
to the other measures of vulnerability. The risk of first event hospitalization was 1.37 (95% CI 
1.02-1.83) times higher for CHSrel pre-frail residents and 2.11 (95% CI 1.53-2.92) times higher 
for frail, when compared to robust residents in adjusted analyses. The Full FI showed a higher 
risk of first event hospitalization for pre-frail residents (HR=1.51, 95% CI 1.19-1.92) than for 
frail residents (HR=1.33, 95% CI 1.02-1.75) when compared to robust residents. Those at 
intermediate risk according to CHESS had a hazard ratio for first event hospitalization of 1.40 
(95% CI 1.13-1.73) while those at high risk had a hazard ratio of 1.53 (95% CI 1.18-1.99), when 
compared to low risk participants. After adjustment, residents with minimal fatigue did not have 
a significantly greater risk of first event hospitalization than those without fatigue; however, 
those with moderate to severe fatigue were 1.81 (95% CI 1.37-2.40) times more likely to be 
hospitalized as a first event, compared to residents without fatigue. 
5.5 Objective 2b: Examine Association between Exposure to High-Risk and 
Antipsychotic Medication Measures and First Event Hospitalization during a 1-
year follow-up 
5.5.1 Bivariate Analyses: High-Risk/Antipsychotic Medication Exposure and Outcome (Table 
5.5.1) 
Chi-square analyses examining the association between use of relevant medication classes and 
first-event outcomes of interest are shown in table 5.5.1.  No significant association was 
observed between first-event outcome and use of oral anticoagulants or overall use of oral 
antiplatelets. However, significantly higher rates of hospitalization and lower rates of death/LTC 
transfer, and remaining in DAL were observed among residents using only non-ASA antiplatelet 
agents when compared to those not using any antiplatelet agents, or those using ASA antiplatelet 
agents (with or without non-ASA).  
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Insulin use was not found to be significantly associated with first-event outcome, and oral 
antidiabetic use was borderline significant (p-value = 0.095). However, two measures combining 
insulin use with oral antidiabetic use (insulin and/or sulfonylurea use; and any diabetic drug use) 
were both found to be significantly associated with first-event outcome, with higher rates of 
hospitalization and death/transfer to LTC as a first-event (and lower rates of remaining in DAL 
over 1-year follow-up) among those using the medications of interest when compared to those 
not using these medications.  
The rate of 1-year first-event hospitalization was found to be significantly higher for those 
residents who used medications from one of the HR drug classes of interest, and increased 
further for those using medications from 2 or more of the HR drug classes of interest, when 
compared to residents using no medications from any of the four HR classes (p-value = 0.038).  
Prevalence of antipsychotic use had a marginally significant association with first-event outcome 
(p-value=0.084) with rates of death/transfer to LTC higher (and hospitalization or remaining in 
DAL lower) among antipsychotic users, compared to those not using antipsychotic agents. 
Rates of first-event hospitalization were observed to increase with increasing number of distinct 
medications used by residents, while rates of remaining in DAL over the 1-year follow-up were 
generally found to decrease (p-value = 0.0002). 
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Table 5.5.1. Distribution of First Event Outcome by Baseline High-risk and Antipsychotic 
Medication Use among DAL Residents 
  Outcome; % of row total (n) †  
 Total* % (n) Hospital LTC or death Still in DAL p value 
 1066 38.7 (413) 10.8 (115) 50.1 (534)  
Oral Anticoagulant Use      
 No anticoagulant use 84.6 (902) 37.8 (339) 11.0 (99) 51.2 (460) 0.2049 
 Use of 1+ anticoagulant(s) 15.4 (164) 45.1 (74) 9.8 (16) 45.1 (74)  
Oral Antiplatelet Use      
 No antiplatelet use 53.7 (572) 36.7 (209) 11.2 (64) 52.1 (297) 0.2785 
 Use of 1+ antiplatelet(s) 46.3 (494) 41.5 (204) 10.4 (51) 48.2 (237)  
 Use of non-ASA 
antiplatelet only 
5.0 (53) 58.5 (31) 9.4 (5) 32.1 (17) 0.0389 
 Use of 1+ ASA 
(with/without non-ASA 
antiplatelet(s) 
41.3 (441) 39.4 (173) 10.5 (46) 50.1 (220)  
Oral Antidiabetic Use      
 No oral antidiabetic use 85.5 (911) 37.8 (343) 10.6 (96) 51.7 (469) 0.0948 
 Use of 1+ oral 
antidiabetic(s) 
14.5 (155) 45.5 (70) 12.3 (19) 42.2 (65)  
Insulin Use      
 No insulin use 94.2 (1004) 38.6 (386) 10.6 (106) 50.8 (508) 0.3488 
 Use of 1+ insulin(s) 5.8 (62) 43.6 (27) 14.5 (9) 41.9 (26)  
Insulin/Sulfonylurea Use      
 No insulin or sulfonylurea 
use 
88.6 (945) 38.2 (359) 10.2 (96) 51.6 (486) 0.0272 
 Use of insulin and/or 
sulfonylurea 
11.4 (121) 44.6 (54) 15.7 (19) 39.7 (48)  
Any Diabetic Drug Use      
 No insulin or oral 
antidiabetic use 
82.0 (874) 37.3 (325) 10.6 (92) 52.1 (454) 0.0355 
 Use of insulin and/or oral 
antidiabetic(s) 
18.0 (192) 46.1 (88) 12.0 (23) 41.9 (80)  
No. of Separate High-risk 
Medication Classes Used Ɏ  
 
     
 No use of any of the 4 HR 
drug classes 
36.5 (389) 33.9 (131) 10.3 (40) 55.8 (216) 0.0377 
 Use of 1 HR drug class 47.6 (507) 40.1 (203) 11.5 (58) 48.4 (245)  
 Use of 2+ HR drug classes 15.9 (170) 46.7 (79) 10.1 (17) 43.2 (73)  
Antipsychotic Use      
 No antipsychotic use 73.9 (788) 39.5 (310) 9.6 (75) 50.9 (399) 0.0839 
 Use of 1+ antipsychotic(s) 26.1 (278) 37.1 (103) 14.4 (40) 48.6 (135)  
No. of medications      
 0-6 32.7 (349) 30.5 (106) 10.3 (36) 59.2 (206) 0.0002 
 7 or 8 21.8 (232) 37.9 (88) 13.4 (31) 48.7 (113)  
 9 or 10 20.1 (214) 41.0 (87) 9.4 (20) 49.5 (105)  
 ≥11 25.4 (271) 48.9 (132) 10.4 (28) 40.7 (110)  
Abbreviations: LTC=Long Term Care; DAL=designated assisted living 
* Sample excludes 3 residents with unknown outcome who discontinued the study and 20 who refused consent for linkage of 
administrative data. 
† Four residents (0.4% of the cohort) had other outcomes (censored at date of first discharge from DAL) and were omitted from 
the comparisons. 
Ɏ  Number of HR medication classes is a measure of the number of distinct high-risk medication classes used (i.e. 1 HR 
medication class is  any number of medications from only 1 of the 4 HR classes) 
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5.5.2 Cox Proportional Hazards Models: High-Risk and Antipsychotic Medication Use and 
Hospitalization (Table 5.5.2) 
In age- and sex-adjusted models, many high-risk medication variables of interest were found to 
be significantly associated with time to first-event hospitalization, including use of one or more 
oral anticoagulants, oral antiplatelet agents, and oral antidiabetic agents, as well as both measures 
of combined insulin/oral antidiabetic use (insulin and/or sulfonylurea use, and any diabetic drug 
use). Additionally, in age- and sex-adjusted models, a dose-response relationship was observed 
between the number of distinct high-risk drug classes used and risk of first-event hospitalization. 
In general, these associations were no longer statistically significant in models with higher levels 
of adjustment for potential confounders, including selected diagnoses (some of which 
represented  underlying indications for receiving the selected drugs of interest), number of 
hospitalizations in the past year, and number of distinct drugs used (excluding the drug(s) of 
interest). 
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Table 5.5.2.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1 year follow-up 
associated with selected drug measures, DAL Residents (n=1,066). 
    Model A
† 
HR (95% CI) 
Model B
† 
HR (95% CI) 
Model C
† 
HR (95% CI) 
Model D
† 
HR (95% CI) 
    N=1,066 N=1,066 N=1,066 N=1,066 
Oral Anticoagulant Use 
ɸ
 
Reference: no anticoagulant use 
    
 Use of 1+ anticoagulant(s)  
(n=164) 
1.31 (1.02-1.68) 1.15 (0.91-1.47) 1.11 (0.87-1.42) 1.14 (0.89-1.45) 
Oral Antiplatelet Use
 ¶ 
Reference: no antiplatelet use
 
    
 Use of 1+ antiplatelet(s) 
(n=494) 
1.20 (1.00-1.44) 1.15 (0.97-1.36)
 
1.16 (0.98-1.37)
|| 
1.13 (0.96-1.33) 
  Use of non-ASA antiplatelet 
 only (n=53) 
2.02 (1.28-3.19) 2.02 (1.32-3.08) 1.90 (1.26-2.86) 1.79 (1.23-2.59) 
  Use of 1+ ASA 
 (with/without non-ASA) 
 antiplatelet(s) (n=441) 
1.12 (0.93-1.33) 1.07 (0.91-1.27) 1.09 (0.92-1.28) 1.07 (0.91-1.26) 
Oral Antidiabetic Use
 Ɏ
 
Reference: no oral antidiabetic 
use 
    
 Use of 1+ oral antidiabetic(s) 
(n=155) 1.35 (1.10-1.65) 1.04 (0.71-1.53) 1.12 (0.76-1.66) 1.12 (0.75-1.66) 
Insulin Use 
ǁ 
Reference: no insulin use
 
    
 Use of 1+ insulin(s) (n=62) 1.36 (0.89-2.09) 1.03 (0.66-1.63) 0.99 (0.63-1.55) 1.03 (0.65-1.63) 
Insulin/Sulfonylurea Use 
Ɏǁ
 
Reference: no insulin or 
sulfonylurea use 
    
 Use of insulin and/or 
sulfonylurea (n=121) 
1.36 (1.05-1.78) 1.10 (0.76-1.60) 1.09 (0.76-1.57) 1.12 (0.77-1.64) 
Any Diabetic Drug Use 
¥ǁ
 
Reference: no insulin or oral 
antidiabetic use 
    
 Use of insulin and/or oral 
antidiabetic(s) (n=192) 
1.44 (1.18-1.75) 1.30 (0.85-2.00) 1.38 (0.93-2.06) 1.33 (0.88-2.02) 
# High-Risk (HR) Drug  
Classes 
ɸ ¶ Ɏ ǁ
 
Reference: no use of any of the 4 
HR drug classes 
    
 Use of 1 HR drug class (n=507) 1.28 (1.01-1.63) 1.24 (0.97-1.59)
|| 
1.26 (0.98-1.61)
|| 
1.21 (0.95-1.53) 
 Use of 2+ HR drug classes 
(n=170) 1.69 (1.25-2.29) 1.42 (0.98-2.04)
|| 
1.39 (0.97-1.99)
|| 
1.31 (0.92-1.86) 
Antipsychotic Drug Use * 
Reference: no antipsychotic use 
    
 Use of 1+ antipsychotic(s) 
(n=278) 0.98 (0.75-1.28) 1.05 (0.79-1.39) 1.08 (0.81-1.45) 1.09 (0.82-1.44) 
Abbreviations: DAL=designated assisted living; CI=confidence interval.  
§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data 
linkage. Estimates in Bold indicate p≤0.05; || p<0.10. 
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† Model A: adjusted for age and sex only; Model B adjusted for age, sex, selected diagnoses (see tables 5.6.1a-5.6.1i); Model C 
adjusted for age, sex, selected diagnoses (see tables 5.6.1a-5.6.1i), # hospitalizations/past year; Model D: adjusted for age, sex, 
selected diagnoses, # hospitalizations/past year, # drugs (excluding drug(s) of interest). 
ɸ Models B-D selected diagnoses adjusted for included stroke, coronary heart disease, congestive heart failure, cardiac 
dysrhythmias, venous disorders (deep vein thrombosis, chronic venous insufficiency, pulmonary embolism, superficial venous 
thrombosis or phlebitis, varicose veins). 
¶ Models B-D selected diagnoses adjusted for included stroke, hypertension, coronary heart disease, diabetes, lipid abnormality. 
Ɏ Models B-D selected diagnoses adjusted for included diabetes, congestive heart failure, lipid abnormality, hypertension, 
coronary heart disease. 
ǁ Models B-D selected diagnoses adjusted for included diabetes, congestive heart failure, hypertension, chronic obstructive 
pulmonary disease 
* Models B-D selected diagnoses adjusted for included dementia, schizophrenia, anxiety, depression. 
Note: Comparable estimates were observed for all models based on sample size n=930 (sample available for Cardiovascular 
Health Study Frailty Criteria analyses). 
 
When considering the subclass of oral antiplatelet agents used, use of ASA antiplatelet agents 
(with or without additional use of non-ASA antiplatelets) was not significantly associated with 
an increased risk of hospitalization in age- and sex-adjusted models. Use of non-ASA antiplatelet 
agents (largely clopidogrel), however, was found to be associated with a two-fold risk of first-
event hospitalization when compared to residents not using oral antiplatelet agents. The 
statistically significant relationship between non-ASA antiplatelet use and hospitalization 
persisted in models with greater adjustment for potential confounders (including age, sex, 
selected diagnoses (stroke, hypertension, coronary heart disease, diabetes, lipid abnormality), 
number of hospitalizations in past year, and number of medications (excluding antiplatelet 
agents)), with a hazard ratio of 1.79 (95% CI 1.23-2.59) in the  most fully adjusted model. 
Use of antipsychotic agents was not found to be associated with an increased risk of first-event 
hospitalization in age- and sex-adjusted models, or in any of the more fully adjusted models. 
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5.6 Objective 3: Determine whether Frailty Measures act to modify the 
Associations between specific High-Risk Medication use and Hospitalization 
during the 1-year Follow-up. 
5.6.1 Cox Proportional Hazards Models: High-Risk and Antipsychotic Medication Use, Frailty 
and Hospitalization 
Using Cox proportional hazards models, categorical measures capturing an interaction between 
the selected frailty measure and medication class of interest were analyzed to explore potential 
effect modification of the medication – hospitalization association by frailty measure. In these 
initial analyses, the reference group was composed of non-frail residents not exposed to the 
medication measure/class of interest. The categorical frailty-medication measures were analysed 
in several models, adjusting for potential confounders. Model A included adjustment for age and 
sex only; model B included adjustment for age, sex and selected diagnoses; model C included 
adjustment for age, sex, selected diagnoses and number of hospitalizations in the past year, and 
model D included adjustment for all factors in model C, in addition to the total number of 
medications used by the resident (excluding medications from the class of interest). 
The findings from the analyses are shown in tables 5.6.1a – 5.6.1i. For all medication variables 
considered, the age- and sex-adjusted model (model A) revealed that frail individuals (both those 
using the medication of interest, and those not using the medication), had a significantly 
increased risk of first-event hospitalization when compared to non-frail individuals not using the 
medication of interest, regardless of the frailty measure used. For the majority of medication 
variables in the model A analyses, the risk was highest among frail individuals using the 
medication of interest (with the exception of antipsychotic use in CHESS frail residents).  
In some cases, when CHESS was used to classify frailty, use of the medications of interest in 
non-frail residents was associated with significantly elevated risk of hospitalization (when 
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compared to non-frail individuals not using the drug of interest). However, in all cases but three 
(i.e., use of non-ASA antiplatelet agents, use of any diabetes medication, and use of 2 or more 
high-risk drugs), this risk was no longer significant upon further adjustment. When considering 
model A for antipsychotic use, residents using antipsychotic agents who were robust according 
to the Full FI were at a significantly decreased risk of hospitalization compared to non-frail non-
antipsychotic users, but this observation was no longer significant after further adjustment. 
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Table 5.6.1a.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with anticoagulant drug – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
 
Full FI 
Adj HR (95% CI) 
 
CHESS 
Adj HR (95% CI) 
 
    N=930 N=1066 N=1066 
Model A 
Adjusted for age, sex only 
 
 Not frail - no anticoagulant use 1.00 1.00 1.00 
 Not frail – use of 1+ 
anticoagulant(s)  
1.15 (0.61-2.17) 1.02 (0.61-1.72) 1.43 (1.01-2.03) 
 Frail – no anticoagulant use 1.57 (1.14-2.17) 1.50 (1.13-1.98) 1.56 (1.28-1.90) 
 Frail – use of 1+ anticoagulant(s) 2.03 (1.39-2.98) 2.08 (1.44-3.00) 1.88 (1.38-2.56) 
Model B
† 
Adjusted for age, sex, selected 
diagnoses
 
 
 Not frail – no anticoagulant use 1.00 1.00 1.00 
 Not frail – use of 1+ 
anticoagulant(s) 
1.13 (0.56-2.26) 0.95 (0.56-1.59) 1.31 (0.93-1.85) 
 Frail – no anticoagulant use 1.50 (1.08-2.08) 1.41 (1.07-1.85) 1.47 (1.20-1.80) 
 Frail – use of 1+ anticoagulant(s) 1.78 (1.21-2.60) 1.74 (1.22-2.47) 1.56 (1.12-2.15) 
Model C
† 
Adjusted for age, sex, selected 
diagnoses, #hospitalizations/past year
 
 
 Not frail – no anticoagulant use 1.00 1.00 1.00 
 Not frail – use of 1+ 
anticoagulant(s) 
1.03 (0.51-2.08) 1.01 (0.59-1.72) 1.35 (0.94-1.93) 
 Frail – no anticoagulant use 1.46 (1.04-2.04) 1.44 (1.09-1.89) 1.48 (1.21-1.82) 
 Frail – use of 1+ anticoagulant(s) 1.64 (1.10-2.45) 1.64 (1.13-2.39) 1.45 (1.04-2.02) 
Model D
† 
Adjusted for age, sex, selected 
diagnoses, #hospitalizations/past 
year, # drugs
‡ 
 
 Not frail – no anticoagulant use 1.00 1.00 1.00 
 Not frail – use of 1+ 
anticoagulant(s) 
1.02 (0.50-2.09) 1.00 (0.59-1.69) 1.37 (0.96-1.96) 
 Frail – no anticoagulant use 1.43 (1.02-2.00) 1.37 (1.05-1.79) 1.43 (1.17-1.75) 
 Frail – use of 1+ anticoagulant(s) 1.64 (1.09-2.47) 1.63 (1.12-2.36) 1.44 (1.03-2.01) 
Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index, CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval.  
§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05. 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models B-D: selected diagnoses adjusted for included stroke, coronary heart disease, congestive heart failure, cardiac 
dysrhythmias, venous disorders (deep vein thrombosis, chronic venous insufficiency, pulmonary embolism, superficial venous 
thrombosis or phlebitis, varicose veins); 
‡drug number excludes use of anticoagulant(s) 
95 
 
Table 5.6.1b.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with oral antiplatelet – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
 
Full FI 
Adj HR (95% CI) 
 
CHESS 
Adj HR (95% CI) 
 
    n=930 N=1066 N=1066 
Model A 
Adjusted for age, sex only 
 
 Not frail - no oral antiplatelet use 1.00 1.00 1.00 
 Not frail – use of 1+ oral 
antiplatelet(s)  
1.25 (0.81-1.93) 0.93 (0.66-1.31) 1.27 (0.95-1.70) 
 Frail – no oral antiplatelet use 1.67 (1.23-2.27) 1.34 (1.04-1.71) 1.59 (1.20-2.11) 
 Frail – use of 1+ oral antiplatelet(s) 2.00 (1.45-2.75) 1.76 (1.28-2.42) 1.83 (1.41-2.39) 
Model B
† 
Adjusted for age, sex, selected 
diagnoses
 
 
 Not frail – no oral antiplatelet use 1.00 1.00 1.00 
 Not frail – use of 1+ oral 
antiplatelet(s) 
1.22 (0.77-1.91) 0.90 (0.64-1.27) 1.23 (0.90-1.66) 
 Frail – no oral antiplatelet use 1.63 (1.18-2.26) 1.30 (1.01-1.67) 1.54 (1.16-2.06) 
 Frail – use of 1+ oral antiplatelet(s) 1.84 (1.32-2.57) 1.65 (1.23-2.23) 1.70 (1.31-2.22) 
Model C
† 
Adjusted for age, sex, selected 
diagnoses, #hospitalizations/past year
 
 
 Not frail – no oral antiplatelet use 1.00 1.00 1.00 
 Not frail – use of 1+ oral 
antiplatelet(s) 
1.24 (0.79-1.96) 0.94 (0.68-1.31) 1.24 (0.93-1.65) 
 Frail – no oral antiplatelet use 1.60 (1.13-2.25) 1.32 (1.03-1.70) 1.51 (1.12-2.04) 
 Frail – use of 1+ oral antiplatelet(s) 1.80 (1.28-2.54) 1.67 (1.25-2.23) 1.69 (1.30-2.21) 
Model D
† 
Adjusted for age, sex, selected 
diagnoses, #hospitalizations/past year, 
# drugs
‡ 
 
 Not frail – no oral antiplatelet use 1.00 1.00 1.00 
 Not frail – use of 1+ oral 
antiplatelet(s) 
1.28 (0.81-2.02) 0.95 (0.68-1.33) 1.22 (0.91-1.64) 
 Frail – no oral antiplatelet use 1.60 (1.12-2.28) 1.31 (1.01-1.68) 1.47 (1.11-1.96) 
 Frail – use of 1+ oral antiplatelet(s) 1.76 (1.24-2.48) 1.58 (1.20-2.09) 1.59 (1.24-2.06) 
Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index; CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval. 
§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05. 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models B-D: selected diagnoses adjusted for included stroke, hypertension, coronary heart disease, diabetes, lipid abnormality. 
‡drug number excludes use of antiplatelet(s) 
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In more fully adjusted models, the highest risk most often remained among frail individuals 
using the drug of interest, when compared to non-frail individuals who were not using the drug. 
However, in some cases, the risk was no longer statistically significant (i.e. CHSrel frailty and 
CHESS frailty with oral antidiabetic use, or with insulin/sulfonylurea use; any measure of frailty 
with insulin use) in the fully adjusted model (Model D). In all cases but one (CHSrel frailty with 
antipsychotic use), frail individuals who were not using the drug of interest were still at a 
significant risk for first-event hospitalization compared to non-frail individuals not using the 
drug of interest in the fully adjusted model. 
 
Table 5.6.1c.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with categorical antiplatelet drug – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
 
Full FI 
Adj HR (95% CI) 
 
CHESS 
Adj HR (95% CI) 
 
    n=930 N=1066 N=1066 
Model A 
Adjusted for age, sex only 
 
 Not frail_no oral antiplatelet use 1.00 1.00 1.00 
 Not frail_use of non-ASA antiplatelet only 1.86 (0.52-6.75) 2.08 (0.81-5.35) 2.30 (1.23-4.32) 
 Not frail_use of 1+ ASA (with/without 
non-ASA) antiplatelet(s) 
1.22 (0.79-1.89) 0.85 (0.61-1.19) 1.18 (0.89-1.57) 
 Frail_no oral antiplatelet use 1.67 (1.23-2.27) 1.34 (1.04-1.71) 1.59 (1.20-2.11) 
 Frail_use of non-ASA antiplatelet only 3.12 (1.74-5.58) 2.56 (1.50-4.36) 2.87 (1.69-4.90) 
 Frail_use of 1+ ASA (with/without non-
ASA) antiplatelet(s) 
1.88 (1.37-2.58) 1.66 (1.20-2.30) 1.72 (1.32-2.23) 
Model B
† 
Adjusted for age, sex, selected diagnoses
 
 
 Not frail_no oral antiplatelet use 1.00 1.00 1.00 
 Not frail_use of non-ASA antiplatelet only 1.89 (0.56-6.37) 2.11 (0.86-5.18) 2.30 (1.19-4.42) 
 Not frail_use of 1+ ASA (with/without 
non-ASA) antiplatelet(s) 
1.19 (0.76-1.88) 0.83 (0.59-1.16) 1.15 (0.85-1.55) 
 Frail_no oral antiplatelet use 1.63 (1.18-2.26) 1.30 (1.01-1.67) 1.54 (1.16-2.06) 
 Frail_use of non-ASA antiplatelet only 3.11 (1.75-5.51) 2.56 (1.54-4.23) 2.80 (1.73-4.54) 
 Frail_use of 1+ ASA (with/without non-
ASA) antiplatelet(s) 
 
1.73 (1.24-2.40) 1.57 (1.16-2.13) 1.60 (1.23-2.08) 
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    CHSrel 
Adj HR (95% CI) 
 
Full FI 
Adj HR (95% CI) 
 
CHESS 
Adj HR (95% CI) 
 
    n=930 N=1066 N=1066 
Model C
† 
Adjusted for age, sex, selected diagnoses, 
#hospitalizations/past year
 
 
 Not frail_no oral antiplatelet use 1.00 1.00 1.00 
 Not frail_use of non-ASA antiplatelet only 1.70 (0.55-5.26) 2.12 (0.93-4.79)
|| 
2.02 (1.11-3.66) 
 Not frail_use of 1+ ASA (with/without 
non-ASA) antiplatelet(s) 
1.22 (0.77-1.95) 0.87 (0.62-1.20) 1.17 (0.88-1.57) 
 Frail_no oral antiplatelet use 1.60 (1.14-2.25) 1.32 (1.03-1.70) 1.52 (1.13-2.05) 
 Frail_use of non-ASA antiplatelet only 2.97 (1.69-5.22) 2.41 (1.46-3.96) 2.78 (1.74-4.45) 
 Frail_use of 1+ ASA (with/without non-
ASA) antiplatelet(s) 
1.69 (1.21-2.38) 1.60 (1.20-2.13) 1.59 (1.22-2.08) 
Model D
† 
Adjusted for age, sex, selected diagnoses, 
#hospitalizations/past year, # drugs
‡ 
 
 Not frail_no oral antiplatelet use 1.00 1.00 1.00 
 Not frail_use of non-ASA antiplatelet only 1.52 (0.50-4.62) 2.06 (0.96-4.42)
|| 
1.93 (1.06-3.54) 
 Not frail_use of 1+ ASA (with/without 
non-ASA) antiplatelet(s) 
1.27 (0.80-2.01) 0.88 (0.63-1.23) 1.16 (0.86-1.56) 
 Frail_no oral antiplatelet use 1.60 (1.12-2.28) 1.31 (1.01-1.69) 1.48 (1.11-1.97) 
 Frail_use of non-ASA antiplatelet only 2.73 (1.57-4.74) 2.23 (1.39-3.58) 2.53 (1.63-3.90) 
 Frail_use of 1+ ASA (with/without non-
ASA) antiplatelet(s) 
1.66 (1.17-2.34) 1.52 (1.14-2.01) 1.51 (1.16-1.96) 
Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index; CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval. 
§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05; || p<0.10. 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models B-D: selected diagnoses adjusted for included stroke, hypertension, coronary heart disease, diabetes, lipid abnormality. 
‡Drug number excludes use of antiplatelet(s) 
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Table 5.6.1d.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with oral antidiabetic – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
 
Full FI 
Adj HR (95% CI) 
 
CHESS 
Adj HR (95% CI) 
 
    n=930 N=1066 N=1066 
Model A 
Adjusted for age, sex only 
 
 Not frail - no oral antidiabetic use 1.00 1.00 1.00 
 Not frail – use of 1+ oral 
antidiabetic(s)  
1.46 (0.89-2.39) 1.23 (0.81-1.86) 1.45 (1.09-1.95) 
 Frail – no oral antidiabetic use 1.62 (1.22-2.17) 1.55 (1.19-2.01) 1.55 (1.30-1.85) 
 Frail – use of 1+ oral antidiabetic(s) 2.27 (1.56-3.30) 2.30 (1.66-3.18) 1.99 (1.42-2.80) 
Model B
† 
Adjusted for age, sex, selected 
diagnoses
 
 
 Not frail – no oral antidiabetic use 1.00 1.00 1.00 
 Not frail – use of 1+ oral 
antidiabetic(s) 
1.01 (0.56-1.85) 0.99 (0.57-1.74) 1.12 (0.76-1.65) 
 Frail – no oral antidiabetic use 1.54 (1.15-2.05) 1.45 (1.12-1.87) 1.45 (1.20-1.75) 
 Frail – use of 1+ oral antidiabetic(s) 1.48 (0.89-2.45) 1.69 (1.05-2.71) 1.45 (0.86-2.43) 
Model C
† 
Adjusted for age, sex, selected 
diagnoses, #hospitalizations/past year
 
 
 Not frail – no oral antidiabetic use 1.00 1.00 1.00 
 Not frail – use of 1+ oral 
antidiabetic(s) 
1.13 (0.59-2.15) 1.09 (0.61-1.95) 1.27 (0.84-1.91) 
 Frail – no oral antidiabetic use 1.50 (1.10-2.03) 1.46 (1.12-1.89) 1.46 (1.21-1.76) 
 Frail – use of 1+ oral antidiabetic(s) 1.58 (0.95-2.61) 1.82 (1.12-2.97) 1.52 (0.91-2.55) 
Model D
† 
Adjusted for age, sex, selected 
diagnoses, #hospitalizations/past year, 
# drugs
‡ 
 
 Not frail – no oral antidiabetic use 1.00 1.00 1.00 
 Not frail – use of 1+ oral 
antidiabetic(s) 
1.23 (0.64-2.37) 1.15 (0.65-2.05) 1.30 (0.86-1.97) 
 Frail – no oral antidiabetic use 1.49 (1.10-2.02) 1.44 (1.11-1.85) 1.45 (1.21-1.73) 
 Frail – use of 1+ oral antidiabetic(s) 1.52 (0.91-2.55) 1.70 (1.04-2.77) 1.45 (0.86-2.44) 
Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index; CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval. 
§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05. 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models B-D: selected diagnoses adjusted for included diabetes, congestive heart failure, lipid abnormality, hypertension, 
coronary heart disease. 
‡drug number excludes use of oral antidiabetic(s) 
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Table 5.6.1e.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with insulin – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
 
Full FI 
Adj HR (95% CI) 
 
CHESS 
Adj HR (95% CI) 
 
    n=930 N=1066 N=1066 
Model A 
Adjusted for age, sex only 
 
 Not frail - no insulin use 1.00 1.00 1.00 
 Not frail – use of 1+ insulin(s)  1.18 (0.37-3.83) 1.25 (0.52-3.01) 1.55 (0.80-3.00) 
 Frail – no insulin use 1.59 (1.20-2.10) 1.56 (1.23-1.98) 1.54 (1.29-1.84) 
 Frail – use of 1+ insulin(s) 2.42 (1.41-4.16) 2.01 (1.23-3.26) 1.89 (1.01-3.53) 
Model B
† 
Adjusted for age, sex, selected 
diagnoses
 
 
 Not frail – no insulin use 1.00 1.00 1.00 
 Not frail – use of 1+ insulin(s) 0.82 (0.24-2.78) 0.92 (0.36-2.33) 1.15 (0.57-2.35) 
 Frail – no insulin use 1.55 (1.17-2.05) 1.51 (1.21-1.90) 1.45 (1.20-1.76) 
 Frail – use of 1+ insulin(s) 1.70 (0.98-2.97) 1.48 (0.91-2.41) 1.38 (0.74-2.55) 
Model C
† 
Adjusted for age, sex, selected 
diagnoses, #hospitalizations/past year
 
 
 Not frail – no insulin use 1.00 1.00 1.00 
 Not frail – use of 1+ insulin(s) 0.74 (0.21-2.65) 0.92 (0.33-2.60) 1.24 (0.61-2.51) 
 Frail – no insulin use 1.49 (1.10-2.01) 1.52 (1.21-1.91) 1.45 (1.19-1.77) 
 Frail – use of 1+ insulin(s) 1.67 (0.95-2.94) 1.41 (0.88-2.26) 1.21 (0.62-2.34) 
Model D
† 
Adjusted for age, sex, selected 
diagnoses, #hospitalizations/past 
year, # drugs
‡ 
 
 Not frail – no insulin use 1.00 1.00 1.00 
 Not frail – use of 1+ insulin(s) 0.73 (0.21-2.58) 0.96 (0.35-2.61) 1.26 (0.62-2.54) 
 Frail – no insulin use 1.43 (1.06-1.93) 1.46 (1.18-1.82) 1.42 (1.17-1.72) 
 Frail – use of 1+ insulin(s) 1.74 (0.98-3.09) 1.42 (0.88-2.30) 1.24 (0.64-2.40) 
Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index; CHESS=Changes in Health, End-Stage Disease; Signs, and Symptoms Scale; CI=confidence interval. 
§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05. 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models B-D: selected diagnoses adjusted for included diabetes, congestive heart failure, hypertension, chronic obstructive 
pulmonary disease. 
‡drug number excludes use of insulin 
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Table 5.6.1f.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with insulin/sulfonylurea – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
Full FI 
Adj HR (95% CI) 
CHESS 
Adj HR (95% CI) 
    n=930 N=1066 N=1066 
Model A 
Adjusted for age, sex only 
 
 Not frail - no insulin or sulfonylurea 
use 
1.00 1.00 1.00 
 Not frail – use of insulin and/or 
sulfonylurea 
1.42 (0.73-2.77) 1.13 (0.68-1.88) 1.60 (1.00-2.55) 
 Frail – no insulin or sulfonylurea use 1.62 (1.22-2.15) 1.53 (1.21-1.93) 1.57 (1.31-1.88) 
 Frail – use of insulin and/or 
sulfonylurea 
2.29 (1.52-3.45) 2.19 (1.53-3.13) 1.87 (1.30-2.69) 
Model B
† 
Adjusted for age, sex, selected diagnoses
 
 
 Not frail – no insulin or sulfonylurea 
use 
1.00 1.00 1.00 
 Not frail – use of insulin and/or 
sulfonylurea 
1.04 (0.49-2.21) 0.92 (0.48-1.77) 1.25 (0.72-2.17) 
 Frail – no insulin or sulfonylurea use 1.53 (1.14-2.03) 1.43 (1.14-1.79) 1.44 (1.18-1.76) 
 Frail – use of insulin and/or 
sulfonylurea 
1.61 (0.98-2.63) 1.63 (1.10-2.42) 1.39 (0.93-2.10) 
Model C
† 
Adjusted for age, sex, selected diagnoses, 
#hospitalizations/past year
 
 
 Not frail – no insulin or sulfonylurea 
use 
1.00 1.00 1.00 
 Not frail – use of insulin and/or 
sulfonylurea 
1.06 (0.47-2.38) 0.94 (0.48-1.85) 1.33 (0.78-2.28) 
 Frail – no insulin or sulfonylurea use 1.49 (1.10-2.01) 1.44 (1.14-1.82) 1.46 (1.19-1.78) 
 Frail – use of insulin and/or 
sulfonylurea 
1.60 (0.98-2.62) 1.62 (1.11-2.36) 1.33 (0.89-2.00) 
Model D
† 
Adjusted for age, sex, selected diagnoses, 
#hospitalizations/past year, # drugs
‡ 
 
 Not frail – no insulin or sulfonylurea 
use 
1.00 1.00 1.00 
 Not frail – use of insulin and/or 
sulfonylurea 
1.08 (0.47-2.49) 1.00 (0.51-1.97) 1.34 (0.78-2.32) 
 Frail – no insulin or sulfonylurea use 1.45 (1.08-1.95) 1.42 (1.14-1.76) 1.44 (1.19-1.76) 
 Frail – use of insulin and/or 
sulfonylurea 
1.63 (0.97-2.74) 1.60 (1.08-2.38) 1.37 (0.90-2.09) 
Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index; CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval. 
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§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05. 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models B-D: selected diagnoses adjusted for included diabetes, congestive heart failure, lipid abnormality, hypertension, 
coronary heart disease, chronic obstructive pulmonary disease. 
‡drug number excludes use of insulin and sulfonylurea agent 
 
When considering different types of antiplatelet use (see table 5.6.1c), the highest risk was 
associated with frail individuals using non-ASA antiplatelet agents, regardless of frailty measure 
used. Frail individuals using one or more ASA antiplatelet agents (with or without non-ASA 
antiplatelet) were also at a significantly increased risk when compared to non-frail non-
antiplatelet users. However, the magnitude of the risk was considerably lower among frail 
residents using ASA antiplatelet agents compared to those using non-ASA (e.g., HR = 2.73 for 
CHS frail users of non-ASA antiplatelets, HR = 1.66 for CHS frail users of ASA antiplatelets in 
fully adjusted models). The risk of first-event hospitalization was also elevated in non-frail 
individuals using non-ASA antiplatelet agents when compared to non-frail non-antiplatelet users; 
this risk was significant when CHESS was used to classify frailty and marginally significant 
when the Full FI was used. 
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Table 5.6.1g.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with diabetic drug – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
 
Full FI 
Adj HR (95% CI) 
 
CHESS 
Adj HR (95% CI) 
 
    n=930 N=1066 N=1066 
Model A 
Adjusted for age, sex only 
 
 Not frail - no insulin or oral antidiabetic 
use 
1.00 1.00 1.00 
 Not frail – use of insulin and/or oral 
antidiabetic(s)  
1.42 (0.85-2.36) 1.27 (0.87-1.85) 1.58 (1.17-2.12) 
 Frail – no insulin or oral antidiabetic use 1.59 (1.18-2.15) 1.52 (1.18-1.96) 1.57 (1.31-1.87) 
 Frail – use of insulin and/or oral 
antidiabetic(s) 
2.44 (1.69-3.52) 2.35 (1.70-3.25) 2.09 (1.52-2.87) 
Model B
† 
Adjusted for age, sex, selected diagnoses
 
 
 Not frail – no insulin or oral antidiabetic 
use 
1.00 1.00 1.00 
 Not frail – use of insulin and/or oral 
antidiabetic(s) 
1.15 (0.58-2.27) 1.22 (0.70-2.11) 1.40 (0.93-2.13) 
 Frail – no insulin or oral antidiabetic use 1.51 (1.12-2.05) 1.43 (1.12-1.84) 1.44 (1.19-1.76) 
 Frail – use of insulin and/or oral 
antidiabetic(s) 
1.82 (1.04-3.18) 2.00 (1.22-3.30) 1.72 (1.02-2.90) 
Model C
† 
Adjusted for age, sex, selected diagnoses, 
#hospitalizations/past year
 
 
 Not frail – no insulin or oral antidiabetic 
use 
1.00 1.00 1.00 
 Not frail – use of insulin and/or oral 
antidiabetic(s) 
1.30 (0.62-2.72) 1.35 (0.79-2.30) 1.57 (1.06-2.33) 
 Frail – no insulin or oral antidiabetic use 1.48 (1.08-2.04) 1.46 (1.13-1.88) 1.46 (1.20-1.77) 
 Frail – use of insulin and/or oral 
antidiabetic(s) 
1.98 (1.15-3.41) 2.12 (1.32-3.39) 1.78 (1.09-2.91) 
Model D
† 
Adjusted for age, sex, selected diagnoses, 
#hospitalizations/past year, # drugs
‡ 
 
 Not frail – no insulin or oral antidiabetic 
use 
1.00 1.00 1.00 
 Not frail – use of insulin and/or oral 
antidiabetic(s) 
1.30 (0.61-2.80) 1.36 (0.79-2.33) 1.53 (1.02-2.31) 
 Frail – no insulin or oral antidiabetic use 1.46 (1.06-2.00) 1.43 (1.12-1.83) 1.45 (1.20-1.75) 
 Frail – use of insulin and/or oral 
antidiabetic(s) 
1.90 (1.08-3.32) 1.96 (1.22-3.17) 1.68 (1.02-2.78) 
Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index; CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval.  
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§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05. 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models B-D: selected diagnoses adjusted for included diabetes, congestive heart failure, lipid abnormality, hypertension, 
coronary heart disease, chronic obstructive pulmonary disease. 
‡Drug number excludes use of insulin and oral antidiabetic agents 
 
Table 5.6.1h displays the results of the survival analysis models for exposure to the high-risk 
drug classes in combination. For all models using CHSrel and Full FI to identify frailty (and 
models A and B using CHESS), a dose-response effect was observed in which the risk of 
hospitalization increased among frail individuals with use of medications from more high-risk 
drug classes. In the fully adjusted models (model D), for all frailty measures, the risk of first 
event hospitalization in frail residents using medications from one HR drug class and in frail 
residents using medications from two or more HR drug classes, were significantly elevated over 
the risk in the reference group (non-frail individuals not using any HR drugs). For models in 
which CHSrel or the Full FI were used to identify frailty, frail residents using drugs from two or 
more HR classes were at highest risk of first-event hospitalization. When CHESS was used to 
identify frailty, the highest risk was associated with frailty and use of medications from one HR 
class.  
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Table 5.6.1h.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with # high-risk drug – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
Full FI 
Adj HR (95% CI) 
CHESS 
Adj HR (95% CI) 
    n=930 N=1066 N=1066 
Model A 
Adjusted for age, sex only 
 
 Not frail_no use of any of the 4 HR classes 1.00 1.00 1.00 
 Not frail_use of 1 HR drug class 1.63 (0.96-2.79)
|| 
0.98 (0.65-1.47) 1.27 (0.90-1.79) 
 Not frail_use of 2+ HR drug classes 1.64 (0.84-3.20) 1.11 (0.66-1.87) 2.00 (1.37-2.94) 
 Frail_no use of any of the 4 HR classes 1.88 (1.24-2.84) 1.18 (0.82-1.70) 1.62 (1.17-2.24) 
 Frail_use of 1 HR drug class 2.27 (1.46-3.54) 1.69 (1.15-2.49) 2.02 (1.46-2.80) 
 Frail_use of 2+ HR drug classes 3.29 (2.01-5.38) 2.37 (1.50-3.74) 2.40 (1.60-3.60) 
Model B
† 
Adjusted for age, sex, selected diagnoses
 
 
 Not frail_no use of any of the 4 HR classes 1.00 1.00 1.00 
 Not frail_use of 1 HR drug class 1.66 (0.97-2.83)
|| 
1.02 (0.67-1.57) 1.27 (0.89-1.82) 
 Not frail_use of 2+ HR drug classes 1.34 (0.66-2.73) 1.02 (0.56-1.84) 1.71 (1.10-2.64) 
 Frail_no use of any of the 4 HR classes 1.84 (1.19-2.84) 1.23 (0.83-1.82) 1.55 (1.11-2.15) 
 Frail_use of 1 HR drug class 2.13 (1.34-3.39) 1.68 (1.12-2.52) 1.84 (1.30-2.60) 
 Frail_use of 2+ HR drug classes 2.56 (1.53-4.29) 2.06 (1.19-3.57) 1.89 (1.19-3.01) 
Model C
† 
Adjusted for age, sex, selected diagnoses, 
#hospitalizations/past year
 
 
 Not frail_no use of any of the 4 HR classes 1.00 1.00 1.00 
 Not frail_use of 1 HR drug class 1.67 (0.98-2.86)
|| 
1.06 (0.69-1.63) 1.25 (0.87-1.79) 
 Not frail_use of 2+ HR drug classes 1.29 (0.63-2.64) 1.08 (0.59-1.95) 1.82 (1.18-2.78) 
 Frail_no use of any of the 4 HR classes 1.80 (1.16-2.81) 1.27 (0.85-1.90) 1.55 (1.10-2.18) 
 Frail_use of 1 HR drug class 2.12 (1.32-3.40) 1.73 (1.15-2.61) 1.90 (1.34-2.69) 
 Frail_use of 2+ HR drug classes 2.47 (1.47-4.14) 1.99 (1.13-3.51) 1.71 (1.06-2.76) 
Model D
† 
Adjusted for age, sex, selected diagnoses, 
#hospitalizations/past year, # drugs
‡ 
 
 Not frail_no use of any of the 4 HR classes 1.00 1.00 1.00 
 Not frail_use of 1 HR drug class 1.66 (0.96-2.85)
|| 
1.04 (0.68-1.59) 1.23 (0.86-1.75) 
 Not frail_use of 2+ HR drug classes 1.27 (0.63-2.57) 1.04 (0.57-1.88) 1.72 (1.12-2.64) 
 Frail_no use of any of the 4 HR classes 1.82 (1.17-2.84) 1.26 (0.85-1.86) 1.53 (1.09-2.15) 
 Frail_use of 1 HR drug class 2.03 (1.26-3.27) 1.63 (1.09-2.45) 1.79 (1.27-2.52) 
 Frail_use of 2+ HR drug classes 2.32 (1.39-3.87) 1.84 (1.06-3.20) 1.60 (1.00-2.54) 
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Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index; CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval. 
§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05; || p<0.10. 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models B-D: selected diagnoses adjusted for included stroke, coronary heart disease, congestive heart failure, cardiac 
dysrhythmias, venous disorders, hypertension, diabetes, lipid abnormality, chronic obstructive pulmonary disease, dementia, 
schizophrenia, anxiety, depression. 
‡Drug number excludes use of drug(s) of interest 
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Table 5.6.1i.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with antipsychotic – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
 
Full FI 
Adj HR (95% CI) 
 
CHESS 
Adj HR (95% CI) 
 
    n=930 N=1066 N=1066 
Model A 
Adjusted for age, sex only 
 
 Not frail - no antipsychotic use 1.00 1.00 1.00 
 Not frail – use of 1+ 
antipsychotic(s)  
0.66 (0.41-1.06) 0.63 (0.40-0.98) 1.02 (0.71-1.48) 
 Frail – no antipsychotic use 1.47 (1.06-2.04) 1.45 (1.09-1.92) 1.54 (1.26-1.89) 
 Frail – use of 1+ antipsychotic(s) 1.51 (1.05-2.15) 1.50 (1.11-2.02) 1.48 (1.06-2.07) 
Model B
† 
Adjusted for age, sex, selected 
diagnoses
 
 
 Not frail – no antipsychotic use 1.00 1.00 1.00 
 Not frail – use of 1+ 
antipsychotic(s) 
0.70 (0.42-1.15) 0.71 (0.44-1.14) 1.08 (0.73-1.59) 
 Frail – no antipsychotic use 1.44 (1.04-2.01) 1.53 (1.16-2.04) 1.53 (1.25-1.87) 
 Frail – use of 1+ antipsychotic(s) 1.59 (1.08-2.34) 1.73 (1.23-2.44) 1.59 (1.13-2.25) 
Model C
† 
Adjusted for age, sex, selected 
diagnoses, #hospitalizations/past year
 
 
 Not frail – no antipsychotic use 1.00 1.00 1.00 
 Not frail – use of 1+ 
antipsychotic(s) 
0.72 (0.43-1.21) 0.70 (0.43-1.14) 1.07 (0.73-1.59) 
 Frail – no antipsychotic use 1.41 (0.98-2.01) 1.47 (1.09-1.98) 1.47 (1.20-1.80) 
 Frail – use of 1+ antipsychotic(s) 1.60 (1.08-2.37) 1.74 (1.24-2.43) 1.63 (1.16-2.29) 
Model D
† 
Adjusted for age, sex, selected 
diagnoses, #hospitalizations/past 
year, # drugs
‡ 
 
 Not frail – no antipsychotic use 1.00 1.00 1.00 
 Not frail – use of 1+ 
antipsychotic(s) 
0.72 (0.43-1.21) 0.71 (0.44-1.15) 1.09 (0.74-1.59) 
 Frail – no antipsychotic use 1.39 (0.96-2.00) 1.38 (1.03-1.84) 1.41 (1.16-1.72) 
 Frail – use of 1+ antipsychotic(s) 1.59 (1.08-2.35) 1.63 (1.18-2.26) 1.56 (1.12-2.18) 
Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index; CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval. 
§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05. 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models B-D: selected diagnoses adjusted for included dementia, schizophrenia, anxiety, depression. 
‡drug number excludes use of antipsychotic(s) 
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5.6.2 Cox Proportional Hazards Models: High-Risk and Antipsychotic Medication Use, Frailty 
and Hospitalization (Comparator Groups: Non-frail Medication Users) 
In order to more directly compare the impact of frailty as a modifier of the association between 
high-risk (HR) or antipsychotic medication use and hospitalization, analyses were conducted 
using different comparator (reference) groups. For the following results, the reference group for 
each of the medication classes of interest was non-frail residents who were using at least one 
medication from the class. Changing the reference group allows for examination of whether there 
is a significant difference in the observed risk of hospitalization among the different levels of 
frailty-medication use for each of the medication classes (i.e., among the levels presented in each 
of tables 5.6.1a-5.6.1i). 
Table 5.6.2a displays hazard ratios for first-event hospitalization when non-frail residents who 
were using the medication of interest were used as the reference group. Findings for oral 
antidiabetic use or insulin use (and any combination of the two classes) were not found to be 
significantly associated with increased risk of hospitalization in frail residents, compared to non-
frail residents, and are not shown.  
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Table 5.6.2a.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with selected drug – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
Full FI 
Adj HR (95% CI) 
CHESS 
Adj HR (95% CI) 
    n=930 N=1066 N=1066 
Anticoagulant Use 
Model A
† 
 Reference: not frail - use of 1+ 
 anticoagulant(s) 
 
 Not frail – no anticoagulant use 0.87 (0.46-1.63) 0.98 (0.58-1.64) 0.70 (0.49-0.99) 
 Frail – no anticoagulant use 1.36 (0.77-2.42) 1.46 (0.96-2.21)|| 1.09 (0.79-1.51) 
 Frail – use of 1+ anticoagulant(s) 1.77 (0.95-3.29)|| 2.03 (1.36-3.03) 1.31 (0.93-1.86) 
Model D
† 
 Reference: not frail - use of 1+ 
 anticoagulant(s)
 
 
 Not frail – no anticoagulant use 0.98 (0.48-2.01) 1.01 (0.59-1.71) 0.73 (0.51-1.05)| 
 Frail – no anticoagulant use 1.40 (0.73-2.68) 1.38 (0.90-2.10) 1.05 (0.76-1.45) 
 Frail – use of 1+ anticoagulant(s) 1.61 (0.83-3.13) 1.64 (1.06-2.53) 1.05 (0.71-1.55) 
Antiplatelet Use 
Model A
† 
 Reference: not frail - use of 1+ 
 antiplatelet(s) 
 
 Not frail – no antiplatelet use 0.80 (0.52-1.23) 1.08 (0.77-1.53) 0.79 (0.59-1.05) 
 Frail – no antiplatelet use 1.33 (0.89-2.00) 1.45 (1.06-1.98) 1.26 (1.00-1.58) 
 Frail – use of 1+ antiplatelet(s) 1.60 (1.03-2.48) 1.90 (1.29-2.79) 1.44 (1.12-1.86) 
Model D
† 
 Reference: not frail - use of 1+ 
 antiplatelet(s)
 
 
 Not frail – no antiplatelet use 0.78 (0.50-1.24) 1.05 (0.75-1.46) 0.82 (0.61-1.10) 
 Frail – no antiplatelet use 1.25 (0.82-1.91) 1.37 (0.99-1.88)|| 1.21 (0.96-1.53) 
 Frail – use of 1+ antiplatelet(s) 1.38 (0.88-2.14) 1.66 (1.15-2.38) 1.31 (1.01-1.70) 
Antipsychotic Use 
Model A
† 
 Reference: not frail - use of 1+ 
 antipsychotic(s) 
 
 Not frail – no antipsychotic use 1.52 (0.95-2.45)|| 1.59 (1.02-2.49) 0.98 (0.68-1.41) 
 Frail – no antipsychotic use 2.24 (1.34-3.74) 2.31 (1.41-3.78) 1.51 (1.05-2.17) 
 Frail – use of 1+ antipsychotic(s) 2.29 (1.39-3.78) 2.38 (1.47-3.86) 1.45 (0.92-2.72) 
Model D
† 
 Reference: not frail - use of 1+ 
 antipsychotic(s)
 
 
 Not frail – no antipsychotic use 1.39 (0.82-2.33) 1.41 (0.87-2.28) 0.92 (0.63-1.35) 
 Frail – no antipsychotic use 1.92 (1.10-3.35) 1.94 (1.19-3.17) 1.30 (0.88-1.92) 
 Frail – use of 1+ antipsychotic(s) 2.20 (1.30-3.74) 2.30 (1.43-3.70) 1.44 (0.91-2.26) 
Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index, CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval.  
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§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05; || p<0.10 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models A: adjusted for age and sex only; Models D: adjusted for age, sex, selected diagnoses (see tables5.6.1a, 5.6.1b, 5.6.1i), 
# hospitalizations/past year, # drugs (excluding drug(s) of interest). 
As shown in table 5.6.2a, only residents using anticoagulants who were considered frail by the 
Full FI were at a statistically significant increased risk of first-event hospitalization in the fully-
adjusted models (HR = 1.64, 95% CI 1.06-2.53) when compared to robust residents using oral 
anticoagulants. 
With robust residents using antiplatelet agents as the reference group, Full FI frail residents using 
antiplatelets had the greatest associated risk of hospitalization (HR = 1.66, 95% CI 1.15-2.38), 
while CHESS frail residents using antiplatelet agents also had a statistically significant increased 
risk (HR = 1.31, 95% CI 1.01-1.70). However, looking specifically at ASA antiplatelet use, there 
was no significant difference in risk for frail individuals using these drugs compared to non-frail 
individuals using these drugs, regardless of frailty measure used (see table 5.6.2b). 
With a reference group of non-frail residents using one or more antipsychotic agents, individuals 
who were classified as frail, according to CHSrel and the Full FI were at a significantly elevated 
risk for first-event hospitalization (regardless of antipsychotic medication use status). For both 
frailty measures, frail individuals who were using antipsychotic agents were at the highest risk. 
Individuals identified as frail by the Full FI who were using antipsychotics were at the greatest 
risk for first-event hospitalization (HR = 2.30, 95% CI 1.43-3.70), followed by CHSrel frail 
individuals using antipsychotics (HR = 2.20, 95% CI 1.43-3.70). In model A, individuals who 
were identified as frail by CHESS and were not using antipsychotic agents had a significantly 
elevated risk, compared to non-frail antipsychotic users; however, this risk was no longer 
significant in the fully adjusted model. CHESS frail individuals using one or more antipsychotic 
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agents were not at a significantly increased risk of hospitalization, when compared to non-frail 
antipsychotic users, in any of the models. 
Table 5.6.2b.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with ASA/non-ASA antiplatelet – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
 
Full FI 
Adj HR (95% CI) 
 
CHESS 
Adj HR (95% CI) 
 
    n=930 N=1066 N=1066 
Reference: not frail – non-ASA 
antiplatelet only 
Model A
† 
 
 Not frail – no antiplatelet use 0.54 (0.15-1.94) 0.48 (0.19-1.24) 0.44 (0.23-0.81) 
 Not frail – use of ASA 
(with/without non-ASA) 
0.66 (0.19-2.30) 0.41 (0.16-1.03)
 ||
 0.52 (0.29-0.91) 
 Frail – no antiplatelet use 0.90 (0.25-3.21) 0.64 (0.26-1.58) 0.69 (0.42-1.16) 
 Frail – use of ASA (with/without 
non-ASA) 
1.01 (0.28-3.67) 0.80 (0.33-1.97) 0.75 (0.42-1.32) 
 Frail – use of non-ASA only 1.67 (0.48-5.83) 1.23 (0.48-3.17) 1.25 (0.71-2.21) 
Model D
†  
 Not frail – no antiplatelet use 0.66 (0.22-2.01) 0.49 (0.23-1.04) || 0.52 (0.28-0.95) 
 Not frail – use of ASA 
(with/without non-ASA) 
0.84 (0.28-2.48) 0.43 (0.20-0.92) 0.60 (0.35-1.04)
 ||
 
 Frail – no antiplatelet use 1.05 (0.36-3.12) 0.64 (0.31-1.31) 0.77 (0.47-1.24) 
 Frail – use of ASA (with/without 
non-ASA) 
1.09 (0.37-3.12) 0.74 (0.36-1.51) 0.78 (0.46-1.33) 
 Frail – use of non-ASA only 1.80 (0.61-5.30) 1.08 (0.49-2.39) 1.31 (0.73-2.33) 
Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index, CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval.  
§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05; || p<0.10 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models A: adjusted for age and sex only; Models D: adjusted for age, sex, selected diagnoses (stroke, hypertension, coronary 
heart disease, diabetes, lipid abnormality), # hospitalizations/past year, # drugs (excluding drug(s) of interest). 
As seen in table 5.6.2c, the hospitalization risk associated with use of any one HR medication 
class was significantly higher among frail residents compared to non-frail residents in fully 
adjusted models, when frailty was defined by the Full FI (HR = 1.57, 95% CI 1.15-2.14). A 
heightened risk was also observed for the use of two or more HR medication classes when Full 
FI frail residents were compared to non-frail residents (HR = 1.77, 95% CI 1.09-2.89). 
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Table 5.6.2c.  Adjusted hazard ratios
§
 (95% CIs) for hospitalization during 1-year follow-up 
associated with High-Risk Medication – frailty¶ measures, DAL Residents (n=1,066). 
    CHSrel 
Adj HR (95% CI) 
 
Full FI 
Adj HR (95% CI) 
 
CHESS 
Adj HR (95% CI) 
 
    n=930 N=1066 N=1066 
Reference: not frail - use of drugs 
from 1 HR class 
Model A
† 
 
 Not frail – no HR drug use 0.61 (0.36-1.05) || 1.02 (0.68-1.53) 0.79 (0.56-1.12) 
 Not frail – use of 2+ HR classes 1.00 (0.59-1.71) 1.13 (0.74-1.73) 1.58 (1.16-2.16) 
 Frail – no HR drug use 1.15 (0.77-1.73) 1.20 (0.88-1.65) 1.28 (0.95-1.73) 
 Frail – use of 1 HR class 1.39 (0.96-2.02) || 1.73 (1.28-2.33) 1.60 (1.26-2.02) 
 Frail – use of 2+ HR classes 2.02 (1.34-3.04) 2.41 (1.73-3.37) 1.89 (1.35-2.66) 
Model D
†  
 Not frail – no HR drug use 0.60 (0.35-1.04) || 0.96 (0.63-1.46) 0.81 (0.57-1.16) 
 Not frail – use of 2+ HR classes 0.77 (0.41-1.44) 1.00 (0.63-1.58) 1.40 (0.95-2.05) || 
 Frail – no HR drug use 1.10 (0.74-1.64) 1.20 (0.88-1.66) 1.25 (0.93-1.67) 
 Frail – use of 1 HR class 1.23 (0.85-1.79) 1.57 (1.15-2.14) 1.45 (1.10-1.93) 
 Frail – use of 2+ HR classes 1.40 (0.85-2.32) 1.77 (1.17-2.67) 1.30 (0.85-1.99) 
Reference: not frail - use of drugs 
from 2+ HR classes 
Model A
† 
 
 Not frail – no HR drug use 0.61 (0.31-1.19) 0.90 (0.54-1.51) 0.50 (0.34-0.73) 
 Not frail – use of 1 HR class 1.00 (0.58-1.70) 0.88 (0.58-1.35) 0.63 (0.46-0.86) 
 Frail – no HR drug use 1.15 (0.64-2.07) 1.06 (0.70-1.62) 0.81 (0.57-1.16) 
 Frail – use of 1 HR class 1.39 (0.79-2.42) 1.52 (0.96-2.41) || 1.01 (0.76-1.34) 
 Frail – use of 2+ HR classes 2.01 (1.07-3.77) 2.13 (1.29-3.51) 1.20 (0.83-1.73) 
Model D
†  
 Not frail – no HR drug use 0.79 (0.39-1.58) 0.96 (0.53-1.74) 0.58 (0.38-0.90) 
 Not frail – use of 1 HR class 1.30 (0.70-2.44) 1.01 (0.63-1.59) 0.72 (0.50-1.05) || 
 Frail – no HR drug use 1.43 (0.73-2.82) 1.21 (0.76-1.92) 0.89 (0.60-1.33) 
 Frail – use of 1 HR class 1.60 (0.85-3.00) 1.57 (0.945-2.62) || 1.04 (0.73-1.50) 
 Frail – use of 2+ HR classes 1.82 (0.92-3.62) || 1.77 (1.09-2.89) 0.93 (0.62-1.39) 
Abbreviations: DAL=designated assisted living; CHSrel=Cardiovascular Health Study Frailty Criteria (with relative cut-points); 
Full FI=Full Frailty Index, CHESS=Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; CI=confidence interval.  
§ Derived from Cox proportional hazards regression models (first event analysis), also adjusted for clustering by facility; sample 
excludes 3 residents with unknown outcome who discontinued study and 20 who refused consent for administrative data linkage. 
Estimates in Bold indicate p<0.05; || p<0.10 
¶ For frailty measures, frail = frail + pre-frail residents (vs. not-frail) 
† Models A: adjusted for age and sex only; Models D: adjusted for age, sex, selected diagnoses # hospitalizations/past year, # 
drugs (excluding drug(s) of interest); 
Selected diagnoses adjusted for included stroke, coronary heart disease, congestive heart failure, cardiac dysrhythmias, venous 
disorders (see table 5.6.1a), hypertension, coronary heart disease, diabetes, lipid abnormality, chronic obstructive pulmonary 
disease 
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5.6.3 Facility Factors Associated with Frailty/Med Use 
The categorical frailty – medication class variables were examined for their associations with 
certain facility-level factors relevant to medication oversight using chi-square analyses. For the 
purposes of these analyses, frailty as determined by the Full FI was used since this measure was 
most often observed to be an effect modifier of the drug exposure – hospitalization relationship. 
Few frailty–medication exposure variables were significantly associated with LPN/RN coverage 
(availability of licensed practical nurses [LPNs] and/or registered nurses [RNs] on site). 
However, it was observed that a significantly greater proportion of frail individuals using 
antipsychotics were residents of facilities with no LPN/RN coverage (25.5% of residents) when 
compared to non-frail residents using antipsychotic agents (13.6% of residents) (p-value = 
0.0339, not shown in figure). 
Figure 5.6.3a displays the proportion of residents living in a facility with an affiliated physician 
by their frailty - medication use status. Regardless of medication use status, the proportion of 
frail residents living in a facility with an affiliated GP was significantly lower than the proportion 
of non-frail residents. Furthermore, among frail residents using certain medication classes of 
interest (oral anticoagulants and oral antidiabetics), an even lower proportion of residents lived in 
facilities with an affiliated GP. When considering antipsychotic agents, frail antipsychotic users 
resided in facilities with physicians more often than non-frail antipsychotic users. However, 
residents who were non-frail and not using antipsychotic agents resided in facilities with 
physicians more frequently than residents who were frail and/or using antipsychotics. 
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The proportion of participants residing in facilities with pharmacist involvement by frailty - 
medication use status is shown in Figure 5.6.3b. In the case of oral anticoagulant use, oral 
antiplatelet use, and antipsychotic use, when comparing frail residents to non-frail residents 
based on medication-use status, the proportion of residents living in a facility with pharmacist 
involvement was significantly lower for frail residents than it was for non-frail residents. When 
considering oral antidiabetic use and insulin use, non-frail residents not using the drugs of 
interest most frequently lived in facilities with pharmacist involvement, compared to the other 
three frailty-medication use categories, followed by frail residents using the drugs of interest. 
Residents who were either frail or using medication from one of these two drug classes (oral 
antidiabetics and insulin) had a significantly lower probability of living in a facility with 
pharmacist involvement. Similar patterns were observed when the medication variable of interest 
was either use of any diabetic medication, or use of insulin and/or sulfonylurea. 
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6. DISCUSSION 
Interpretation 
The aim of the current research was to investigate whether selected measures of frailty act as 
effect modifiers of associations between certain high-risk and antipsychotic medications and 
hospitalization risk in a vulnerable older population. In order to address this question, the 
following research objectives were explored: the baseline distribution and resident-level 
correlates of (1a) frailty status (as identified by three measures of vulnerability), and (1b) high-
risk/antipsychotic medication use, were investigated; (2a) associations between frailty status and 
first-event hospitalization were explored; (2b) associations between high-risk/antipsychotic 
medication use and first-event hospitalization were explored; and finally, (3) combined measures 
of frailty and high-risk/antipsychotic medication use were investigated for association with first-
event hospitalization. The following sections address the interpretation of the research findings. 
6.1 Univariate Descriptive Results 
6.1.1 Baseline Resident Characteristics 
The population studied in the ACCES designated assisted living (DAL) sample were more 
vulnerable than a community based sample of older adults, but less impaired than older adults 
residing in long-term care (LTC). Compared to the 2009 Canadian Community Health Survey 
(Healthy Aging),
162
 the DAL residents participating in ACCES were observed to be older (48.9% 
over 85 v. 11.2%); have a higher proportion of female residents (76.7% v. 54.9%); greater 
activities of daily living (ADL) impairment (42.1% independent in ADLs v. 77.4%); and higher 
rates of diagnosed dementia (57.6% v. 1.6%), depression (34.3% v. 5.1%), and other co-morbid 
conditions, including hypertension (56.5% v. 50.2%), arthritis (53.8% v. 43.4%), heart disease 
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(29.2% v. 22.6%), osteoporosis (31.6% v. 18.1%), diabetes (22.6% v. 17.2%), COPD (18.4% v. 
8.8%), and stroke (24.4% v. 4.2%). 
As reported in previous ACCES publications,
112,163
 compared to the ACCES LTC cohort, DAL 
residents had stronger social relationships, higher activity levels, fewer overall health concerns 
and comorbidities, lower levels of functional and cognitive impairment, and fewer mood and 
behavioural challenges, but had similarly high levels of medication use and were more likely to 
have been hospitalized in the year prior to baseline (see Appendix H).  
The average age of the ACCES DAL residents, 84.9 ± 7.3, was similar to that observed in two 
US AL studies: 84.1 ± 7.7,
122 
and 85.4 ± 8.6.
164
 There was also a similar sex distribution, with 
76.7% female in the ACCES population and 75.6% and 75.2% female in the two US assisted 
living (AL) populations.
122,164
 However, the Alberta DAL population studied here had slightly 
higher rates of selected diagnoses including diabetes (22.6% v. 17.8%), CHF (22.4% v. 14.5%) 
and COPD (18.4% v. 10.5%), compared to one of the US AL studies.
164 
A high prevalence of diagnosed dementia was observed in the ACCES DAL cohort (57.6%), 
slightly higher than rates reported in a nationally representative US study, which reported a 42% 
prevalence of diagnosed dementia among AL residents.
165
 The prevalence of depression 
observed in the ACCES DAL cohort (34.3%) was also similar but slightly higher than that 
reported in a Maryland AL sample (24%).
166 
The high rates of dementia and mental health 
disorders among AL residents (along with associated medication use for management of 
behavioural and mood concerns)
165
 add to the complexity of care and medication management 
for this vulnerable population.
165-167 
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6.1.2 Baseline Facility Characteristics 
Considering the vulnerability of the ACCES DAL sample in terms of age, comorbidity as well as 
cognitive and functional impairment, the limited skilled staffing available in many of these 
facilities, including LPN/RN staffing, physician affiliation and pharmacist involvement, is a 
source of concern. In particular, the absence of licensed practical nurse (LPN) and/or registered 
nurse (RN) staff in certain AL facilities poses concerns regarding the quality of care and 
oversight in these AL settings, which house over a quarter of residents identified in this study. 
An additional 10.8% of participating residents were living in a facility with LPN/RN staff on site 
for fewer than 24 hours/day, 7 days/week. Concerning figures have also been reported regarding 
the presence of licensed staff in AL facilities across the US, where it was noted that 
approximately one-quarter (24%) of facilities did not employ an RN or an LPN, while one-half 
(49%) had an RN and/or LPN on staff less than 24 hours/day.
168 
6.1.3 Baseline Medication Use 
The proportion of residents using one or more antipsychotic agents in the ACCES DAL cohort 
was found to be 26.4%, similar to the 21% and 27.5% prevalence rates of antipsychotic use 
reported in US AL facilities,
167
 and French AL facilities,
169 
respectively. Higher rates of 
antipsychotic use were reported in ACCES LTC residents (32%)
158
 and in Ontario LTC facilities 
(32.1% in 2010 and 28.8% in 2013),
170
 as expected given the higher level of care in LTC 
compared to AL.  
ACCES DAL residents had a similar, but slightly elevated prevalence of use of any diabetes 
medication (17.9%) compared to that reported in a Maryland AL study (14.6%).
113
 Compared to 
residents of a Saskatchewan LTC facility, the ACCES DAL residents had a similar prevalence of 
oral antidiabetic medication use (14.4% in Alberta DAL, compared to 12.7% in Saskatchewan 
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LTC).
171
 The proportion of residents using insulin was also similar across the three cohorts, with 
5.8% of ACCES residents using insulin, and 5.6% of residents each from the Maryland AL study 
and the Saskatchewan LTC study. Additionally, 41.9% of insulin users in the Saskatchewan LTC 
study were observed to also be using oral antidiabetic agents, similar to the 39.7% of insulin 
users in the ACCES DAL cohort.  
The prevalence of warfarin use among ACCES DAL residents was considerably higher, at 
15.1%, than the 7.6% reported in the Maryland AL study.
113
 Considerable variation in the 
prevalence of warfarin prescription in continuing care facilities was shown in a systematic 
review of warfarin use in LTC facilities, which reported prevalence rates from eight studies, 
ranging from 17% to 57% among those individuals with a condition for which warfarin was 
indicated.
172 
Prevalence of polypharmacy was similar among the ACCES DAL cohort (45.4% of residents 
using 9 or more distinct drugs), compared to the ACCES LTC cohort (42.7% of residents using 9 
or more drugs), whereas Bronskill and colleagues
173
 observed a much lower prevalence of 
polypharmacy among Ontario LTC residents (15.5% of residents using 9 or more distinct drugs). 
However, considerable variation was observed in polypharmacy prevalence between different 
Ontario LTC facilities (7.9% to 26.2%), and contrary to ACCES, non-prescription drugs were 
generally not included in medication counts in the Ontario LTC study.
173 
6.1.4 Baseline Frailty Measures 
Examining the cohort of the Cardiovascular Health Study (the original cohort studied using the 
CHS frailty criteria), Fried and colleagues observed that the prevalence of frailty in the cohort 
was 6.9% and that 46.6% of the cohort were intermediate (pre-) frail.
80
 Using similar cut-points 
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to those used in the CHS study, the prevalence of frailty in the ACCES cohort was 48.0%, with 
48.5% pre-frail. Since the Cardiovascular Health Study was carried out in a community-dwelling 
population, it is not surprising that the prevalence of frailty in this population would be lower 
than that observed in the comparatively vulnerable ACCES DAL population. However, given 
that only 3.5% of the ACCES DAL cohort was identified as robust using this method, the use of 
the absolute cut-points for the CHS frailty measure would not be expected to differentiate well 
among the more vulnerable DAL residents examined here. Using the relative cut-points designed 
for this cohort (and used previously in ACCES studies),
123 
a prevalence of 19.2% frail and 55.0% 
pre-frail was detected. 
Another concern with respect to the CHS measures is the difficulty of obtaining all necessary 
information for the determination of frailty status from all residents, particularly for the 
performance-based items.
123
 For some residents, missing CHS items were supplemented with 
similar items from the inter-RAI assessment in order to calculate the measure. However, the 
absence of certain items prevented the calculation of CHS frailty for 15% of residents. These 
feasibility concerns call into question the utility of the CHS measure as a means of identifying 
frailty in more vulnerable populations, such as residents of assisted living and continuing care 
settings. 
Although Rockwood and colleagues (the developers of the FI) have stated that the FI is not 
meant to be categorized, in previous publications
174,175
 they have offered various cut-points for 
classifying frailty, with FI=0.25 being the cut-point between pre-frail and frail in community-
dwelling populations. In a study of French nursing home residents, it was concluded that a cut-
point of 0.25 to identify frailty by the FI was inadequate for the NH population, identifying 
64.8% of residents as frail.
176
 The cut-points for classification of frailty (>0.3) and pre-frailty 
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(>0.2) used in the present study are the same as those used by Rockwood and colleagues in a 
nursing home population.
174
  
Using the Full FI, the prevalence of frailty (27.5%) and pre-frailty (38.9%) were quite similar to 
the prevalence values obtained from community-dwelling older adults in the Canadian 
Community Health Survey (24% frail, 32% pre-frail) when different cut-off values were used 
(frailty=FI score > 0.21 vs. >0.3 for ACCES).
177
 This observation is consistent with the 
expectation that DAL residents would be more vulnerable than community-dwelling older adults.  
As with the absolute cut-points for the CHS measure, the Armstrong FI identified the vast 
majority of residents as frail or pre-frail (88.2%), limiting the ability of this measure to 
differentiate across the relative levels of vulnerability in this population.  
Although CHESS is not specifically a frailty measure, it identified a similar proportion of frail 
and pre-frail residents (24.4%; 29.5%) as the Full FI (27.5%; 38.9%). CHESS and the Full FI 
also had a higher level of agreement (kappa = 0.36) than many of the other combinations of 
frailty measures (table 5.1.4), with only the two different versions of the FI having a higher level 
of agreement. 
Given the generally low level of agreement between the frailty measures as well as the limited 
overlap observed between three of these measures in Figure 5.1.4b, it appears that these 
measures are not classifying the same residents as frail. It is possible that there is limited 
agreement between measures because each of the frailty measures is detecting different forms of 
vulnerability. Such a concept would not be surprising given the differing means of assessing 
vulnerability and the different interpretations of frailty associated with each of these measures. 
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6.1.5 Outcome 
The cumulative incidence of first-event hospital admission over 1 year observed in the ACCES 
DAL cohort (38.7%)
112
 was similar to the incidence reported in 2 US AL studies. Hedrick and 
colleagues
125
 observed that 40.2% of assisted living residents in their study were admitted to 
hospital at least once over a year. Zimmerman and colleagues
122
 observed a hospitalization rate 
of 12.7% per standardized 100-day quarter (46%–51% per year). The rate of hospitalization of 
AL residents has been observed to be higher than the hospitalization rate among LTC residents 
in both the ACCES study
112 
as well as a US LTC study.
178 
6.2 Objective 1a: Examine Frailty Status (as identified by 3 measures of 
vulnerability) by Resident-Level Characteristics 
6.2.1 Frailty Status by Resident-Level Characteristics 
In the following section, only the three key frailty measures selected for the final analyses 
(objective 3, section 6.6) are discussed. A subsequent section (section 6.4) will include 
discussion of the five original frailty measures considered and the reasons for selecting the three 
key measures. With a few exceptions, the three key frailty measures considered were observed to 
be significantly associated with many of the same resident-level characteristics. The following 
are notable exceptions: CHESS vulnerability was not associated with increasing age or strength 
of social relationships, while the Full FI and CHSrel were; and CHSrel was not associated with 
cognitive function or aggressive behaviour, while the other frailty measures were.  
The differences in resident-level correlates of the three frailty measures likely reflect the 
differing methods of assessing and identifying frailty. Frailty status defined by the Full FI was 
associated with almost every resident characteristic considered (with the exception of sex), 
perhaps because many of the characteristics considered are closely related to items in the Full FI 
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(see Appendix C). The association between the Full FI and a variety of resident characteristics is 
also consistent with the frailty index conceptualization of frailty as the accumulation of deficits 
across numerous domains.  
There was no association between CHSrel frailty and cognitive impairment, or aggressive 
behaviour (which is frequently associated with dementia in continuing care populations). The 
absence of an association between CHSrel frailty and cognition-related characteristics may be 
explained by the items assessed in the CHS measure, which focus on physical and (to a certain 
extent) psychological items (e.g., questions for the exhaustion item, which are derived from a 
depression scale) to define frailty, without inclusion of items assessing cognition (see Appendix 
E). A 2007 study by Rockwood and colleagues
174
 also reported that cognition was more highly 
correlated with the FI than with CHS, when using a different measure of cognition (3MS). 
In contrast, the CHESS measure includes items related to physical function, disease status and 
cognition, but does not include any psychological or social items (see Appendix F), which may 
explain the absence of an association between CHESS and strength of social relationships. 
CHESS vulnerability was also observed to not be associated with age, unlike the other frailty 
measures. This is consistent with previous studies using CHESS, which showed a weak 
correlation between age and CHESS score.
88
 This lack of association with age may be related to 
the fact that CHESS items are focused on acute measures of health instability (e.g., vomiting, 
changes in decision making or activity level over the past 90 days), which may make this 
measure more relevant to recent changes in health status that accompany disease, than it is to the 
slower progression of frailty related to accumulation of deficits or a changing phenotype over 
longer periods of time. 
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6.2.2 Frailty, Depression and Dementia 
In a recent editorial,
 91
 Hubbard offered evidence that dementia and depression frequently 
coexist, along with frailty in older adults. She suggests that each of these three conditions is also 
likely to put older adults at greater risk for the development of the other two conditions. 
Analyses were carried out in order to examine the extent to which depression and dementia 
coexist with frailty, as defined by different frailty measures of interest. 
For the purpose of the analysis underlying the Venn diagrams presented in section 5.2.2, ‘frail’ 
residents were restricted to those who had been classified as frail, and pre-frail residents were 
grouped with non-frail. Unlike the analyses for objective 3 (where frail and pre-frail residents 
were collapsed together because we wished to capture a broader range of vulnerability in relation 
to drug use and hospitalization risk), for the examination of coexisting dementia, depression and 
frailty, we were primarily interested in considering the condition or state of ‘being frail’ as 
specifically defined by the measures used. 
The highest proportion of residents were identified as having frailty, depression and dementia 
when frailty was classified by the Armstrong FI. However, since the Armstrong FI identified 
more individuals as ‘frail’ than any of the other frailty measures, the higher degree of overlap 
across the three conditions may not reflect that Armstrong FI frailty coexists most often with the 
other two conditions. Indeed, of all of the frailty measures, the Armstrong FI classified the 
second highest number of residents with neither depression nor dementia as frail. 
Frail residents, as classified by the Full FI, more frequently also had at least one of the two other 
conditions when compared to residents classified as frail by the other measures. Additionally, the 
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Full FI classification system resulted in the fewest total residents classified as only frail, without 
having either of the other two conditions. 
There was moderate overlap between CHESS frailty and the other two conditions, with an 
equivalent proportion of frail residents having either depression or dementia as was observed 
using the Armstrong FI. 
Regardless of the frailty measure used, there was always a higher proportion of frail residents 
with depression than frail residents without depression. However, using either CHS measure, 
there was a higher proportion of frail residents without dementia than frail residents with 
dementia. This may be explained by the fact that the CHS measure does not include any items 
pertaining to cognition, as explained above. Using the two CHS measures, the lowest proportion 
of residents identified as frail also had either dementia or depression, when compared to the other 
frailty measures.  
It is not surprising that frailty, as defined by the FI, more frequently co-exists with dementia and 
depression when compared to frailty, as defined by CHS. Although the CHS measure includes an 
exhaustion item, which may serve as a marker of depression, it is mostly focused on physical or 
phenotypic decline. There are no items assessing cognition in the CHS measure. The FI, in 
contrast, focusing on accumulation of deficits across numerous domains, includes items related 
to cognitive and psychosocial concerns. In fact, according to the FI conceptualization of frailty, 
depression and dementia would be items that, when combined with other deficits, could lead to a 
state of frailty. 
It is clear that depending on the measure used to classify frailty, the extent to which the condition 
co-exists with dementia and depression will vary. In order to understand the complex interplay 
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between these three conditions, it will be important to carefully consider the specific frailty 
measure used, and thus the conceptualization of frailty that is being investigated. 
6.3 Objective 1b: Examine High-Risk and Antipsychotic Medication Use by 
Resident-Level Characteristics and by Frailty Status, as identified by 3 measures of 
vulnerability 
6.3.1 High-Risk and Antipsychotic Medication Use by Resident -Level Characteristics 
Findings regarding the distribution in use of many HR/antipsychotic medications by resident-
level characteristics are, in many cases, likely related to the distribution of conditions indicating 
the use of these medications. For example, the higher rates of oral antidiabetic use in men, 
compared to women, is likely related to the higher incidence of diabetes in men compared to 
women, while decreased use of insulin and oral antidiabetic agents in those aged 80 and over 
compared to those aged 65-79 is supported by the decreased prevalence of diabetes among the 
oldest old in Canada.
179 
Antipsychotic use was observed to be significantly more common in those with fewer social 
supports (i.e., those who were never married/separated/divorced, compared to married residents; 
and those with low-no social relationships, compared with moderate-high social relationships). 
Possible explanations for this observation include close family members advocating for residents 
with dementia and opposing the use of antipsychotics, or informal caregivers easing the burden 
for AL staff, leading to decreased need for sedation of these residents. With respect to strength of 
social relationships, it is also possible that a portion of residents with dementia (frequent users of 
antipsychotic agents), have reduced capacity to maintain strong social relationships. 
As expected, those with higher cognitive impairment (CPS score) were significantly more likely 
to be using antipsychotic agents. This observation is most likely reflective of the prescription of 
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antipsychotics to those with dementia (generally considered an off-label use of these agents), in 
order to sedate residents and control behavioural symptoms. It follows that residents with higher 
aggressive behaviour scores (ABS) would also be more likely to be using antipsychotic agents, a 
finding which was observed in this population. 
The frequency of antipsychotic use among residents with dementia in this study is troubling 
given the increased risk of death associated with use of these drugs in those with dementia;
66-70
 
however, the observed prevalence appears to be consistent with rates reported in the literature. In 
a study of Ontario LTC residents, Bronskill and colleagues
173
 observed that roughly 20.5% of 
residents were on antipsychotic agents with a diagnosis of dementia, consistent with the 20.7% 
(225/1089) of residents in the present study. The prevalence of antipsychotic use among nursing 
home residents with dementia was found to vary considerably among 8 European countries 
(Germany, England, Finland, France, Italy, Netherlands, Czech Republic, and Israel) ranging 
from 18% (Israel) to 60% (Czech Republic) with an average of 32.8%,
180
 similar to the 35.9% 
(225/627) of ACCES DAL residents with dementia using antipsychotic agents. Despite the 
similar rates observed in LTC facilities across Ontario and Europe, there have also been findings 
from a previous ACCES study that rates of antipsychotic use among residents with dementia 
were significantly higher among DAL residents compared to LTC residents.
163 
For all medication classes studied, the prevalence of use of one or more medications from the 
drug class increased in those residents with higher levels of comorbidity (with the exception of 
oral antiplatelet agents), and with increasing levels of medication number. These findings are 
consistent with expectations since the medications considered are often used for the treatment of 
disease, and thus, use of the medications would be associated with comorbidity count. 
Additionally, use of medications from a specific drug class would be expected to be associated 
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with overall number of unique medications used, particularly since the medications of interest 
were not removed from the medication number variable for the purpose of these preliminary 
analyses (but were excluded from the drug count in all multivariable models, presented in 
sections 5.5-5.6). 
Use of oral anticoagulants was found to be significantly associated with increasing number of 
hospital admissions in the previous year, whereas, use of antipsychotic agents was lowest among 
those who had experienced two or more hospital admissions in the past year. None of the other 
medication classes of interest were found to be significantly associated with previous 
hospitalizations. The association between use of oral anticoagulants and previous 
hospitalizations may be explained by the fact that anticoagulants would frequently be prescribed 
following a stroke or cardiac event which required hospitalization. Prescription of antipsychotic 
agents, in contrast, may be reconsidered upon hospitalization if the attending physicians feel that 
the patient is at risk of adverse events due to the drugs (or if a drug-related adverse event was the 
reason for hospitalization). Narrow therapeutic window (NTW) drugs are beneficial and often 
necessary, if used properly, and thus, it is unlikely that use of these drugs would be discontinued. 
Antipsychotic agents, in contrast, are frequently used in those with dementia, against 
recommendations, which may explain why antipsychotic use would be discontinued upon 
hospitalization. 
6.3.2 High-Risk and Antipsychotic Medication Use by Frailty Status 
The association observed between antipsychotic medication use and both Full FI frailty and 
CHESS instability is likely related to the cognition items included in each of these indices. These 
items increase the likelihood that residents with dementia, and resulting high rates of 
antipsychotic use, will be identified as frail (or at high risk) by these indices. No such association 
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was observed with CHSrel, likely because the CHS measure contains no items related to 
cognitive function. 
Notably, although no significant associations were observed between the use of HR medication 
classes and frailty status (defined by any of the 3 key frailty measures, see table 5.3.2a-c), there 
were significant associations between the diagnoses potentially indicating use of certain HR 
medication classes and frailty status (see Appendix G). This may suggest potential under-
treatment of medical conditions in frail individuals, or it may indicate rational prescribing to 
limit polypharmacy or burdensome therapies (potentially at the request of patient or family 
members) in frail patients. However, since many of the diagnoses considered were simply 
associated with use of the medication class, and did not necessarily represent indications for the 
use of the medication, it is difficult to conclude whether under-prescribing was a true concern. 
Furthermore, observed associations are likely related to the methodology for measuring frailty. 
For example, it is not surprising that diagnoses associated with use of each of the medication 
classes of interest were significantly associated with Full FI frailty status since many of these 
diagnoses would have counted as deficits contributing to the calculation of the frailty index. 
6.4 Objective 2a: Examine Association between Frailty Status and First Event 
Hospitalization during a 1-year follow-up 
6.4.1 Resident-Level Covariates and Outcome 
The chi-square analyses revealed that DAL residents with higher levels of comorbidity, 
functional disability and social vulnerability were more often hospitalized compared to residents 
who were less vulnerable with respect to these characteristics. However, residents with greater 
vulnerability in terms of cognitive impairment and depression, as well as those exhibiting more 
aggressive behaviour were less likely to be hospitalized. Previous publications have observed 
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similar findings regarding decreased risk of hospitalization with increasing cognitive impairment 
among nursing home residents.
181-183  
Although residents with cognitive impairment and depression may be expected to be more 
vulnerable to adverse events compared to those without, it is possible that these residents are 
unlikely to recognize health concerns and/or communicate these concerns to AL staff, thus 
reducing the number of hospitalizations in these groups when compared to cognitively intact and 
non-depressed residents. These findings may also indicate a preference toward less aggressive 
treatment for depressed and cognitively impaired individuals. Notably, increased levels of 
cognitive impairment, depressive symptoms and aggressive behaviour are all associated with 
increased risk of first-event transfer to LTC or death, suggesting that these characteristics are 
indicative of increased vulnerability to adverse outcomes, even if they are not associated with 
increased rate of first-event hospitalization. 
6.4.2. Bivariate Analyses: Frailty and Outcome 
In bivariate analyses, all measures of vulnerability (CHSabs, CHSrel, Full FI, Armstrong FI, 
CHESS and fatigue) were found to be significantly associated with first-event outcome. 
However, Cox proportional hazards models revealed that only CHSrel, Full FI, and CHESS 
vulnerability as well as the single fatigue item from the interRAI-AL tool were significant risk 
factors for time to first-event hospitalization. No significant difference in risk of first-event 
hospitalization was observed among those with increasing levels of frailty, as judged by CHSabs 
or Armstrong FI. Both CHSabs and the Armstrong FI detected a high prevalence of frailty and 
pre-frailty among DAL residents, classifying only 3.5% and 11.8% of residents as robust, 
respectively. It is possible that these measures were not highly predictive of hospitalization 
because they did not differentiate between the higher degrees of vulnerability common in 
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assisted living residents. The paper by Armstrong and colleagues (which was used as the basis 
for development of the Armstrong FI used in the present study), reported that the Armstrong FI 
and CHESS were both significantly associated with adverse outcomes (institutionalization or 
death) for home care clients, but higher hazard ratios were observed for CHESS.
90
 In previous 
publications from the ACCES study it has been observed that Armstrong FI frailty was 
significantly associated with an increased risk of death and transfer to long-term care, but not 
hospitalization.
85
 CHSabs, as well, was more highly associated with risk of death or transfer to 
long-term care than with risk of hospitalization.
85 
In this analysis, the CHS frailty measure (relative cut-points), was found to be the most 
predictive of hospitalization. The Full FI was associated with a lower risk of first-event 
hospitalization than both CHSrel and CHESS. In a previous publication comparing the CHS 
frailty criteria to a deficit accumulation approach to detecting frailty (similar to the FI), 
Kulminski and colleagues observed that the deficit accumulation approach predicted mortality 
better than the CHS phenotypic approach.
161
 It is clear that across different populations, settings, 
and outcomes considered, there is no consistently superior frailty measure for predicting adverse 
outcomes. Indeed, the definition and conceptualization of frailty, as well as the merit for 
inclusion of social, psychological and cognitive items in frailty measures has been an ongoing 
source of debate.
19,20,23
 
In a previous ACCES study it was shown that the interRAI-AL measure of fatigue was highly 
associated with hospitalization.
85
 In order to explore whether this single item could predict 
hospitalization with similar strength as the full measures, fatigue was included as a vulnerability 
measure in this analysis. In the survival analysis models, moderate to severe fatigue was found to 
be a strong predictor of hospitalization (adjusted HR = 1.81, 95% CI 1.37-2.40), second only to 
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CHSrel frailty (adjusted HR = 2.11, 95% CI 1.53-2.92). This finding suggests that a simple 
measure of fatigue may be worthy of exploration and further comparison with other vulnerability 
measures as a predictor of adverse outcomes. However, the fatigue variable considered here is an 
acute measure, defined as inability to complete normal daily activities in the past 3 days due to 
diminished energy. As such, it is possible that this measure of fatigue may not be a strong 
indicator of vulnerability to adverse events relating to prevalent use of high-risk medications. 
For the remaining analyses, the CHSrel, Full FI and CHESS measures were selected in order to 
explore frailty as an effect modifier of the association between high-risk/antipsychotic 
medication use and hospitalization. This decision was made based on evidence from previous 
publications using ACCES data regarding the appropriateness of these measures for this 
population
85,123 
as well as from preliminary analyses explored in this research.
85
 The analyses 
discussed here offer further support for the selection of these measures as predictors of 
hospitalization. Additionally, the three measures selected each emphasize very different 
methodologies for detecting vulnerability, allowing for comparison of different 
conceptualizations of frailty.  
6.5 Objective 2b: Examine Association between Exposure to High-
Risk/Antipsychotic Medication Measures and First Event Hospitalization during a 
1-year follow-up 
Use of certain high-risk medication classes was associated with adverse first-event outcomes in 
the chi-square analysis, and with hospitalization in age- and sex-adjusted models. However, in 
fully-adjusted models, for the majority of medications considered, no significant association was 
observed between medication use and hospitalization. The risk associated with use of these 
medications in the age- and sex-adjusted models appears to have been strongly influenced by 
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confounding. In particular, it appears that confounding by indication was relevant in these 
analyses. For almost all medication classes considered, the hazard ratios dropped closer to one 
and were no longer significant after adjusting for the presence of selected diagnoses (which 
represented likely indications for use of the selected drug/drug class) and which would be 
expected to be independent risk factors for hospitalization. 
The only medication class which remained significantly associated with first-event 
hospitalization in the fully-adjusted models was use of non-acetylsalicylic acid (ASA) 
antiplatelet agents (without ASA antiplatelet agents). It is possible that use of non-ASA 
antiplatelet agents causes adverse drug events or declining health, leading to higher rates of 
hospitalization. Use of clopidogrel (the primary non-ASA antiplatelet agent prescribed in this 
population) has been found to be associated with an increased risk of gastro-intestinal (GI) 
bleeding; however, the risk of such an adverse event was found to be higher with use of ASA 
than with use of clopidogrel, and highest with combined use of both ASA and coplidogrel.
184,185
 
Therefore, the risk of GI bleeding would not explain the elevated risk of hospitalization in those 
using non-ASA antiplatelets compared to those using ASA (with or without non-ASA) 
antiplatelets. Clopidogrel use has also been reported to be more effective than ASA at reducing 
the risk of stroke, myocardial infarction, and vascular death,
186 
 suggesting that the observed 
association is not related to limited effectiveness of non-ASA antiplatelet agents.
 
However, it has 
been observed that risk of adverse events among patients with acute coronary symptoms 
increased significantly in the 90-day interval after discontinuing clopidogrel treatment.
187
 Given 
that medication exposure was assessed at baseline during data collection for ACCES, the 
elevated risk of hospitalization observed in residents using non-ASA antiplatelet agents could be 
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related to the discontinuation of this medication at some point during the 1-year follow-up period 
and the increased risk of adverse events in the days following discontinuation. 
It is also possible that the observed association is the result of confounding by indication, despite 
adjustment for possible confounders. The following scenarios are potential examples of how 
confounding by indication could lead to an observed association between non-ASA antiplatelet 
use and hospitalization: (i) non-ASA antiplatelet agents are preferentially used in those with a 
higher severity of disease, and the disease severity results in a higher likelihood of hospital 
admission; or (ii) residents who were using non-ASA antiplatelet agents were using these drugs 
because of existing health conditions contraindicating the use of ASA antiplatelet agents (other 
than the diagnoses adjusted for), and these health conditions were the reason for the increased 
risk of hospitalization. 
In fact, clopidogrel has been reported to be more effective than ASA at preventing stroke in 
high-risk subgroups of patients
186,189 
If clopidogrel, and other non-ASA antiplatelet agents are 
frequently used in those with a higher baseline risk of stroke, this could explain the higher 
hospitalization rate among non-ASA antiplatelet users. 
Additionally, the 2002 recommendations on the treatment of patients with unstable angina, 
released by the American College of Cardiology/American Heart Association (ACA/AHF) Task 
Force, recommended the use of clopidogrel in patients who experienced gastrointestinal 
intolerance with the use of ASA.
190
 Later studies revealed that clopidogrel was also associated 
with an increased risk of recurrent ulcer bleeding, suggesting that it is not a suitable alternative to 
ASA treatment for prevention of GI bleeding.
191 
The 2008 version of the ACA/AHF 
recommendations no longer suggested clopidogrel for patients with GI concerns.
184
 However, 
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given that the ACCES study began in 2006, it is possible that the elevated risk of hospitalization 
associated with use of non-ASA antiplatelet agents is related to the preferential use of 
clopidogrel over aspirin in residents with a history of GI concerns, as suggested in the 2002 
recommendations, potentially resulting in higher rates of GI bleeding in those using non-ASA 
antiplatelets.  
The combined measure of use of high-risk medication classes remained borderline significant in 
models B and C, but was no longer significant in model D, the fully adjusted model. In all 
models, the hazard ratio for hospitalization increased with increasing number of high-risk 
medication classes used. Considering the HR drug classes individually, the major risk associated 
with anticoagulant and antiplatelet use is bleeding,
192,193
 while insulin and oral antidiabetic 
agents are associated with a risk of hypoglycemia or hyperglycemia if their use is not managed 
properly.
59.60
 Certain oral antidiabetic agents have also been reported to be associated with risk 
of myocardial infarction and congestive heart failure.
194
 It might be expected that there would be 
a higher risk of adverse outcomes in those using medications from more than one high-risk class 
because of the potential for interaction between different high-risk medications, which may 
impact the dosage and timing within which these medications are effective and safe; and because 
of the potential errors due to the management of multiple complex medication regimens. Indeed, 
the combined use of anticoagulant and antiplatelet agents has been associated with a heightened 
risk of bleeding compared to use of either individually.
192 
Additionally, a higher risk of edema 
has been identified with combined use of insulin and certain oral antidiabetic agents 
(thiazolidinediones) compared to individual use.
195
 With the combined HR medication classes 
variable and many of the other medication variables considered, it would be useful to conduct 
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analyses with a larger sample in order to investigate whether moderately elevated risks, such as 
those observed for this variable, would be statistically significant.  
Baseline use of antipsychotics was found to be associated with a first-event outcome of death or 
transfer to LTC compared to other outcomes of interest in chi-square analyses. However, use of 
antipsychotic agents was not associated with hospitalization risk in any of the models. Major 
risks associated with antipsychotic use include falls,
31,64
 worsening of symptoms of 
Parkinsonism,
75
 as well as stroke
32
 and sudden cardiac death,
 33 
particularly among those with 
dementia.
 66,67,68
 
6.6 Objective 3: Determine whether Frailty Measures act to modify the 
Associations between specific High-Risk Medication Use and Hospitalization 
during a 1-year Follow-up. 
6.6.1 Cox Proportional Hazards Models: High-Risk and Antipsychotic Medication Use, Frailty 
and Hospitalization 
When compared to a reference group of non-frail residents not using the drug of interest, frail 
residents using the medication were observed to be at the highest risk for most of the medication 
variables and frailty measures explored. In many of these cases, the risk among frail medication 
users was statistically significant (anticoagulants, antiplatelets, any diabetes medication, and 
antipsychotics agents, with any measure of frailty; oral antidiabetics and insulin/sulfonylurea, 
with Full FI frailty).   
Of note were the findings for antipsychotic agents where a significantly heightened risk of 
hospitalization was observed in frail antipsychotic users compared to non-frail non-drug users, 
and a decreased risk of hospitalization was found in non-frail antipsychotic users. Although the 
decreased risk among non-frail users was not statistically significant, it is interesting to consider 
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that use of antipsychotic agents may increase risk of hospitalization in frail individuals, but have 
a protective effect in non-frail individuals. Given the high degree of overlap reported between 
frailty and dementia,
91
 it is possible that the risk associated with antipsychotic use in individuals 
with dementia could be partially explained by frailty status. 
Another notable observation involved the use of non-ASA antiplatelet agents. A heightened risk 
of hospitalization was observed in non-ASA antiplatelet users, which was significant for frail 
non-ASA users (for all three measures of frailty), but only significant in non-frail residents when 
frailty status was determined by CHESS. The highest risk was observed for frail non-ASA users 
and this risk was considerably higher in magnitude than the risk associated with any of the other 
frailty/antiplatelet use combinations, regardless of frailty measure used. As stated, the heightened 
risk of hospitalization in users of non-ASA antiplatelet agents may be related to some risk of 
adverse events resulting from use of these drugs, or it may result from confounding by some 
factor related to use of non-ASA antiplatelets over ASA antiplatelets. Regardless, frailty status 
(as measured by Full FI and CHS, in particular) appears to have differentiated a group of non-
ASA antiplatelet users who were at a higher risk of hospitalization.  
Although the models included adjustment for diagnoses which represented common indications 
for the medication of interest, information was not available regarding disease severity. Thus, it 
is possible that the combination of high-risk medication use and frailty status captured residents 
with higher disease severity, who thus would be expected to have a greater risk of hospitalization 
as a result of the severity of their disease status, rather than the effects of the medication. 
However, it is also possible that, as hypothesized, physiological changes resulting from a state of 
frailty alter the range at which high-risk medications are safe and effective, or that 
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cognitive/social/psychological deficits impact the management of medications, resulting in an 
increased number of adverse drug events from the use of NTW drugs.  
6.6.2 Cox Proportional Hazards Models: High-Risk and Antipsychotic Medication Use, Frailty 
and Hospitalization (Comparator Groups: Non-frail Medication Users)  
In order to allow for direct comparison of the effect of frailty on the hospitalization risk 
associated with use of HR/antipsychotic medications, analyses were conducted using a reference 
group of non-frail residents using the drug of interest (table 5.6.2a).  
In fully adjusted models, the Full FI was the frailty measure that was most often associated with 
a significantly increased risk of hospitalization in residents using certain medication classes, 
when compared to non-frail users of the medication classes. When considering HR drugs, use of 
anticoagulants and use of antiplatelet agents were each associated with a significantly increased 
risk of hospitalization in Full FI frail residents (HR = 1.64, 95% CI 1.06-2.53; HR = 1.66, 95% 
CI 1.15-2.38, respectively). In most cases, the hazard ratios were elevated for frail non-users; 
however, these findings were not statistically significant in the fully adjusted model.   
The other high-risk medication variables considered (oral antidiabetics, insulin, and combined 
variables of the two classes) were not associated with a significantly increased risk of 
hospitalization when frail users were compared to non-frail users. Given that there were 
relatively few residents using insulin or oral antidiabetic agents, it is not surprising that findings 
were non-significant. However, the evidence that the risk of hypoglycemia may be elevated in 
individuals with dementia using oral antidiabetics,
111
 along with the frequent co-occurrence of 
dementia and frailty,
91
 suggest that it may be worthwhile to explore this question further in a 
sample with more participants or with a higher proportion of diabetic participants. 
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Using both the Full FI and CHS measures, use of antipsychotic agents in frail individuals was 
significantly associated with first-event hospitalization when compared to non-frail users (see 
table 5.6.2a). Again, it is interesting to note that no association was observed between 
antipsychotic use and hospitalization risk in models that were not stratified by frailty. However, 
upon stratification, a significant risk associated with antipsychotic use in frail residents was 
observed. This finding may indicate that certain frailty measures can, in fact, be used to 
differentiate between individuals who are at risk of poor outcomes from the use of antipsychotics 
and individuals who benefit from their use.  
6.6.3 Facility Factors Associated with Frailty/Medication Use 
The observation that frail users of antipsychotics were more frequently residents of facilities with 
no oversight by registered nurses (RNs) or licensed practical nurses (LPNs) compared to non-
frail users of antipsychotics is a troubling finding. As hypothesized in the present research, a 
state of frailty may increase the risks associated with the use of certain medications. Indeed, it 
was observed that frail individuals were at a higher risk of hospitalization compared to non-frail 
individuals when using antipsychotic medications. This finding suggests that the presence of 
skilled nursing staff (who are trained to monitor medication use and identify signs of adverse 
effects) in the AL facility may be particularly important in facilities where frail residents 
frequently use such medications. Indeed, it has been reported that a higher proportion of RN or 
LPN nursing staff hours in AL facilities may reduce the risk of hospitalization among 
residents.
121,122
 Although frail residents using antipsychotic agents were more likely to reside in a 
facility with an affiliated general practitioner (GP) compared to non-frail residents using 
antipsychotics, an even greater proportion of residents living in a facility with an affiliated GP 
were non-frail and not using antipsychotics.  
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In fact, for all other medication classes of interest, non-frail residents using the medication of 
interest were more likely to be in a facility with an affiliated GP compared to frail residents using 
the medication of interest. These findings, again, raise concerns that individuals who are most 
vulnerable are living in the facilities with lower skilled staffing while comparatively robust 
individuals are living in facilities with greater oversight by skilled medical professionals. 
Similarly, non-frail residents not using the drug of interest (high-risk or antipsychotic 
medications) more frequently resided in facilities with pharmacist involvement compared to frail 
residents for all drugs considered. Although these observations may be a reflection of trained 
medical professionals acting to prevent the development of frailty or taking steps to reduce use 
of unnecessary medications by residents of these facilities, it may also demonstrate 
incompatibility between skilled staffing in AL facilities and the level of vulnerability and 
complexity of the residents. Such a discrepancy between the complexity of resident medication 
regimens and skill level of staff was also found in a US AL study.
113 
Strengths and Limitations 
The present research has several strengths stemming from the strengths of the ACCES study. 
These include the large sample size of 1,066 participants, the relatively high response rate of 
72%, linkage to validated data for the hospitalization outcome, inclusion of participants from a 
variety of different DAL facilities, and the collection of comprehensive prospective data. 
Additionally, the examination of first-event outcomes ensures that observed hospitalization 
events are related to care received in the AL facility and not related to another care transition; 
and the use of survival analysis methods optimizing the sample size by extracting information 
from participants censored prior to the study end date. Finally, compared to other studies which 
141 
 
often utilize data on prescribed or dispensed medication (not necessarily indicative of actual 
medications used), the collection of data on actual medication use is a strength of this study. 
There are also some limitations that must be considered. Approximately 28% of eligible 
residents from participating AL facilities were not enrolled. Although the age and sex 
distribution of these individuals were similar to those of the participants, the generalizability of 
the study results may be limited. Enrollment into ACCES was restricted to residents of 
designated assisted living. These publicly subsidized AL facilities fall under regulation of the 
Alberta provincial health service and are accessed through a single point of entry. Thus, there 
may be concerns with generalizing the findings of this study to private-pay facilities or AL in 
other provinces. Despite this, there are common elements among all AL facilities which 
differentiate them from other settings. 
The exposure of interest was the use of high-risk or antipsychotic medications. One limitation of 
the research approach is that prevalent, rather than incident, medication use is considered, 
allowing for the possibility of healthy user bias. Information on incident medication use was not 
available in the ACCES database, and if it were, consideration of incident, rather than prevalent, 
medication use would have considerably reduced the number of participants with the exposure of 
interest. Regardless, it is possible that by considering prevalent medication use, the present 
research has an exposure group made up of participants who are especially tolerant to these high-
risk medications, while those who would be sensitive to adverse effects resulting from these 
drugs had already ceased taking them or been lost to follow-up due to death or transfer to LTC.  
In addition to the limitations regarding potential healthy user bias, there are further limitations 
related to the exposure. The dose of medication used was not considered in analyses. 
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Additionally, the measure of medication use utilized was based on the baseline assessment only. 
Any potential changes in medication use over the follow-up period were not explored. However, 
concerns regarding changing medication exposure over the follow-up period or the potential for 
healthy user bias may be less problematic in this study, considering that the primary medication 
exposure of interest is high-risk medications. High-risk medications, as defined above, are 
necessary treatment for many older adults. Thus, discontinuation of the drugs following adverse 
effects would be less likely for users of these medications than for other, less essential 
pharmacotherapy. 
The outcome of consideration for the present research was limited to hospitalization. It is 
possible that other outcomes are more relevant to high-risk medication use such as falls, 
functional decline or death (particularly in the case of antipsychotic use for those with dementia). 
Future studies with longer follow-up may be better suited to investigating such outcomes. 
Hospitalization was identified using provincial data. Thus, any hospitalization events that 
occurred outside of Alberta may be missed. 
The current study did not assess the reason for hospitalization, and as such, there is no way to 
confirm whether the observed hospitalizations were related to medication use. Although most-
responsible-diagnosis information was available through the Alberta Inpatient Discharge 
Abstract Database (and is shown in Appendix I), it is possible that observed hospitalization 
events could have been related to medication use, either directly or indirectly, without the 
knowledge of the health care provider, and could go unnoticed and unreported. As a result, 
limiting analyses to only those hospitalizations designated as adverse drug events would 
potentially overlook some important outcomes related to medication use. 
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Data collection for ACCES took place between 2006 and 2009. Given the changes that have 
taken place in Alberta AL facilities since that time, these data may not represent the most up-to-
date trends in AL. Despite this limitation, the findings of this study will likely be applicable to 
AL facilities in Alberta and beyond with respect to the continued use of high-risk medications 
among vulnerable residents. 
Almost 40% of participants did not complete one or both of the physical measures of the CHS 
frailty assessment. As pointed out in earlier publications from the ACCES study, the inability of 
some DAL residents to carry out the CHS frailty assessment as originally designed suggests that 
this assessment may not be a feasible means of identifying vulnerability in an AL setting.
85,123
 In 
order to supplement missing data for those residents who did not complete the full CHS frailty 
assessment, responses to applicable questions from the interRAI-AL assessment were 
substituted. Using this modification, the proportion of participants with missing data for the CHS 
frailty assessment was reduced to 15%, decreasing the sample size to 930 for this measure. 
Modifications to the CHS frailty assessment have been necessary in other studies, including an 
analysis of frailty in the Women’s Health and Aging Studies, carried out by Fried and 
colleagues.
196
 
Despite these limitations, the present research offers some important insights into the feasibility 
of frailty as an indicator of vulnerability to adverse outcomes related to HR/antipsychotic 
medication use. 
Implications and Future Research 
The present research offers evidence suggesting that a state of frailty may increase the risk of 
adverse outcomes associated with the use of antipsychotic and high-risk medications. In 
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particular, the risk of hospitalization appears to be significantly elevated in frail individuals using 
oral anticoagulants, oral antiplatelet agents, medications from any HR drug class (particularly 
when two or more HR classes are used concurrently), and antipsychotic agents. 
The inter-RAI CHESS measure of vulnerability was not particularly useful for differentiating 
risk associated with use of these medications; however, the CHS frailty measure, with relative 
cut-points, and in particular, the Full FI were often able to differentiate residents with a higher 
degree of vulnerability.  
The observation that frail antipsychotic users were at a considerably elevated risk compared to 
non-frail antipsychotic users has interesting implications. It has been observed that antipsychotic 
use is associated with an increased risk of stroke, cardiac failure and death in individuals with 
dementia,
66,67,68
 and the frequent co-occurrence of frailty and dementia has been highlighted by 
Hubbard.
91
 However, even after controlling for dementia status, the risk among frail individuals 
using antipsychotic agents remained significantly elevated. Perhaps those individuals at highest 
risk due to the use of antipsychotic agents are not just those with dementia, but also frail 
individuals. Frailty status could be considered as a means for determining whether antipsychotic 
agents can be safely prescribed to certain older adults. However, further support for this research 
question in future studies would be necessary before such policies could be implemented. 
The findings regarding non-ASA antiplatelet use are not fully understood. Frail users of non-
ASA antiplatelet agents were found to be at the highest risk of hospitalization compared to the 
other possible frailty-antiplatelet use combinations. However, it appears that, unlike many of the 
other medication classes examined, a substantial portion of the observed risk was associated with 
use of the medication itself (and a smaller portion of the risk was associated with frailty status). 
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Additionally, unlike other medication exposures, it appears that the CHSrel frailty measure, 
rather than the full FI, may be the most suitable for differentiating levels of risk associated with 
use of non-ASA antiplatelet agents. There was limited evidence in the literature suggesting that 
there is a true increased risk resulting from non-ASA antiplatelet use compared to ASA use.  
However, possible explanations for the risk associated with non-ASA antiplatelet use include 
risk related to the discontinuation of these medications,
187
 or confounding due to preferential use 
of non-ASA antiplatelets over ASA antiplatelets in those with a history of GI bleeding,
191
 or 
those with a higher severity of disease.
188,189
 
Given the strong associations between adverse drug events and the use of high-risk and 
antipsychotic medications in older adults,
30,55
 using a frailty measure as a means of determining 
which older adults are more vulnerable to adverse outcomes may be advantageous for identifying 
those in need of careful medication management and additional monitoring by trained staff. 
Considering the findings suggesting that the presence of skilled medical staff in AL facilities is 
often not associated with higher levels of frailty or use of more complex medications, it may be 
particularly relevant to consider the level of medication monitoring available to vulnerable 
residents in these settings.  
Although levels of comorbidity and physical impairment are generally lower in AL facilities, 
compared to LTC facilities, a high prevalence of dementia and mental health concerns have been 
observed in the ACCES DAL cohort, as well as other AL studies.
165,166 
Additionally, compared 
to LTC facilities, the DAL population studied in ACCES was found to have similarly high levels 
of medication use. The high degree of cognitive and mental health concerns in this setting would 
be expected to lead to greater dependence on AL staff for medication management. In 
combination with the high degree of polypharmacy in this setting, these findings suggest that a 
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higher degree of professional oversight is required in AL settings, particularly with respect to 
medication management and monitoring. 
The need for increased oversight in AL facilities is further indicated by the high rates of 
hospitalization from these facilities. The reported rates of hospital admission from AL facilities 
are significantly higher than those from LTC.
112
 Given that acute care hospitalizations come at a 
considerable cost,
139,143
 measures to reduce hospitalization (related to adverse drug events, or 
other concerns) should be prioritized. Requirements for 24-hour oversight of AL residents by 
RNs or LPNs may be a valuable policy in order to improve the quality of care provided to 
residents and reduce costs associated with acute care hospitalizations (resulting from adverse 
drug events, or other quality of care concerns). Indeed, increased RN and LPN staffing per 
resident has been found to be associated with reductions in the number of adverse drug events in 
AL facilities.
121,122,132
 Additional policies which may be valuable include involvement of on-staff 
physicians or pharmacists in the medication management of AL residents. 
Although the findings of the present research are not enough to support conclusive statements or 
policy recommendations regarding the use of frailty measures to identify those at highest risk of 
adverse events related to their medication use, these findings offer sufficient evidence to support 
the continuation of research in this area. In order to further explore this research question, future 
studies should be conducted with a larger sample of participants. Since some findings were not 
statistically significant, larger sample sizes would allow for assessment of whether moderately 
elevated risks are meaningful. Such larger sample sizes would be particularly useful when 
considering diabetes medications as the exposure of interest. Given the relatively low proportion 
of residents with diabetes, findings associated with this exposure were often not significant in the 
present sample. Larger sample sizes may also allow the opportunity to restrict the study sample 
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to only those participants with a medical condition indicating the use of the medication exposure 
of interest. Such restriction may be more precise than model adjustment as a means of 
controlling for possible confounding by indication.  
Another consideration for future research would be exploration of incident medication use as the 
exposure of interest, rather than prevalent medication use, eliminating the concern over healthy 
user bias. An assessment of the severity of disease that indicates the use of the medication of 
interest would also be a useful addition to future studies. Controlling for the severity of the 
disease in analyses would allow for determination of whether frailty status indicates a level of 
vulnerability above that captured by disease severity. 
Future research may also consider the relationship between high-risk medications and adverse 
outcomes, as modified by frailty status, in community-dwelling older adults, or those residing in 
LTC. Another path for future research could be the consideration of additional outcomes which 
are potentially relevant to the exposure of high-risk/antipsychotic medication use, such as death, 
falls or decreased functional capacity. 
This study did not provide any obvious conclusions regarding the best frailty measure for 
identifying individuals particularly vulnerable to medication-related adverse events. However, 
the CHS measure (with relative cut-points) and the full FI appear promising for use in future 
research. In particular, full FI frailty was best able to identify residents at greater risk when using 
antipsychotics, anticoagulants, antiplatelet agents and medications from multiple HR drug 
classes, while CHSrel may be particularly relevant for distinguishing risk among non-ASA 
antiplatelet users. When assessing frailty using these measures, researchers should utilize cut-
points relevant to the study population under investigation. 
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7. CONCLUSIONS 
The prevalence of use of high-risk (HR) medications in the ACCES designated assisted living 
(DAL) population was observed to be quite high with 63.3% of residents using at least one HR 
medication. The HR medications considered in the present study (oral anticoagulants, oral 
antiplatelet agents, insulin and oral antidiabetic agents) have a narrow therapeutic window in 
terms of dosage and timing. Outside of this window, the medications can be ineffective, or even 
hazardous. Indeed, it has been reported that these medication classes are responsible for the 
majority of medication-related hospitalizations.
30,55
 Additionally, despite warnings against the 
use of antipsychotic agents in older adults with dementia, 35.9% of residents with dementia were 
observed to be using an antipsychotic agent in the ACCES DAL cohort. 
Within the ACCES DAL cohort, the full FI (86-item frailty index), CHSrel (CHS frailty measure 
with relative cut-points) and the interRAI CHESS scale each allocated a balanced distribution of 
residents into the categories frail, pre-frail and robust, suggesting that each of these measures is 
suitable for differentiating levels of vulnerability within the vulnerable assisted living (AL) 
population. Additionally, frailty, as determined by each of these three measures, was found to be 
associated with significantly increased risk of first-event hospitalization. 
Although use of HR/antipsychotic medication was not found to be associated with 
hospitalization risk (except in the case of non-ASA antiplatelet agents), upon stratification by 
frailty status, it was found that frail individuals had an increased risk of hospitalization when 
using antipsychotic agents (Full FI or CHSrel frailty), anticoagulants (Full FI frailty), antiplatelet 
agents (Full FI frailty), or medications from any of the high-risk drug classes (Full FI frailty). 
The risk of hospitalization among frail users of insulin or oral antidiabetic agents was not found 
to be significantly elevated above the risk for non-frail users. This observation may be related to 
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the relatively small proportion of residents with diabetes, resulting in small exposure groups for 
insulin and oral antidiabetic use. The significantly heightened hospitalization risks observed for 
frail users of the other medication classes support the hypothesis that frailty status may modify 
the risk associated with HR/antipsychotic medication use. 
Descriptive results demonstrated potential concerns with the match between skilled care 
provision and frailty/medication use in AL settings by revealing that residents identified as frail 
by the Full FI, and residents using HR/antipsychotic medications less often resided in facilities 
with skilled care staff (registered nurse and/or licensed practical nurse staff, physician affiliation, 
pharmacist involvement) compared to non-frail residents and residents not using the medication 
classes of interest. These findings may indicate a need for better balance between the skilled care 
provision in AL facilities and the complexity of residents (in terms of medication use and frailty 
status). 
Based on the findings of this research and the peer-reviewed literature, it is recommended that 
policy be introduced to dictate a minimum level of skilled medication oversight required in AL 
facilities, potentially based on the complexity of residents. Additionally, it is recommended that 
future research should be conducted to further explore the role of frailty as a predictor of adverse 
medication-related outcomes with larger sample sizes and the use of rigorous 
pharmacoepidemiologic methodology. 
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APPENDICES 
Appendix A: Summary of Studies Considering Frailty, Medication Use and Adverse Outcomes 
Author, 
year 
Design/ 
Sample/ Setting 
Independent 
Variables 
Outcome Findings Strengths Limitations 
Runganga, 
2014
17 
-Prospective 
cohort study; 
-351 older 
patients 
receiving post-
discharge 
transitional 
home care at six 
sites in two 
states of 
Australia; 
-Data collection 
carried out from 
Nov 2009 - Sept 
2010 
Exposure: 
Polypharmacy (5-9 
drugs) 
Hyper-
polypharmacy    (≥ 
10 drugs); 
Frailty Measure: 
57-item Frailty 
Index (derived 
from interRAI-HC) 
Failure to 
improve ADL or 
IADL,
197
 or falls 
over the 
transitional care 
period (TCP) 
-Increased level of 
polypharmacy was 
associated with reduced 
improvements in ADLs and 
IADLs, although only one 
OR reached statistical 
significance: Hyper-
polypharmacy was 
associated with failure to 
improve IADLs (OR = 
3.42, 95% CI = 1.13-10.38) 
-The polypharmacy group 
was most strongly 
associated with falls (OR = 
4.69, 95% CI = 1.06 - 
20.68); 
-Frailty status was observed 
to mediate the effect of 
polypharmacy 
-Prospective data 
collection 
 
-Short follow-up 
period (average 7 
weeks); 
-No inclusion of 
possible confounders 
in multivariate model 
(despite having a 
great deal of data on 
potential confounders 
available from the 
interRAI-HC);  
-Few findings 
reached statistical 
significance; 
-Drug use determined 
from hospital records, 
no information on 
continued 
use/adherence 
Pugh, 
2014
15 
-Retrospective 
cohort study; 
-135,155 
veterans aged 65 
and older with at 
least 1 hospital 
admission 
between Oct 
2005 and Sept 
2006; 
Exposure: Use of 
any HEDIS high 
risk medications in 
the elderly 
(HRME);
29 
Frailty Measure: 
Presence of one or 
more of the 
following 
diagnoses (which 
Hospital re-
admission 
within 30 days 
of discharge 
-Exposure to chronic 
HRME without frailty is 
protective over re-
admission (OR = 0.87, 95% 
CI = 0.82-0.92) 
-Frail participants exposed 
to chronic HRME were not 
protected (OR = 1.08, 95% 
CI = 0.97-1.20; 
-No interaction between 
-Large sample; 
-Consideration of 
both chronic and 
incident 
medication use; 
-Inclusion of 
relevant 
covariates 
(supported by 
existing 
-Determine frailty 
based on diagnoses 
associated with 
frailty, rather than 
measuring frailty 
directly; 
-Short follow-up 
period (30 days); -
Drug use determined 
from pharmacy data, 
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-US National 
Veterans Affairs 
(VA) data 
have been found to 
be associated with 
the CHS frailty 
measure in prior 
studies): 
coagulotherapy, 
involuntary weight 
loss, fluid and 
electrolyte 
imbalance, anemia, 
and fall or fracture 
frailty-related diagnoses 
and incident HRME 
literature) in 
multivariate 
model 
no information on 
medication 
adherence; 
 
Bennett, 
2014
16 
-Prospective 
cohort study; 
-204 older 
patients (≥ 60 
years) admitted 
to the 
emergency 
department of a 
Sydney, AUS 
tertiary referral 
hospital due to a 
fall  
-Data collection 
from June 2012 
- March 2013 
Exposure:  
-Use of fall-risk 
increasing drugs 
(FRIDs),
 
-Number of 
medications,
 
or 
-Potential drug-
drug interactions 
(DDIs)  
at admission and 
discharge
 
Frailty Measure: 
The Reported 
Edmonton Frail 
Scale, assessed at 
admission 
-Recurrent falls, 
-Functional 
decline (as 
assessed by 
ADLs and 
IADLs),
197 
-Institutional-
ization (nursing 
home admission 
or rehabilitation 
hospital),  
-Rehospital-
isation  
in the two 
months 
following index 
hospital 
admission 
-Frail participants were 
more likely than robust to 
use FRIDs, high number of 
medications and have 
potential DDIs; 
-Number of FRIDs was 
associated with falls (OR = 
1.7, 95% CI = 1.3-2.1), 
institutionalization (OR 
=1.3, 95% CI =1.1-1.6), and 
functional decline (OR = 
1.3, 95% CI = 1.1-1.6); 
-Overall number of 
medications was associated 
with falls, hospitalization 
and functional decline to a 
lesser degree; 
-Potential DDIs were not 
found to be significantly 
associated with adverse 
outcomes; 
-The threshold for the 
number of  FRIDs that 
predicts falls was 2.5 in the 
robust and 1.5 in the frail  
-Prospective data 
collection;  
-Inclusion of 
relevant 
covariates 
(supported by 
existing 
literature) in 
multivariate 
model 
-Short follow-up 
period (2 months); 
-Subjects recruited 
from a single hospital 
- limits 
generalizability; 
-Drug use determined 
from hospital records, 
no information on 
adherence before and 
after hospitalization; 
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Appendix B: High Risk and Antipsychotic Medications 
The following table lists the specific medications included within each of the medication classes 
considered in the present research, along with the corresponding ATC codes 
Drug Measure Drug Name (generic) ATC code 
Any use of  Oral 
Anticoagulant 
Warfarin B01AA03 
Acenocoumarol B01AA07 
Any use of Oral 
Antiplatelet 
Clopidogrel B01AC04 
Ticlopidine B01AC05 
Dipyridamole B01AC07 
ASA + dipyridamole B01AC30 
ASA N02BA01 
ASA + other combinations N02BA51 
N02BA71 
Sulfasalazine§ A07EC01 
Aminosalicylic acid, Mesalazine§ A07EC02 
Olsalazine§ A07EC03 
Any Use of Oral 
Antidiabetic Agents 
Metformin (Biguanide) A10BA02 
Glyburide (Sulfonylurea) A10BB01 
Gliclazide (Sulfonylurea) A10BB09 
Acarbose (alpha-glucosidase inhibitor) A10BF01 
Rosiglitazone (Thiazolidinedione) A10BG02 
Pioglitazone (Thiazolidinedione) A10BG03 
Sitagliptin (DPP-4 Inhibitor) A10BH01 
Repaglinide (Meglitinide) A10BX02 
Any use of Insulin(s) Insulin (human): Toronto, Novolin, Humulin R, etc. A10AB01 
Insulin Aspart A10AB05 
A10AD05 
Insulin (human): Humulin N, Novolin NPH, etc. A10AC01 
Insulin (human): Novolin 30/70, Humulin 30/70, etc. A10AD01 
Insulin Glargine A10AE04 
Insulin Detemir A10AE05 
Insulin, not specified† A10A 
Any use of Antipsychotics Chlorpromazine (phenothiazines) N05AA01 
Methotrimeprazine (phenothiazines) N05AA02 
Fluphenazine (phenothiazines) N05AB02 
Perphenazine (phenothiazines) N05AB03 
Prochlorperazine (phenothiazines) N05AB04 
Trifluoperazine (phenothiazines) N05AB06 
Haloperidol (butyrophenones) N05AD01 
Flupentixol (thioxanthenes) N05AF01 
Zuclopenthixol (thioxanthenes) N05AF05 
Loxapine (misc. antipsychotic) N05AH01 
Clozapine (atypical antipsychotic) N05AH02 
Olanzapine (atypical) N05AH03 
Quetiapine (atypical) N05AH04 
Risperidone (atypical) N05AX08 
§ Sulfasalazine (and its metabolites) were included as they have been shown to have antiplatelet effects comparable 
to ASA 
†In some instances, type of insulin was not recorded during ACCES data collection, so 4-digit ATC code was used 
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Appendix C: Full Frailty Index
82
 
The following 86-item frailty index is based on the criteria used by Searle et al.
83
 and utilizes 
information from the interRAI-AL. The presence of each condition adds “1” to the person’s 
index score (unless otherwise indicated). 
Name of Frailty Item by Subject Header 
Psychosocial Well Being 
 Not close to someone in the facility 
 No strong supportive relationships with family 
 Infrequent participation in long-standing social activities 
 Infrequent visits from family/friends 
 Infrequent interaction with family/friends 
Mood 
 Makes negative statements 
 Persistent anger 
 Unrealistic fears 
 Repetitive health complaints 
 Repetitive anxiety 
 Sad, pained, worried facial expressions 
 Crying, tearfulness 
 Withdrawal from activities of interest 
 Reduced social interactions 
 Lack of pleasure in life 
Cognition 
 Minimally impaired (0.5), or moderately/severely impaired (1) decision-making skills 
 Short-term memory problems 
 Procedural memory problems 
 Situational memory problems 
 Easily distracted 
 Episodes of disorganized speech 
 Declined decision-making in last 90 days 
Communication 
 At least some difficulty to make self understood 
 At least some difficulty understanding 
 Moderate/severe hearing problems 
 Moderate/severe vision problems 
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Functional status 
 Limited help (0.5), extensive help (1) with phone use 
 Limited help (0.5), extensive help (1) with stair climbing 
 Limited help (0.5), extensive help (1) with shopping 
 Limited help (0.5), extensive help (1) with bathing 
 Limited help (0.5), extensive help (1) with personal hygiene 
 Limited help (0.5), extensive help (1) with dressing upper body 
 Limited help (0.5), extensive help (1) with dressing lower body 
 Limited help (0.5), extensive help (1) with walking 
 Limited help (0.5), extensive help (1) with locomotion 
 Limited help (0.5), extensive help (1) with transferring 
 Minimal help (0.5), extensive help (1) with toilet use 
 Minimal help (0.5), extensive help (1) with bed mobility 
 Minimal help (0.5), extensive help (1) with eating 
 Less than 1 hour of physical activity in last 3 days 
 Did not go out within a 3 day period 
 Declined in ADL over last 90 days 
Incontinence 
 Some (0.5), daily (1) bladder incontinence 
 Some (0.5), daily (1) bowel incontinence 
Disease diagnosis 
 Hip fracture, other fractures, osteoporosis 
 Arthritis 
 Alzheimer’s disease/dementia 
 Hemiplegia 
 Multiple sclerosis 
 Paraplegia/quadriplegia 
 Parkinson’s disease 
 Stroke or CVA 
 Hypertension 
 Coronary heart disease 
 Congestive heart failure 
 COPD/Emphysema/Asthma 
 Cancer 
 Diabetes 
 Renal disease 
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 Peripheral vascular disease 
 Cardiac arrhythmias 
 Thyroid disease 
 Anemia 
 Macular Degeneration 
Health conditions 
 At least 1 fall in last 30 dyas 
 Balance - turning around 
 Balance - dizziness 
 Balance - unsteady gait 
 Chest pain 
 Abnormal thought process 
 Delusions 
 Hallucinations 
 Aphasia 
 Vomiting 
 Non-restful sleep/insomnia 
 Too much sleep 
 Peripheral edema 
 Shortness of breath 
 Fatigue - cannot complete day-to-day activities 
 Pain present 
 Poor self-reported health 
 Unstable health 
Nutrition/Medications 
 BMI 30-40 (0.5), BMI > 40 (1) 
 Weight loss 5% or more in last 30 days or 10% in last 180 days 
 Ten or more medications 
 Allergy to any drug 
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Appendix D: Armstrong Frailty Index
90 
The following 44-item frailty index is based on index used by Armstrong et al.
90
 and utilizes 
information from the interRAI-AL. The presence of each condition adds “1” to the person’s 
index score (unless otherwise indicated). 
Name of Frailty Item by Subject Header 
Mood 
 Persistent anger 
 Unrealistic fears 
 Repetitive health complaints 
 Sad, pained, worried facial expressions 
 Withdrawal from activities of interest 
 Reduced social interactions 
Communication 
 Moderate/severe vision problems 
Functional status 
 Limited help (0.5), extensive help (1) with meal preparation 
 Limited help (0.5), extensive help (1) with ordinary housework 
 Limited help (0.5), extensive help (1) with managing finances 
 Limited help (0.5), extensive help (1) with managing medications 
 Limited help (0.5), extensive help (1) with stair climbing 
 Limited help (0.5), extensive help (1) with shopping 
 Limited help (0.5), extensive help (1) with bathing 
 Limited help (0.5), extensive help (1) with personal hygiene 
 Limited help (0.5), extensive help (1) with dressing upper body 
 Limited help (0.5), extensive help (1) with dressing lower body 
 Limited help (0.5), extensive help (1) with locomotion 
 Limited help (0.5), extensive help (1) with transferring 
 Minimal help (0.5), extensive help (1) with toilet use 
 Minimal help (0.5), extensive help (1) with eating 
Incontinence 
 Some (0.5), daily (1) bladder incontinence 
 Some (0.5), daily (1) bowel incontinence 
Disease diagnosis 
 Hip fracture, other fractures, osteoporosis 
 Arthritis 
 Alzheimer’s disease/dementia 
184 
 
 Hemiplegia 
 Multiple sclerosis 
 Parkinson’s disease 
 Stroke or CVA 
 Hypertension 
 Coronary heart disease 
 Congestive heart failure 
 COPD/Emphysema/Asthma 
 Diabetes 
 Renal disease 
 Peripheral vascular disease 
 Cardiac arrhythmias 
 Thyroid disease 
Health conditions 
 Balance - unsteady gait 
 Poor self-reported health 
 Unstable health 
Nutrition/Medications 
 BMI 30-40 (0.5), BMI > 40 (1) 
 Weight loss 5% or more in last 30 days or 10% in last 180 days 
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Appendix E: CHS Frailty Assessment† (CHSabs and CHSrel) 
The following represents the criteria used in order to assess frailty, according to the CHS model 
with absolute cut-points (CHSabs) and relative cut-points (CHSrel). Frailty cut-points identify 
residents with the poorest scores relative to the cohort, as outlined by Freiheit, et al.
123
 These 
criteria utilize data from the interRAI-AL as well as supplemental physical measures added to 
the resident assessment. 
Criterion Measure CHSabs* CHSrel
ɸ
 
Slow gait Determined by taking 
the better of two timed 
3-meter walks. 
≥7 seconds, men ≤ 173 cm; 
≥ 7 seconds, women ≤ 159 cm;  
≥ 6 seconds, men > 173 cm;  
≥ 6 seconds, women > 159 cm 
Slowest quartile of 
walk times: 
> 9 seconds, men; 
> 10 seconds, women 
Muscle 
weaknesses 
Average of three grip 
strength readings using a 
handheld 
dynamometer.
Ɏ 
BMI-specific thresholds: 
≤ 29-32 kg, men; 
≤ 17-21 kg, women 
Lowest quartile of 
grip-strength readings: 
< 15 kg, men; 
< 7 kg, women 
Low physical 
activity 
Reported minutes over two 
weeks per activity type - 
from the interRAI-AL 
“Exercise or Leisure 
Activities”§ 
Activities were mapped to 
Minnesota Leisure Time 
Activity Questionnaire.
198
  
Kcals per week calculated based 
on the intensity codes: 
< 383 Kcals/week, men; 
< 270 Kcals/week, women 
< 140 minutes/two 
weeks (< 10 
minutes/day on 
average) ǁ 
Unintentional 
weight loss 
Answer to question: “In the 
past year have you lost 
more than 
10 pounds 
unintentionally”¶ 
Response of “yes” Response of “yes” 
Exhaustion Answers to 3 questions: “In 
the past month, on average, 
have you been:  
1) Feeling unusually tired 
during the day?;  
2) Feeling unusually 
weak?; and/or,  
3) Feeling an unusually low 
energy level?”ǂ 
Response of “yes” to any of the 
3 questions 
Response of “yes” to 
any of the 3 questions 
Abbreviations: CHS = Cardiovascular Health Study, AL = assisted living, cm = centimeters, BMI = body mass 
index, kg = kilograms, kcals = kilocalories. 
†Based on the measure detailed in Fried, 2001.80 
*CHSabs frailty assessed with CHS-specified absolute cut-points.
80 
ɸ CHSrel frailty assessed with DAL-population based relative cut-points (identified the poorest scores in the cohort) 
as defined by Freiheit, et al.
123 
Ɏ JAMAR®, Sammons Preston Rolyan, Bolingbrook, IL. 
§Include: aquasize/swimming; bowling; dancing; exercise bike/treadmill; exercise program; floor curling/lawn 
bowling; gardening; household chores; shuffleboard/pool; Tai chi/yoga; walking/wheeling indoors & outdoors. 
¶CHS also allowed actual unintentional 5% weight loss over 1-year (not assessed in ACCES). 
ǂ CHS used 2 items from the CES-D Scale [35]: “I feel that everything I do is an effort” and “I cannot get going” 
(those reporting feeling this way at least 3–4 days/previous week fulfilled the criterion). 
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Appendix F: CHESS Scale
88 
The CHESS scale offers a measure of health instability. The score is derived from interRAI 
assessments and can range from 0 to 5, with 0 representing stability and 5 representing unstable 
health. The following criteria are used to determine CHESS score with the score for each item 
shown in brackets. 
Symptoms (No symptoms = 0 ;1 symptom present = 1 ; 2+ symptoms present = 2) 
 Vomiting 
 Dehydration (insufficient fluid)
* 
 Decline in fluid/food intake
* 
 Weight loss 
 Shortness of breath 
 Edema 
Worsening of decision making over previous 90 days (1) 
Decline in activities of daily living over past 90 days (1) 
End-stage disease (1) 
*
Two of the items from the CHESS scale were not included in the interRAI-AL, and thus, cannot be used for the 
calculation of the CHESS score in the proposed research  
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Appendix G: Diagnoses associated with the Use of High-Risk / Antipsychotic Medication and 
Associations with Frailty Status 
Table a. Baseline Distribution of Diagnoses Related to High-Risk / Antipsychotic Medication 
Use by Frailty Status [CHSrel Frailty Measure] among DAL Residents 
 Total 
% (n) 
CHSrel Frailty; % of column total (n)  
Robust Pre-Frail Frail p-value 
Overall 946 25.8 (244) 55.0 (520) 19.2 (182)  
Diagnoses Related to Anticoagulant Use 
ɸ
      
 No diagnoses related to anticoagulant use 42.9 (406) 50.8 (124) 43.1 (224) 31.9 (58) 0.0005 
 1+ diagnoses related to anticoagulant use 57.1 (540) 49.2 (120) 56.9 (296) 68.1 (124)  
Diagnoses Related to Oral Antiplatelet 
Use
 ¶
 
     
 No diagnoses related to antiplatelet use 22.1 (209) 24.6 (60) 22.5 (117) 17.6 (32) 0.2138 
 1+ diagnoses related to antiplatelet use 77.9 (737) 75.4 (184) 77.5 (403) 82.4 (150)  
Diagnoses Related to Oral Antidiabetic 
Use 
Ɏ
 
     
 No diagnoses related to oral antidiabetic 
use 
23.2 (220) 26.2 (64) 24.2 (126) 16.5 (30) 0.0459 
 1+ diagnoses related to oral antidiabetic 
use 
76.7 (726) 73.8 (180) 75.8 (394) 83.5 (152)  
Diagnoses Related to Insulin Use 
ǁ
      
 No diagnoses related to insulin use 23.9 (226) 25.8 (63) 24.6 (128) 19.2 (35) 0.2438 
 1+ diagnoses related to insulin use 76.1 (720) 74.2 (181) 75.4 (392) 80.8 (147)  
Diagnoses Related to 
Insulin/Sulfonylurea Use
 Ɏǁ
 
     
 No diagnoses related to insulin or 
sulfonylurea use 
19.5 (184) 21.7 (53) 20.8 (108) 12.6 (23) 0.0338 
 1+ diagnoses related to insulin and/or 
sulfonylurea use 
80.5 (762) 78.3 (191) 79.2 (412) 87.4 (159)  
Diagnoses Related to any Diabetic Drug 
Use
 Ɏǁ
 
     
 No diagnoses related to insulin or oral 
antidiabetic use 
19.5 (184) 21.7 (53) 20.8 (108) 12.6 (23) 0.0338 
 1+ diagnoses related to insulin and/or 
oral antidiabetic use 
80.5 (762) 78.3 (191) 79.2 (412) 87.4 (159)  
Diagnoses Related to High-risk 
Medication Use 
ɸ¶ Ɏǁ
 
     
 No diagnoses related to use of any of the 
4 HR drug classes 
15.0 (142) 17.6 (43) 15.4 (80) 10.4 (19) 0.1140 
 1+ diagnoses related to HR drug use 85.0 (804) 82.4 (201) 84.6 (440) 89.6 (163)  
Diagnoses Related to Antipsychotic Drug 
Use * 
     
 No diagnoses related to antipsychotic use 25.7 (243) 21.7 (53) 27.7 (144) 25.3 (46) 0.210 
 1+ diagnoses related to antipsychotic use 74.3 (703) 78.3 (191) 72.3 (376) 74.7 (136)  
Abbreviations: DAL=Designated Assisted Living; CHSrel=Cardiovascular Health Study Frailty Measure (relative cut-points) 
ɸ Diagnoses related to oral anticoagulant use included stroke, coronary heart disease, congestive heart failure, cardiac 
dysrhythmias, venous disorders (deep vein thrombosis, chronic venous insufficiency, pulmonary embolism, superficial venous 
thrombosis or phlebitis, varicose veins). 
¶ Diagnoses related to oral antiplatelet use included stroke, hypertension, coronary heart disease, diabetes, lipid abnormality. 
Ɏ Diagnoses related to oral antidiabetic use included diabetes, congestive heart failure, lipid abnormality, hypertension, coronary 
heart disease. 
ǁ Diagnoses related to insulin use included diabetes, congestive heart failure, hypertension, chronic obstructive pulmonary disease 
* Diagnoses related to antipsychotic use included dementia, schizophrenia, anxiety, depression. 
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Table b. Baseline Distribution of Diagnoses Related to High-Risk / Antipsychotic Medication 
Use by Frailty Status [Full FI Frailty Measure] among DAL Residents 
 Total 
% (n) 
Full FI Frailty; % of column total (n)  
Robust Pre-Frail Frail p-value 
Overall 1089 33.6 (366) 38.9 (424) 27.5 (299)  
Diagnoses Related to Anticoagulant Use 
ɸ
      
 No diagnoses related to anticoagulant use 55.8 (608) 46.7 (195) 41.5 (176)  36.8 (110) < 0.0001 
 1+ diagnoses related to anticoagulant use 44.2 (481) 53.3 (171) 58.5 (248) 63.2 (189)  
Diagnoses Related to Oral Antiplatelet 
Use
 ¶
 
     
 No diagnoses related to antiplatelet use 22.8 (52) 29.5 (108) 20.7 (88) 17.4 (52) 0.0005 
 1+ diagnoses related to antiplatelet use 77.2 (841) 70.5 (258) 79.3 (336) 82.6 (247)  
Diagnoses Related to Oral Antidiabetic 
Use 
Ɏ
 
     
 No diagnoses related to oral antidiabetic 
use 
23.9 (260) 32.5 (119) 20.8 (88) 17.7 (53) <0.0001 
 1+ diagnoses related to oral antidiabetic 
use 
76.1 (829) 67.5 (247) 79.2 (336) 82.3 (246)  
Diagnoses Related to Insulin Use 
ǁ
      
 No diagnoses related to insulin use 24.5 (267) 30.9 (113) 22.9 (97) 19.1 (57) 0.0012 
 1+ diagnoses related to insulin use 75.5 (822) 69.1 (253) 77.1 (327) 80.9 (242)  
Diagnoses Related to 
Insulin/Sulfonylurea Use
 Ɏǁ
 
     
 No diagnoses related to insulin or 
sulfonylurea use 
20.0 (218) 27.1 (99) 17.5 (74) 15.1 (45) 0.0001 
 1+ diagnoses related to insulin and/or 
sulfonylurea use 
80.0 (871) 72.9 (267) 82.5 (350) 84.9 (254)  
Diagnoses Related to any Diabetic Drug 
Use
 Ɏǁ
 
     
 No diagnoses related to insulin or oral 
antidiabetic use 
20.0 (218) 27.1 (99) 17.5 (74) 15.1 (45) 0.0001 
 1+ diagnoses related to insulin and/or 
oral antidiabetic use 
80.0 (871) 72.9 (267) 82.5 (350) 84.9 (254)  
Diagnoses Related to High-risk 
Medication Use 
ɸ¶ Ɏǁ
 
     
 No diagnoses related to use of any of the 
4 HR drug classes 
15.7 (171) 20.5 (75) 13.9 (59) 12.4 (37) 0.0072 
 1+ diagnoses related to HR drug use 84.3 (918) 79.5 (291) 86.1 (365) 87.6 (262)  
Diagnoses Related to Antipsychotic Drug 
Use * 
     
 No diagnoses related to antipsychotic use 24.4 (266) 37.2 (136) 25.2 (107) 7.7 (23) <0.0001 
 1+ diagnoses related to antipsychotic use 75.6 (823) 62.8 (230) 74.8 (317) 92.3 (276)  
Abbreviations: DAL=Designated Assisted Living; Full FI= Full (86-item) Frailty Index 
ɸ Diagnoses related to oral anticoagulant use included stroke, coronary heart disease, congestive heart failure, cardiac 
dysrhythmias, venous disorders (deep vein thrombosis, chronic venous insufficiency, pulmonary embolism, superficial venous 
thrombosis or phlebitis, varicose veins). 
¶ Diagnoses related to oral antiplatelet use included stroke, hypertension, coronary heart disease, diabetes, lipid abnormality. 
Ɏ Diagnoses related to oral antidiabetic use included diabetes, congestive heart failure, lipid abnormality, hypertension, coronary 
heart disease. 
ǁ Diagnoses related to insulin use included diabetes, congestive heart failure, hypertension, chronic obstructive pulmonary disease 
* Diagnoses related to antipsychotic use included dementia, schizophrenia, anxiety, depression. 
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Table c. Baseline Distribution of Diagnoses Related to High-Risk / Antipsychotic Medication 
Use by Frailty Status [CHESS Frailty Measure] among DAL Residents 
 Total 
% (n) 
CHESS Frailty; % of column total (n)  
Robust Pre-Frail Frail p-value 
Overall 1089 46.2 (503) 29.4 (320) 24.4 (266)  
Diagnoses Related to Anticoagulant Use 
ɸ
      
 No diagnoses related to anticoagulant use 44.2 (481) 48.3 (243) 40.6 (130) 40.6 (108) 0.0388 
 1+ diagnoses related to anticoagulant use 55.8 (608) 51.7 (260) 59.4 (190) 59.4 (158)  
Diagnoses Related to Oral Antiplatelet 
Use
 ¶
 
     
 No diagnoses related to antiplatelet use 22.8 (248) 23.7 (119) 24.4 (78) 19.2 (51) 0.2656 
 1+ diagnoses related to antiplatelet use 77.2 (841) 76.3 (384) 75.6 (242) 80.8 (215)  
Diagnoses Related to Oral Antidiabetic 
Use 
Ɏ
 
     
 No diagnoses related to oral antidiabetic 
use 
23.9 (260) 27.0 (136) 23.4 (75) 18.4 (49) 0.0279 
 1+ diagnoses related to oral antidiabetic 
use 
76.1 (829) 73.0 (367) 76.6 (245) 81.6 (217)  
Diagnoses Related to Insulin Use 
ǁ
      
 No diagnoses related to insulin use 24.5 (267) 27.0 (136) 23.4 (75) 21.1 (56) 0.1609 
 1+ diagnoses related to insulin use 75.5 (822) 73.0 (367) 76.6 (245) 78.9 (210)  
Diagnoses Related to 
Insulin/Sulfonylurea Use
 Ɏǁ
 
     
 No diagnoses related to insulin or 
sulfonylurea use 
20.0 (218) 23.3 (117) 19.1 (61) 15.0 (40) 0.0223 
 1+ diagnoses related to insulin and/or 
sulfonylurea use 
80.0 (871) 76.7 (386) 80.9 (259) 85.0 (226)  
Diagnoses Related to any Diabetic Drug 
Use
 Ɏǁ
 
     
 No diagnoses related to insulin or oral 
antidiabetic use 
20.0 (218) 23.3 (117) 19.1 (61) 15.0 (40) 0.0223 
 1+ diagnoses related to insulin and/or 
oral antidiabetic use 
80.0 (871) 76.7 (386) 80.9 (259) 85.0 (226)  
Diagnoses Related to High-risk 
Medication Use 
ɸ¶ Ɏǁ
 
     
 No diagnoses related to use of any of the 
4 HR drug classes 
15.7 (171) 17.3 (87) 15.6 (50) 12.8 (34) 0.2618 
 1+ diagnoses related to HR drug use 84.3 (918) 82.7 (416) 84.4 (270) 87.2 (232)  
Diagnoses Related to Antipsychotic Drug 
Use * 
     
 No diagnoses related to antipsychotic use 24.4 (266) 23.5 (118) 30.3 (97) 19.2 (51) 0.0060 
 1+ diagnoses related to antipsychotic use 75.6 (823) 76.5 (385) 69.7 (223) 80.8 (215)  
Abbreviations: DAL=Designated Assisted Living; CHESS= Changes in Health, End-stage disease and Signs and Symptoms of 
medical problems scale 
ɸ Diagnoses related to oral anticoagulant use included stroke, coronary heart disease, congestive heart failure, cardiac 
dysrhythmias, venous disorders (deep vein thrombosis, chronic venous insufficiency, pulmonary embolism, superficial venous 
thrombosis or phlebitis, varicose veins). 
¶ Diagnoses related to oral antiplatelet use included stroke, hypertension, coronary heart disease, diabetes, lipid abnormality. 
Ɏ Diagnoses related to oral antidiabetic use included diabetes, congestive heart failure, lipid abnormality, hypertension, coronary 
heart disease. 
ǁ Diagnoses related to insulin use included diabetes, congestive heart failure, hypertension, chronic obstructive pulmonary disease 
* Diagnoses related to antipsychotic use included dementia, schizophrenia, anxiety, depression. 
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Appendix H: Baseline Characteristics of ACCES DAL (n=1,066) and LTC (n=976) Residents 
(From Hogan, 2014)
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    DAL
*
  
n (% of total) 
LTC
† 
n (% of total) 
p-value 
  n=1066 n=976  
Sociodemographic Characteristics & 
Social Wellbeing 
   
Age                mean ±SD 84.9±7.3 85.4±7.6 0.1163 
 65-79 
80-85 
86-89 
90+ 
268 (25.1) 
280 (26.3) 
243 (22.8) 
275 (25.8) 
226 (23.2) 
251 (25.7) 
210 (21.5) 
289 (29.6) 
0.2672 
 
Sex                             Female
Male 
818 (76.7) 
248 (23.3) 
641 (65.7) 
335 (34.2) 
<0.001 
Marital Status   <0.001 
 Widowed 761 (71.4) 573 (58.7)  
 Married / Partner 156 (14.6) 246 (25.2)  
 Never married / separated / 
divorced 
149 (14.0) 157 (16.1)  
Strength of Social Relationships
‡ 
  <0.001 
 Moderate/High (3-5) 873 (81.9) 641 (65.7)  
 Low/None (0-2) 193 (18.1) 335 (34.3)  
Avg Time Involved in Activities
§ 
  <0.001 
 Most (>2/3 time) 157 (14.7) 105 (10.8)  
 Some (1/3 to 2/3 time) 417 (39.1) 326 (33.4)  
 Little-None (<1/3 time) 492 (46.2) 544 (55.8)  
Health & Functional Status    
 Cognition (CPS Score)   <0.001 
 Intact (0) 223 (20.9) 60 (6.2)  
 Borderline Intact (1) 211 (19.8) 93 (9.5)  
 Mild Impairment (2) 336 (31.5) 252 (25.9)  
 Mod-Severe-Very Severe 
Impairment (3+) 
296 (27.8) 570 (58.5)  
Activities of Daily Living (ADL score)   <0.001 
 Independent (0) 454 (42.6) 50 (5.1)  
 Supervision Required (1) 186 (17.5) 50 (5.1)  
 Limited Impairment (2) 126 (11.8) 81 (8.3)  
 Extensive Assistance 
Req’d/Dependent (3+) 
300 (28.1) 795 (81.5)  
Health Instability (CHESS score)
¶ 
  0.0067 
 Stable (0) 496 (46.5) 382 (39.1)  
 Mild (1) 312 (29.3) 335 (34.3)  
 Mild-Moderate (2) 184 (17.3) 192 (19.7)  
 Moderate-High (3+) 74 (6.9) 67 (6.9)  
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    DAL
*
  
n (% of total) 
LTC
† 
n (% of total) 
p-value 
  n=1066 n=976  
Fatigue, <3 days   <0.001 
 None 433 (40.6) 387 (39.7)  
 Minimal 461 (43.3) 318 (32.6)  
 Moderate-Severe 172 (16.1) 271 (27.8)  
Primary Mode Locomotion   <0.001 
 Walks independently 227 (21.3) 88 (9.0)  
 Walks with Assistive Device 625 (58.6) 205 (21.0)  
 Wheelchair/Scooter
**
  214 (20.0) 683 (70.0)  
Falls CAP   0.4016 
 1+ Falls /  90 days 305 (28.6) 263 (27.0)  
 None 761 (71.4) 713 (73.1)  
Depressive Symptoms (DRS Score)   <0.001 
 Yes (3+) 203 (19.0) 495 (50.9)  
 No (<3) 863 (81.0) 478 (49.1)  
Aggressive Behaviour 
(ABS Score)
†† 
  <0.001 
 None (0) 760 (71.3) 334 (34.2)  
 Moderate (1-2) 174 (16.3) 197 (20.2)  
 Severe (3-5) 102 (9.6) 223 (22.9)  
 Very Severe (6+) 30 (2.8) 222 (22.8)  
# Chronic Conditions    
 mean ±SD 4.7±2.0 5.2±2.1 <0.001 
 0-3 323 (30.3) 199 (20.4) <0.001 
 4-5 398 (37.3) 370 (37.9)  
 6+ 345 (32.4) 407 (41.7)  
# Medications    
 mean ±SD 8.3 ±3.7 7.9±3.7 0.0147 
 0-6 349 (32.7) 351 (36.0) 0.4593 
 7-8 232 (21.8) 209 (21.4)  
 9-10 214 (20.1) 187 (19.2)  
 11+ 271 (25.4) 229 (23.5)  
Adv Directive – Do Not Hospitalize   <0.001 
 Yes 109 (10.2) 290 (29.7)  
 No 957 (89.8) 686 (70.3)  
Previous Inpatient Hospitalizations (prior year)   <0.001 
 0 663 (62.2)  737 (75.5)  
 1 254 (23.8) 156 (16.0)  
 2+ 149 (14.0) 83 (8.5)  
Bladder Incontinence   <0.001 
 Continent 436 (40.9) 93 (9.5)  
 Some control, infrequent episodes 156 (14.6) 112 (11.5)  
 Occasional incontinence 114 (10.7) 96 (9.8)  
 Frequent episodes, no control 360 (33.8) 675 (69.2)  
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    DAL
*
  
n (% of total) 
LTC
† 
n (% of total) 
p-value 
  n=1066 n=976  
Bowel Incontinence   <0.001 
 Continent 766 (71.9) 303 (31.1)  
 Some control, infrequent episodes 165 (15.5) 164 (16.8)  
 Occasional incontinence 83 (7.8) 143 (14.7)  
 Frequent episodes, no control 52 (4.9) 366 (37.5)  
System / Facility Factors    
Region 1 (urban) 311 (29.2) 296 (30.3) 0.7637 
 2 (mixed urban/rural) 228 (21.4) 204 (20.9)  
 3 (rural) 153 (14.4) 143 (14.7)  
 4 (urban) 268 (25.1) 225 (23.1)  
 5 (rural) 106 (9.9) 108 (11.1)  
Ownership   <0.001 
 For-profit 420 (39.4) 278 (28.5)  
 Not-for-profit/RHA 646 (60.6) 698 (71.5)  
Part of Chain   <0.001 
 No / RHA operated 157 (14.7) 337 (34.5)  
 Yes – AL (LTC) Chain only 334 (31.3) 315 (32.3)  
 Yes – AL & LTC Chain 575 (53.9) 324 (33.2)  
Year DAL (LTC) Spaces Opened
‡‡ 
  <0.001 
 <2002 273 (25.6) 866 (94.0)  
 2002-03 362 (34.0) 39 (4.2)  
 2004+ 431 (40.4) 16 (1.7)  
#DAL (LTC) Spaces   <0.001 
 mean ±SD 44±26 131±107  
 median 38 100  
 IQR 27-50 56-188  
#Total Spaces   0.0271 
 mean±SD 140±110 151±116  
 median 112 120  
 IQR 65-154 83-194  
Levels of Care on Site
§§ 
  0.6643 
 DAL (LTC) only / DAL (LTC) + 
Equivalent/Lower 
859 (80.6) 779 (79.8)  
 DAL (LTC) + Higher Level 207 (19.4) 197 (20.2)  
LTC Beds On Site    
 No 865 (81.1) --  
 Yes (LTC/LTC-dem) 201 (18.9) --  
LPN/RN Coverage on Site    
 Neither on site 295 (27.7)   
 LPN &/or RN <24/7 108 (10.1)   
 LPN &/or RN 24/7 663 (62.2) 976 (100.0)  
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    DAL
*
  
n (% of total) 
LTC
† 
n (% of total) 
p-value 
  n=1066 n=976  
Physician (GP) Affiliated with Site   <0.001 
 No 687 (64.5) 17 (1.7)  
 Yes, office on site 169 (15.9) 261 (26.7)  
 Yes, no office on site 210 (19.7) 698 (71.5)  
Community Size   <0.001 
 <10,000 222 (20.8) 325 (33.3)  
 10,000-99,999 292 (27.4) 196 (20.1)  
 1 million+ 552 (51.8) 455 (46.6)  
Abbreviations: ACCES=Alberta Continuing Care Epidemiological Studies; DAL=designated assisted living; 
SD=standard deviation.
 
*  
DAL sample excludes 3 residents with unknown outcome and 20 residents who declined consent for data 
linkage.  
† 
LTC sample excludes 3 residents who could not be linked with administrative data and 21 residents who 
declined consent for data linkage. 
‡ 
Social relationships based on summary score of items assessing whether resident is close to someone in the 
facility, has a strong/supportive relationship with family, participates in social activities of longstanding 
interest and visits/has other interactions with longstanding social relation/family member (in past week). 
§ 
Activity involvement reflects when awake and not receiving treatments or ADL care. 
¶ 
2 items (insufficient fluid, noticeable decline in food/fluid) used to calculate CHESS are not included on 
interRAI-AL tool.
 
** Includes 1 DAL resident and 9 LTC residents who were bedbound. 
†† 
ABS is a summary scale of 4 behaviours (verbal abuse, physical abuse, socially inappropriate or 
disruptive, resists care) with higher scores indicating a greater number and frequency of behavioural issues. 
‡‡ 
For LTC, 55 residents have missing value for year LTC facility opened. 
§§ 
For DAL facilities: Equivalent level of care (private AL, residential, respite [not in LTC], community 
support & transition beds); Lower level of care (independent living, lodge, condo); Higher level of care 
(LTC [including respite], acute care); For LTC facilities: Equivalent level of care (other LTC bed types); 
Lower level of care (DAL, private AL, residential, respite [not in LTC], community support & transition 
beds, independent living, lodge, condo); Higher level of care (acute care). 
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Appendix I: Most Common Causes for Hospitalization
* 
among DAL residents (From Hogan, et 
al.)
112 
Category 
(Most Responsible Diagnosis) 
DAL Resident Hospitalization 
 
 
n % all hospitalizations 
(n=413) 
% of residents 
(n=1066) 
Infectious Diseases 
 Septicemia 
 Respiratory 
 Urinary 
 Other 
 Total 
 
5 
27 
20 
10 
62 
 
1.2% 
6.5% 
4.8% 
2.4% 
15.0% 
 
0.5% 
2.5% 
1.9% 
0.9% 
5.8% 
Injuries 
 Hip Fracture 
 Other Fracture 
 Other Injuries 
 Total 
 
22 
26 
6 
54 
 
5.3% 
6.3% 
1.5% 
13.1% 
 
2.1% 
2.4% 
0.6% 
5.1% 
Heart Failure 28 6.8% 2.6% 
Exacerbation of COPD 22 5.3% 2.1% 
Cognitive Impairment 
 Dementia 
 Delirium 
 Total 
 
20 
2 
22 
 
4.8% 
0.5% 
5.3% 
 
1.9% 
0.2% 
2.1% 
Malignant Diseases  
(includes Palliative Care & 
Pain Management) 
21 5.1% 2.0% 
Cerebrovascular Disease 17 4.1% 1.6% 
Ischemic Heart Disease 15 3.6% 1.4% 
* derived from ICD10CA codes listed for the most responsible discharge diagnosis 
 
 
